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 All cells and organisms consume energy for survival.  A robust system has 
evolved in vertebrates to serve as an energy reservoir.  In particular, specialized 
cells, adipocytes, are responsible for the dynamic storage of energy by 
accumulating and releasing fatty acids.  Fluctuating energy demands require 
adipose tissue to adjust in size, however complications can arise in both 
extremes giving rise to systemic diseases, such as obesity and diabetes mellitus 
(T2D).   
In mammals, leptin production in adipocytes is up-regulated by feeding and 
insulin to provide long-term post-prandial satiety. Although this regulatory 
connection is central to all physiological effects of leptin, the molecular 
mechanism remains unknown for leptin production.  Here, we show that the 
transcription factor Egr1 is rapidly but transiently induced by insulin in adipose 
cells both in vitro and in vivo in a mTORC1-dependent fashion. Induction of Egr1 
 
 vii 
was immediately followed by an increase in leptin transcription.  Chromatin 
immunoprecipitation and luciferase assays demonstrate that Egr1 directly binds 
to and activates the leptin promoter.  Interestingly, the lipid droplet protein Fat 
specific protein 27 (FSP27) may work as a co-factor for Egr1 in regulating leptin 
expression.  By using siRNA-mediated knock out of Egr1 along with its over-
expression in adipocytes, we demonstrate that Egr1 is both necessary and 
sufficient for the stimulatory effect of insulin on leptin transcription.  Knockout of 
the mTORC1-regulated translation repressor 4EBP1/2 increases leptin 
transcription both in vitro and in vivo.  Adipose specific doxycycline-inducible 
constitutively active Rheb transgenic mouse lines contained higher circulating 
leptin and transcription of leptin following doxycycline treatment and were able to 
maintain elevated leptin levels following a 16 hour fast. Thus, insulin and 
nutrients, such as amino acids and glucose, activate leptin expression via the 
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1. The mTOR (mechanistic target of rapamycin) pathway 
 
“This research was originally published in the Journal of Biological Chemistry.  
Omar Mohtar, Cafer Ozdemir, Debasish Roy, Dharti Shantaram, Andrew Emili and 
Konstantin V. Kandror.  Egr1 mediates the effect of insulin on leptin transcription 
in adipocytes. J. Biol. Chem. 2019; 294:5784-5789. © the American Society for 
Biochemistry and Molecular Biology “ 
 
Target of rapamycin (TOR) is the protein kinase target of the macrolide 
compound rapamycin; the Streptomyces hygroscopius bacteria produces this 
anti-fungal compound known for its anti-proliferative properties (Kunz, Henriquez 
et al. 1993).  Genetic screens of budding yeast identified TOR1 and TOR2 as 
mediators of rapamycin toxicity (Cafferkey, Young et al. 1993, Kunz, Henriquez 
et al. 1993).  The mammalian homolog, mTOR, was discovered as the physical 
target of rapamycin (Brown, Albers et al. 1994, Sabatini, Erdjument-Bromage et 
al. 1994, Sabers, Martin et al. 1995).  mTOR associates with several proteins to 
form two unique complexes designated mTOR complex 1 (mTORC1) and 2 
(mTORC2).  mTORC1 comprises of the catalytic mTOR subunit, mammalian 
lethal with sec-13 (mLST8) (Kim, Sarbassov et al. 2003, Jacinto, Loewith et al. 
2004), DEP domain containing mTOR-interacting protein (DEPTOR) (Peterson, 




associated protein of mammalian target of rapamycin (raptor) (Hara, Maruki et al. 
2002, Kim, Sarbassov et al. 2002) and proline-rich Akt substrate 40 kDa 
(PRAS40) (Sancak, Thoreen et al. 2007, Thedieck, Polak et al. 2007, Vander 
Haar, Lee et al. 2007, Wang, Harris et al. 2007).  mTORC2 comprises of mTOR, 
mLST8, DEPTOR, Tti1/Tel2 complex, rapamycin-insensitive companion of 
mTOR (rictor) (Jacinto, Loewith et al. 2004, Sarbassov, Ali et al. 2004), 
mammalian stress-activated map kinase-interacting protein 1 (mSin1) (Frias, 
Thoreen et al. 2006, Jacinto, Facchinetti et al. 2006) and protein observed with 
rictor 1 and 2 (protor1/2) (Pearce, Huang et al. 2007, Thedieck, Polak et al. 2007, 
Pearce, Sommer et al. 2011). 
Rapamycin forms a gain-of-function complex with intracellular 12-kDa FK506-
binding protein (FKBP12) protein that specifically inhibits mTORC1 and not 
mTORC2 (Brown, Albers et al. 1994, Sabatini, Erdjument-Bromage et al. 1994).  
Co-crystal structures of truncated mTOR and mLST8 later revealed rapamycin’s 
mechanism of action (Yang, Rudge et al. 2013).  The mTOR contains HEAT 
(huntingtin, elongation factor 3, PR65/A, and TOR) repeats at the N-terminal 
region, followed by a FAT (FRAP, ATM, and TRRAP) domain, a FRB domain, the 
kinase domain, and FATC (FAT C-terminus) at the C-terminal region (Yoo, Kim 
et al. 2017).  The HEAT domains pack against each other with the first HEAT 
repeat interlocking with the adjacent mTOR FAT domain, forming a dimeric 
interaction. The Raptor armadillo domain forms an α-solenoid stack with mTOR 




through its Raptor N-terminal conserved (RNC) domain.  The FKBP12-rapamycin 
complex binds to mTOR (Aylett, Sauer et al. 2016) and further reduces the active 












 1.1 Upstream regulators and sensing mechanisms of mTORC1 
The mTORC1 pathway receives inputs from numerous intracellular and 
extracellular signals; cues of growth factors, amino acids, energy status, oxygen, 
and stress regulate mTORC1's effects on growth and autophagy (Fig. 1). 
mTORC1 is regulated by a heterodimer consisting of tuberous sclerosis 1 and 2 
(TSC1/2) which function as a GTPase-activating protein (GAP) for Ras homolog 
enriched in brain (Rheb) GTPase (Inoki, Li et al. 2003).  One report suggests 
Tre2-Bub2-Cdc16 1 domain family, member 7 (TBC1D7) as a third subunit of the 
TSC1/2 complex (Dibble, Elis et al. 2012) .  GTP-bound Rheb directly interacts 
with mTORC1, strongly stimulating its kinase activity (Long, Lin et al. 2005).  
TSC1/2 complex converts Rheb to the GDP-bound inactive form thus negatively 
regulating mTORC1 (Tee, Manning et al. 2003).  TSC1/2 complex responds to 
several signals that ultimately regulate the activity of mTORC1. 
 
   1.1.1  Insulin and PI 3-kinase/Akt-mediated pathway 
Insulin acts through its receptor to initiate a cascade of signaling events via PI3K. 
Conformational changes and autophosphorylation occur when the insulin 
receptor is activated, resulting in the recruitment of insulin receptor substrates 
(IRSs).  The IRS proteins are phosphorylated by the insulin receptor; 
phosphotyrosine 612 is recognized by the SH2 domain of the p85 regulatory 




and converts phosphorylate phosphatidylinositol 4, 5 –bisphosphate (PIP2) to 
phosphatidylinositol (3, 4, 5)-triphosphate (PIP3) (Boucher, Kleinridders et al. , 
Cheng, Tseng et al. 2010).  Increased levels of PIP3 activate PIP3-dependent 
serine/threonine kinases, like PDK-1, that phosphorylate and activate Akt, also 
known as protein kinase B.  Akt directly phosphorylates TSC2 at Ser939 disrupting 
the TSC1/2 complex association with Rheb on the cytoplasmic surface of 
lysosomes.  This spatial displacement frees Rheb to activate mTORC1, which 
also resides at the lysosome (Menon, Dibble et al. 2014).  Akt also 
phosphorylates mTOR binding partner PRAS40, responsible for inhibiting 
mTORC1 auto-phosphorylation, to activate mTORC1, providing a way to regulate 
the mTOR pathway independent of the TSC1/2 complex (Thedieck, Polak et al. 
2007, Vander Haar, Lee et al. 2007, Wang, Harris et al. 2007).  Insulin receptor, 
through IRS1 & 2, is able to activate the extracellular signaling-regulated kinase 
(ERK) pathway (Bouzakri, Zachrisson et al. 2006).  Knockdown of IRS-2 resulted 
in the reduction of phosphorylated p38MAPK in muscle cells (Huang, Thirone et 
al. 2005). 
 1.1.2.  Ras/extracellular signal-regulated kinase (ERK) pathway 
Growth factors activate both the PI3K/AKT and ERK pathways.  Binding of 
growth factors to receptor tyrosine kinases (RTK) leads to receptor tyrosine 
phosphorylation thus generating binding sites for the SH2 domain of the growth 
factor receptor-bound protein 2, Grb2. The latter recruits Son of Sevenless 




to the active GTP-bound form able of recruiting Raf family kinases to the 
membrane for activation  (Quilliam, Khosravi-Far et al. 1995).  Raf kinases exists 
in an inactive state in the cytosol, with the N-terminal domain acting as an 
autoinhibitor of the C-terminal kinase domain. Through binding of 14-3-3 dimers 
to the phosphorylation sites on both the N- and C- terminal regions, this inactive 
state is stabilized and the N-terminal region concealed (McKay and Morrison 
2007).  Stimulation of RTK recruits protein phosphatases (PP1 and PP2A) to 
dephosphorylate the inhibitory Raf N-terminal 14-3-3 binding site, thus allowing 
the interaction with Ras and membrane recruitment (Abraham, Podar et al. 2000, 
Jaumot and Hancock 2001, Rodriguez-Viciana, Oses-Prieto et al. 2006). 
Raf activates dual specificity mitogen-activated protein kinase kinase (MEK1) 
and MEK2 by phosphorylating Ser218 and Ser222  (McKay and Morrison 2007).  
MEK goes on to phosphorylate ERK, which phosphorylates TSC2 at Ser664 
dissociating the complex from Rheb (Rozengurt 2007).  ERK also phosphorylates 
Bim and Bid, thus leading to their degradation and sequestration, respectively, 
and ultimately inhibiting apoptosis.  In addition, ERK phosphorylates and 
activates 40S ribosomal protein S6 kinase (RSK1), resulting in activation of 
CREB, Fos, ELK1, ERF, c-Myc and other transcription factors to increase in 
cellular translation (Avruch, Khokhlatchev et al. 2001, Dhillon, Hagan et al. 2007).  
Ribosomal S6 kinase (RSK1) similarly phosphorylates TSC2 at Ser1798 to 
dissociate the complex (Roux, Ballif et al. 2004).  Lastly, ERK plays a role in 





Figure 1.  PI3K/AKT/mTOR signaling pathway 





 1.1.3  Amino acids 
Amino acids were shown to independently activate mTORC1 via the TSC1/2 
complex (Wolfson and Sabatini 2017).  Amino acids, particularly L-leucine and L-
arginine, are imported into the cell by the bidirectional amino acid permease 
SLC7A5/SLC3A2 (Nicklin, Bergman et al. 2009), which exchanges L-glutamine 
out for L-leucine. Upon entry into the cell, L-leucine binds to Rag GTPases to 
activate mTORC1 (Kim, Goraksha-Hicks et al. 2008, Sancak, Peterson et al. 
2008).  Mammals contain four Rag proteins, which form heterodimers consisting 
of RagA, or RagB bound to RagC or RagD.  RagA/B and its bound partner 
RagC/D contain opposing nucleotide loading states that switch upon activation.  
Folliculin (FLCN)-FNIP1/2 complex exhibits GAP activity toward RagC/D (Tsun, 
Bar-Peled et al. 2013). GATOR 1 (GAP activity toward the Rag GTPases 1) is a 
GAP for RagA/B and is regulated by GATOR2, a pentameric complex (Bar-
Peled, Chantranupong et al. 2013).  The KICSTOR complex, comprised of 
KPTN, ITFG2, C12orf66, and SZT2-containing regulator of mTORC1, is a 
scaffold for GATOR1 on the lysosomal surface (Peng, Yin et al. 2017, Wolfson, 
Chantranupong et al. 2017) (Fig. 2).  
Ragulator, a pentameric complex composed of p18, p14, HBXIP, C7orf59, and 
MP1, controls the lysosomal localization and nucleotide loading state of the Rag 
GTPases.  Ragulator binds to SLC38A9, a lysosomal transmembrane protein 
recently identified as a likely arginine transporter, to act as a positive regulator of 




inhibit GATOR2 in leucine-deprived conditions (Wolfson, Chantranupong et al. 
2016).  Leucine-bound Sestrin-2 dissociate from GATOR2 resulting in inhibition 
of GATOR1 (Wolfson and Sabatini 2017).  How Sestrins inhibit GATOR2 is 
unknown, though reports indicate that a conformational change occurs in Sestrin-
2 upon leucine binding  (Saxton, Knockenhauer et al. 2016).  Another set of 
arginine sensors, CASTOR1/2, were identified to bind to GATOR2 under 
arginine-deprived conditions, thereby inhibiting its action.  Together these amino 
acid sensors regulate the Rag heterodimer.  In the GTP-bound RagA/B GDP-
bound RagC/D state, the heterodimer binds to raptor in mTORC1, initiating its 
translocation to the lysosome (Sancak, Peterson et al. 2008).  Ragulator 
facilitates the interaction of Rheb with mTORC1, ensuring that ample amino 
acids are available regardless of other growth signals (Sancak, Bar-Peled et al. 
2010)  
Ragulator is also shown to interact with the lysosomal vacuolar H+-adenoside 
triphosphate ATPase (v-ATPase), an essential component for amino acid  
activation of mTORC1 (Zoncu, Bar-Peled et al. 2011).  Under amino acid 
deprived conditions, v-ATPas, Ragulator and Rags form a tightly bound super 
complex preventing mTORC1 from associating with the lysosomal surface.  
Amino acid accumulation in the lysosomal lumen activates Ragulator GEF 
activity in a v-ATPase-dependent fashion (Zoncu, Bar-Peled et al. 2011). Loss of 
v-ATPase results in blocking of amino acid-induced lysosomal translocation of 




the v-ATPase, thus placing v-ATPase activity upstream of Ragulator (Bar-Peled, 
Schweitzer et al. 2012).  
 1.1.4. Glucose sensing 
AMPK, a heterotrimeric complex comprised of a catalytic unit and two regulatory 
subunits plays an important role in glucose and lipid metabolism (Winder, Martin 
et al. 1999).  In mammals, two genes (α1 and α2) encode for the α catalytic 
subunit, while two genes (β1 and β2) encode regulatory β subunit, and three 
genes (γ1, γ2 and γ3) encode the γ subunit (Li, Xu et al. 2011). 
Mammalian AMPK is activated by rising AMP/ATP and ADP/ATP ratios, and 
switches on alternative catabolic pathways to generate additional ATP. In 
parallel, AMPK switches off anabolic pathways to reduce ATP consumption 
(Dennis, Jaeschke et al. 2001).  AMP-bound AMPK is in a conformational state 
that allows for easier phosphorylation to occur on Thr172, while  ATP reverses the 
confirmation state  (Woods, Vertommen et al. 2003).  ADP mimics AMP 
activation of AMPK, except for the allosteric activation. Thr172 phosphorylated 
AMPK forms a complex with AXIN, a scaffold protein, and LKB1 that is enhanced 
by AMP (Zhang, Guo et al. 2013).  Co-precipitation studies suggest that AXIN 
binds LKB1 constitutively, but that AMP promoted the interaction between AXIN 
and AMPK (Zhang, Guo et al. 2013).   
A Ragulator SU p18 interacts with AXIN on the lysosomal surface (Zhang, Jiang 
et al. 2014).  Knockdown of p18 in mouse embryonic fibroblasts blunted AMPK 




reduced AMPK activation, while association with AXIN, LKB1, AMPK, p18 and 
vATPase is increased under glucose starvation.  The Ragulator complex 
provides docking sites for the AXIN complex to translocate to the lysosome 
(Zhang, Jiang et al. 2014).   
Aldolase, the glycolytic enzyme responsible for the conversion of fructose-1, 6-
bisphosphate (FBP) to glyceraldehydes-3-phosphate and dihydroxyacetone 
phosphate, acts as glucose sensor to regulate AMPK activation.  FBP is depleted 
quickly under glucose starvation conditions, leaving aldolase unoccupied.  When 
unoccupied by FBP, aldolase promotes the formation of lysosomal complexes 
containing v-ATPase, Ragulator, AXIN, LKB1 and AMPK (Zhang, Hawley et al. 
2017).  Knockdown of aldolase activates AMPK even in glucose rich 
environments, suggesting that aldolase is required for FBP to prevent AMPK 
activation (Zhang, Hawley et al. 2017).  FBP disrupts the association of AXIN and 
LKB1 with v-ATPase and regulator.  This effect is independent of the ADP/ATP 
and AMP/ATP mechanism towards AMPK activation. 
 1.1.5. Energy stress and hypoxia 
Energy or glucose deprivation, detected by a drop in intracellular ATP, leads to a 
rise in intracellular AMP to activate AMP-activated protein kinase (AMPK), which 
phosphorylates TSC2 on Ser1387 and Thr1271, thereby activating TSC1/2 complex 
and inhibiting mTORC1 (Inoki, Zhu et al. 2003).  In addition, AMPK directly 
phosphorylates raptor on Ser722 and Ser792 which is also required for suppression 





Figure 2.  Amino Acid Sensing Pathway Upstream of mTORC1 






Furthermore, in response to starvation, cells increase transcription of REDD1/2, 
a hypoxia-inducible factor-1 (HIF-1) target gene also known as RTP801, to inhibit 
mTORC1 (Sofer, Lei et al. 2005).  REDD1 is necessary to signal energy 
deprivation to mTORC1 as REDD1 knockout cells fail to inhibit mTORC1 under 
ATP depleted conditions (Brugarolas, Lei et al. 2004, Sofer, Lei et al. 2005). 
Hypoxia suppresses mTORC1 activity through similar mechanisms involving 
REDD1/2 and AMPK through activation of HIF-1 (Shoshani, Faerman et al. 
2002).  Oxygen activates HIF-1 to increase transcription of REDD1/2, thus 
inhibiting mTORC1 activity (Brugarolas, Lei et al. 2004).  After prolonged 
exposure to hypoxic conditions, however, mTORC1 activity is inhibited by an 
unknown mechanism independent of TSC1/2 complex (Liu, Cash et al. 2006)  
Additionally, promyelocytic leukemia (PML) tumor suppressor binds to mTOR 
under hypoxic conditions preventing association with Rheb and seizing mTOR in 
nuclear bodies (Bernardi, Guernah et al. 2006) 
 1.2.  Downstream effects of mTORC1 
   1.2.1.  Protein synthesis 
mTORC1 plays a key role in the promotion of protein synthesis as a response to 
growth signals, by directly phosphorylating eukaryotic translation initiation factor 
4E- binding protein (4E-BP1) on Thr36 and Thr45. (Burnett, Barrow et al. 1998).  
The 4E-BP1/2 complex interacts with eIF4E, located on the 5'-cap of mRNAs, to 




phosphorylated, 4EBP1/2 dissociate from eIF4E allowing additional eukaryotic 
translation initiation complexes (eIF4G and eIF4A) (Sonenberg and Hinnebusch 
2009) to form the active initiation complex for translation (Burnett, Barrow et al. 
1998, Gingras, Raught et al. 1999, Gingras, Gygi et al. 1999).   
In addition, it was suggested that mTORC1 acutely controls translation of 
mRNAs possessing 5'-terminal oligopyrimidine (TOP) tracts (Jefferies, Reinhard 
et al. 1994), a subset of mRNAs encoding components of translation crucial to 
scaling protein synthesis within the cell.  The mechanism of this effect is still 
unclear. 
Ribosomal S6 protein kinases S6K1,comprised of the p70 and p85 isoforms, and 
S6K2 are direct downstream targets of mTORC1 that control transcription, 
translation, cell growth and cellular metabolism (Magnuson, Ekim et al. 2012).  
S6K activates the eIF4A RNA helicase activity by phosphorylating and recruiting 
eIF4B and phosphorylating and inhibiting programmed cell death 4 protein 
(PDCD4), which degrades eIF4A (Dorrello, Peschiaroli et al. 2006, Dennis, 
Jefferson et al. 2012).   
mTORC1 activates the regulatory element tripartite motif-containing protein-24 
(TIF-1A), which promotes its interaction with RNA Polymerase I (Pol I) and the 
expression of ribosomal RNA (rRNA) (Mayer, Zhao et al. 2004). Also, mTORC1 
phosphorylates and inhibits Maf1, a Pol III repressor, inducing transcription of 5S 
rRNA and transfer RNA (tRNA) (Kantidakis, Ramsbottom et al. 2010, Shor, Wu 




   1.2.2  Lipid synthesis 
mTORC1 signaling is crucial for the formation and maintenance of adipose 
tissue, also known as adipogenesis, to fully store and supply energy for the 
organism (Laplante and Sabatini 2009).  In development, mTORC1 is 
responsible, through S6K1, to commit embryonic stem cells into early 
adiopogenic precursors (Gagnon, Lau et al. 2001, Kim and Chen 2004, Polak, 
Cybulski et al. 2008).  Through an unknown mechanism, mTORC1 promotes 
cleavage and translocation of the sterol regulatory element-binding protein-1 
(SREBP-1), a transcription factor that regulates lipid homeostasis, by increasing 
expression of acetyl-CoA carboxylase (ACC) (Brown, Stefanovic-Racic et al. 
2007), acyl-CoA lyase (ACLY), fatty acid synthase (FASN) (Peng, Golub et al. 
2002), glycerol-3-phosphate acyltransferase (GK), glucokinase (GK) and 
stearoyl-CoA desaturase-1 (SCD1) (Mauvoisin, Rocque et al. 2007, Bakan and 
Laplante 2012).   
4E-BP1/2 also promotes adipogenesis through increasing expression of 
peroxisome proliferator-activated receptor-γ (PPARγ) and CCAAT/enhancer 
binding protein-α (C/EBPα), two late-phase adipocyte differentiation transcription 
factors (Kim and Chen 2004). Mice lacking 4E-BP1 and 4E-BP2 showed reduced 
energy expenditure, reduced lipolysis and increased adipogenesis (Le Bacquer, 
Petroulakis et al. 2007).  Activation of these transcription factors lead to 
stimulation of fatty acid uptake, synthesis, esterification and storage in the 




Suppression of mTORC1 in-vitro in 3T3-L1 adipocytes and in-vivo by knockdown 
of raptor led to severe reduction in adipogenesis (Polak, Cybulski et al. 2008).  
Adipocyte-specific raptor knockdown mice were protected against diet-induced 
obesity, exhibited improved insulin sensitivity and were observed to have smaller 
and fewer white adipose tissue (WAT) cells in spite of no changes of caloric 
intake, lipolysis and lipid absorption from food intake (Polak, Cybulski et al. 
2008). 
 1.3.  Overview of mTORC2 signaling 
Responsible for regulating cell survival, metabolism and cytoskeletal organization 
for cells, mTORC2 controls several members of the AGC (protein kinase A, G 
and C) kinase family, including Akt, serum-and glucocorticoid-induced protein 
kinase 1 (SGK1) and protein kinase C-α (PKC-α). In vitro, mTORC2 activates 
Akt, through phosphorylating Ser473, to inhibit PRAS40 and TSC1/2 complex 
(Sarbassov, Guertin et al. 2005), though this has not been observed in vivo.  
Ablation of mTORC2 partially impairs the ability of Akt to phosphorylate and 
inhibit FoxO1 and FoxO3, but TSC2 and GSK3-activity remain unaffected 
(Guertin, Stevens et al. 2006).  FoxO1 is responsible for stimulating lipolysis, by 
activating ATGL transcription (Chakrabarti and Kandror 2009); inhibiting 
adipogenesis, by preventing PPARγ transcription (Farmer 2003), and inhibiting 
gluconeogenesis, through activating phosphoenolpyruvate carboxykinase 
(Nakae, Kitamura et al. 2001).  Additionally, FoxO1 promotes apoptosis, by 




suppressing cyclin D1 and cyclin D2 (Lu and Huang 2011).  SGK1, a kinase 
involved in stimulating sodium transport into epithelial cells and growth, is 
phosphorylated at Ser422 by mTORC2 and controls FOXO1/3a phosphorylation 
on residues also phosphorylated by Akt.  The last kinase activated by mTORC2, 
protein kinase C-α (PKC-α), regulates cell shape through affecting the actin 
cytoskeleton alongside other effectors such as paxilin and small GTPases Rho 
and Rac (Jacinto, Loewith et al. 2004, Sarbassov, Ali et al. 2004)  
 1.4.  Metabolic dysfunction and manifestation of diabetes through 
insulin resistance 
The ability to expand and retract in size, gives adipose tissue huge flexibility in 
dealing with energy supply, however, complications can arise in both extremes 
giving rise to systemic diseases, such as obesity and diabetes mellitus (T2D).  
(Gesta, Tseng et al. 2007).  As WAT expands by both hyperplasia and 
hypertrophy (Choe, Huh et al. 2016), both the visceral and subcutaneous fat 
depots leak and expose FFAs, adipokines and cytokines exposing more factors 
throughout the body causing systemic insulin resistance and ectopic fat 
deposition on organs such as the liver (Choe, Huh et al. 2016). 
Obese and insulin resistant subjects treated with catecholamines had reduced 
lipolysis in subcutaneous fat while visceral fat became more lipolytic (Arner and 
Langin 2014).  The increasing size of adipose tissue in obese subjects correlated 
with higher basal lipolysis (Lafontan and Langin 2009).  Insulin fails to suppress 





Addition of dibutytyl cAMP, a phosphodiesterase resistant analogue of cAMP, to 
isolated adipocytes obtained from obese and non-obese subjects greatly reduced 
the lipolytic activity in the obese cohort compared to the control cohort (Large, 
Reynisdottir et al. 1999).  This effect is attributed to downstream effects of 
obesity on adrenergic receptor signaling, reducing the maximal stimulation by 
cAMP to activate PKA and phosphorylate hormone sensitive lipase (HSL) and 
adipose triglyceride lipase (ATGL) (Duncan, Ahmadian et al. 2007). 
In addition to promoting growth of the adipocyte, mTORC1 over-activation in 
obese subjects develops insulin resistance in adipose tissue through S6K-
mediated inhibition of insulin signaling (Um, Frigerio et al. 2004).  mTORC1 
phosphorylates and stabilizes the adaptor protein growth factor receptor-bound 
protein 10 (Grb10) at sites Ser501 and Ser503 (Hsu, Kang et al. 2011, Yu, Yoon et 
al. 2011).  Grb10 expression suppresses activation of PI3K by inhibiting insulin 
receptor-dependent phosphorylation of IRS (Lim, Riedel et al. 2004).   
In a nutritional surplus environment, glucose and leucine activate mTOR resulting 
in Raptor directly binding and serving as a scaffold for mTOR-mediated 
phosphorylation of IRS-1 on Ser307, Ser632 and Ser1097 (Harrington, Findlay et al. 
2004, Copps, Hançer et al. 2016).  This prevents IRS-1 from binding to PI3-
kinase upon insulin stimulation, thus suppressing PI3k/Akt signaling, dissociating 




al. 2004) and eventually may lead to degradation of IRS-1 (Tzatsos and Kandror 
2006).  
With obesity being the major risk factor for the development of insulin resistance 
and type 2 diabetes, over-activation of mTORC1 exacerbates systemic insulin 
resistance, as fat depots pathologically expands from overeating.  The hypoxic 
conditions observed contribute to activation of hypoxia-inducible factor-1α (HIF-
α), a subunit of the transcription factor HIF-1. In adipose tissue of obese patients, 
HIF-α levels were found to be elevated prior to surgery-induced weight loss, 
which corrected protein expression of HIF-α (Cancello, Henegar et al. 2005). 
Hypoxia results in decreased ubiquitination of HIF- α caused by missense 
mutations increasing its expression by preventing ubiquitination-proteasome 
mediated degradation.  HIF-α translocates to the nucleus, dimerizes with HIF-1β 
(hydrocarbon receptor nuclear translocator) to activate VEGF transcription, 
promoting angiogenesis (Semenza 2002).  3T3-L1 adipocytes subjected to 
hypoxic conditions secret less adiponectin, an adipocytokine that suppresses 
inflammation and apoptosis while enhancing insulin sensitivity, through the PKR-
like ER kinase (PERK) and inositol-requiring enzyme 1 (IRE) unfolded protein 
response (Guo, Jin et al. 2017).   
Prolonged high-fat feeding in mice leads to increased endoplasmic reticulum 
(ER) stress in both the liver and adipose tissue, contributing to the development 
of insulin resistance (Ozcan, Cao et al. 2004).  Increased demand and errors in 




leading to apoptosis, inflammation and hepatosteatosis (Delibegovic, Zimmer et 
al. 2009).  The inflammatory pathways mediated by c-Jun N-terminal kinase 
(JNK) and nuclear factor κB (NFκB) are upregulated in adipose tissue of insulin 
resistant subjects (Gregor and Hotamisligil 2007). Reactive oxygen species 
(ROS) are overproduced and not readily cleared, causing oxidative damage and 
activating multiple stress and inflammatory signaling pathways (Xue, Piao et al. 
2005).  
The inflammatory state of adipocytes results in activation of cyclic AMP-
responsive element-binding protein (CREB), triggering expression of ATF3 to 
suppress transcription of adiponectin and glucose transporter 4 (GLUT4) (Qi, 
Saberi et al. 2009).  Normally, CREB is activated in low nutrient environment via 
PKA (Montminy, Koo et al. 2004).  Impairment of IR signaling together with pro-
inflammatory responses results in deficient mTORC1 activation, resulting in 
poorer inhibition of lipolysis and an increase in FA release.   
Glucose homeostasis is maintained through management of glucose 
transporters, with skeletal muscles providing the largest pool of glucose uptake 
during food intake or insulin action.  Increased activation of mTORC1 in muscles 
by caloric excess produces S6K1-mediated feedback inhibition of insulin 
signaling, resulting in a reduction of Glut4 translocation to the cell surface and 
diminishing glucose uptake.  Lack of mTORC1 stimulation in muscles of obese 
subjects resulted in a rise of protein catabolism (Wang, Hu et al. 2006).  




subjects may be a result of many other signaling pathways involved (Sparks, Xie 
et al. 2005).   
Insulin-resistant muscles are deficient in glucose uptake, resulting in 
hyperglycemia.  In pancreatic β-cells, responsible for insulin production, 
constitutive mTORC1 activation causes hypoglycemia, hyperinsulinemia and 
improved glucose tolerance in mice in addition to hyperplasia and hypertrophy of 
β-cells (Rachdi, Balcazar et al. 2008).  Sustained activation of mTORC1/S6K in 
insulin-resistant subjects, however, further worsens receptor activation placing 
more stress on β-cells leading to apoptosis and manifestation of T2D.  
In insulin resistant organisms, the liver is burdened with excessive adipocyte 
lipolysis products (glycerol and FAs), lactate and amino acids.  Normally, insulin 
stimulation activates AKT to phosphorylate FOXO1 at residues Thr24, Ser256 and 
Ser319, thus excluding FOXO12 from the nucleus, disabling its transcriptional 
factor activity.  Insulin impaired stimulation, however fails to suppress FoxO1  
transcription activity, thus promoting gluconeogenesis and exacerbating 
hyperglycemia (Nakae, Barr et al. 2000) (Czech 2017).  Within hepatocytes, 
sustained mTORC1 activation with caloric surplus led to increased lipogenesis 
through stimulation of SREBP1 (Donnelly, Smith et al. 2005).  In insulin resistant 
subjects, excessive circulating FAs deposit ectopically in the liver resulting in the 
development of non-alcoholic fatty liver disease, the clinical hallmark in obese 





2.  Lipid droplets  
The lipid droplet (LD) is a multi-functional organelle that is responsible for the 
storage and release of energy.   
Adipose tissue is designed to maintain LDs and supply energy to the whole 
organism.  WAT contains one large LD and brown adipose tissue (BAT) - 
multiple smaller droplets.  The LD core is composed mostly of triacylglycerol 
(TAG) and cholesterol ester (CE) (Zhang and Liu 2017), though retinyl ester 
(O'Mahony, Wroblewski et al. 2015) and polyhydroxyalkanoate (Murphy 2012) 
have been found in LDs.  Surrounding the core of neutral lipids are phospholipids 
forming a monolayer in conjunction with severed associated proteins.  In 
mammalian cells, the LD monolayer is comprised mainly of phosphatidylcholine 
(PC) followed by phosphatidylethanolamine (PE), phosphatidylinositol (PI), 
phosphatidylserine (PS), sphingomyelin (SM) and lyso forms of PC and PE 
(McIntosh, Storey et al. 2010, Chitraju, Trotzmuller et al. 2012).   
 
 2.1.  Lipid droplet formation  
How emerging LDs form in the ER is not completely understood, but 
evolutionarily conserved proteins have been identified to participate in de novo 
LD biogenesis.  Seipin, a liposytrophy protein encoded by the Berardinelli-Seip 
Congenital Lipodystrophy Type 2 (BSCL2) gene, assists in droplet morphology 




phosphatase (PAP), generate diacylglycerol (DAG) and contribute to the 
formation of LDs (Karanasios, Barbosa et al. 2013).  Disruption of the yeast 
ortholog of Lipins, Pah1p, resulted in a significant reduction in droplet number, 
but not in total neutral lipid levels (Adeyo, Horn et al. 2011).  Fat-storage-inducing 
transmembrane proteins 1 and 2 (FIT1 and FIT2) localize to the ER and bind to 
triolein, a symmetrical triglyceride derived from glycerol and three units of oleic 
acid, to concentrate TGs between the leaflets of the ER, eventually leading to 
budding of LD (Gross, Zhan et al. 2011, Goh and Silver 2013) .  
 
 2.2.  Lipid droplet proteins  
LD surface proteins regulate the intracellular interactions and homeostasis of the 
LDs.  Over two hundred different proteins were identified through proteomic 
studies to localize to the LD surface (Brasaemle, Dolios et al. 2004).  Perilipin-1 
(PLIN), adipocyte differentiation related protein (ADRP) and tail-interacting 
protein of 47 kDa, TIP47, are the predominant proteins termed the PAT family of 
LD proteins that regulate cellular lipid stores (Bickel, Tansey et al. 2009).  In 
mammals, the PAT proteins are comprised of PLIN, ADRP, TIP47, S3-12 (Bickel, 
Tansey et al. 2009) and OXPAT (Yamaguchi, Matsushita et al. 2006, Dalen, Dahl 
et al. 2007).  Sharing sequence similarity, these proteins interface between LD 
and their cellular environment either constitutively or via metabolic stimuli (Bickel, 




The PLIN gene gives rise to at least three protein isoforms (PLIN A, B and C) 
sharing a common N-terminal region which contains the PAT domain, PKA 
binding sites, the acidic loop region and hydrophobic regions that anchor the 
proteins to LDs (Subramanian, Garcia et al. 2004) (Lu, Gruia-Gray et al. 2001).  
PPARγ, which receives input from constitutive coactivator of PPARγ (CCPG) and 
tribbles homolog 3 (TRB3), regulates PLIN expression.  PPARγ coactivator-1 
alpha (PGC-1α) activates estrogen receptor related receptor alpha (ERRα)-
dependent PLIN expression, whereas small heterodimer partner (SHP) 
represses expression (Nagai, Shimizu et al. 2004, Akter, Yamaguchi et al. 2008).   
In mammals, cell death-inducing DNA fragmentation factor A (DEFA)-like effector 
(Cide) family proteins that includes CideA, CideB and fat-specific protein 27 
(FSP27 also known as CideC), surround the LD to control lipid growth and 
metabolism  (Xu, Zhou et al. 2012).  CideA is expressed primarily in BAT. It 
supposedly suppresses the activity of uncoupling protein 1 (UCP-1), a 
mitochondrial protein used to promote thermogenesis, to control the rate of 
energy consumption and temperature production (Inohara, Koseki et al. 1998, 
Zhou, Yon Toh et al. 2003).  CideA-deficient mice stimulated by cold exposure 
had higher metabolic rate,  increased lipolysis in BAT and core body temperature 
while maintaining a lean phenotype with less white adipose tissue mass (Zhou, 
Yon Toh et al. 2003).  Cidea was also found to act as a transcriptional coactivator 
of CCAAT/enhancer-binding protein β (C/EBPβ), by promoting the association of 




from HDAC1, a corepressor of C/EBPβ (Wang, Lv et al. 2012).  CideB is highly 
expressed in liver (Inohara, Koseki et al. 1998) and kidney (Li, Ye et al. 2007) 
and plays a role in maintaining LD-LD contact sites, stimulating growth (Xu, Wu 
et al. 2016) and secretion of very-low-density lipoprotein (VLDL) (Ye, Li et al. 
2009, Chen, Norris et al. 2010).   
Studies of TG storage and formation of large LDs in 3T3-L1 adipocytes 
(Brasaemle, Dolios et al. 2004) and WAT (Nishino, Tamori et al. 2008) have 
contributed to the discovery of FSP27.  FSP27 KO mice display multilocular LD 
formation in WAT and hepatic steatosis from excessive release of FAs into the 
blood (Brasaemle, Dolios et al. 2004).  FSP27 is also detected in the nucleus and 
interacts with C/EBPβ to regulate expression of a subset of C/EBPβ downstream 
targets within adipocytes (Wang, Lv et al. 2012) 
 
 2.3.  Regulation of lipid droplet growth and fusion   
The morphology of the LD depends on multiple factors.  One possible 
mechanism to explain LD growth in the adipocyte is SNARE-mediated fusion of 
smaller LDs (Bostrom, Andersson et al. 2007).  Another mechanism suggests 
lateral transfer of synthesized neutral lipids from the ER to the LDs (Thiele and 
Spandl 2008).  The Cide family is essential for the stability of unilocular LD 
formation and plays a protective role in regulating the rate of lipolysis by 
controlling the accessibility of the LD to lipolytic enzymes (Nishimoto and Tamori 




(C/EBP) (Wang, Lang et al. 2014), two factors needed to stimulate adipocyte 
differentiation, are known transcriptional regulators of FSP27 expression within 
the adipocyte.  FSP27 expression in humans is tied to improved insulin sensitivity 
due to increased lipid accumulation in adipose tissue, thus minimizing ectopic fat 
deposition and lipotoxicity (Nishimoto and Tamori 2017).  Overexpression of 
FSP27 led to enlargement of LDs and increased TG accumulation in non-
adipose cells (Puri, Konda et al. 2007, Keller, Petrie et al. 2008, Jambunathan, 
Yin et al. 2011), whereas depletion of FSP27 in adipocytes led to strong increase 
in lipolysis and reduction in LD size (Nishino, Tamori et al. 2008, Jambunathan, 
Yin et al. 2011).  FSP27 KO mice displayed increased energy expenditure due to 
increased free fatty acid oxidation and mitochondrial biogenesis in WAT (Nishino, 
Tamori et al. 2008).   
FSP27 dimerizes at LD-LD contact sites via its n-terminal domain (amino acids 
131 - 239) allowing for the transfer of lipids across the sites to relieve internal 
pressure in smaller LDs (Gong, Sun et al. 2011, Sun, Gong et al. 2013). Perilipin-
1 interacts with the N-terminal domain of FSP27 enhancing FSP27-dependent 
lipid transfer and LD growth (Sun, Gong et al. 2013). Perilipin1-deficient cells 
treated with exogenous truncated perilipin-1, lacking the region (amino acids 
292-319) that interacts with the N-terminal domain of FSP27, restores lipolytic 
activity, but not FSP27-mediated LD fusion and pore widening activity (Sun, 




Rab GTPases, such as Rab8a, are known to positively regulate FSP27-mediated 
LD fusion (Wu, Xu et al. 2014).  Rab8a-GDP binds to the C-terminal domain of 
FSP27 and greatly improves LD fusion compared to Rab8a-GTP.  Knockdown of 
Rab8a results in reduced LD size and fusion in both pre- and mature adipocytes; 
(Wu, Xu et al. 2014).  The GTP-activating protein (GAP) of Rab8a, AS160, 
interacts with the N-terminal domain of FSP27, allowing the GAP to convert 
Rab8a-GTP rapidly into Rab8a-GDP and stabilize the trimeric complex to 
enhance LD fusion. Mammalian suppressor of Sec4 (MSS4), a nucleotide 
exchange factor, negatively regulates LD fusion through a suggested mechanism 
of stabilizing Rab8a in a nucleotide-free state, preventing Rab8a to associate 
with FSP27 (Fig. 3) (Xu, Wu et al. 2016). 
In the basal state, the N-terminal domain (amino acids 120-220) of FSP27 
interacts with LD-associated ATGL, significantly preventing its ability to interact 
with CGI-58 to enhance lipolysis.  FSP27 functions to maintain LD stability to 
reduce FA ectopic deposition, thus reducing insulin resistance and lipotoxicity. 
This is done primarily by controlling the available surface area for lipolytic 
enzymes.  Knockdown of FSP27 through siRNA in adipocytes yielded a strong 
increase in the ATGL mRNA, suggesting regulation at the level of transcription 
(Singh, Kaur et al. 2014).  FSP27 suppresses activity of the ATGL promoter but 
fails to do so when the Egr1 binding site is truncated or mutated.  
Overexpression of FSP27 and Egr1 produced a synergistic effect on the ATGL 




and within the nucleus as well, suggesting that FSP27 inhibits lipolysis by 
interacting with Egr1 to enhance its effect on ATGL (Yonezawa, Kurata et al. 
2011, Singh, Kaur et al. 2014).   
 
Figure 3.  Diagram of CIDE-mediated LD fusion and transfer of TG . 






3.  Adipose tissue lipolysis 
LDs are responsible for the storage and release of fatty acids during feeding and 
fasting cycles.  The complete hydrolysis of TG into bio-available fatty acids (FAs) 
and glycerol requires three enzymes: adipose triglyceride lipase (ATGL) that 
cleaves the first FA from TG, hormone sensitive lipase (HSL) which cleaves the 
second FA from diacylglycerol, and monoacylglycerol lipase (MGL) which 
cleaves monoacylglycerol into FA and glycerol (Jenkins, Mancuso et al. 2004, 
Villena, Roy et al. 2004, Zimmermann 2004, Grönke, Mildner et al. 2005, Kurat, 
Natter et al. 2005, Haemmerle 2006, Kershaw 2006, Smirnova, Goldberg et al. 
2006, Miyoshi, Perfield et al. 2008, Zechner, Kienesberger et al. 2008, Bezaire, 
Mairal et al. 2009). 
Regulation of lipolysis occurs at several levels.  Catecholamines, upon binding to 
β-adrenergic receptors coupled to adenylate cyclase, increase cAMP production 
and activate protein kinase A (PKA).  PKA catalyzes and activates hormone 
sensitive lipase (HSL) by phosphorylating Ser563, Ser659 and Ser660 residues and 
recruiting the lipase to the LD (Holm 2003, Su, Sztalryd et al. 2003).  PKA also 
phosphorylates PLIN-A (residues Ser81, Ser222, Ser276, Ser433, Ser492 and Ser517) 
causing the following changes.  1. CGI-58, which normally binds PLIN-A and is 
an activator of the acyl hydrolase activity of ATGL, dissociates from the droplet 
surface (Duncan, Ahmadian et al. 2007).  2.  Phosphorylated HSL translocates to 
the LD and binds perilipin along with fatty acid binding protein (AFABP) (Sahu-




Ser517 to initiate lipolysis (Egan, Greenberg et al. 1990, Miyoshi, Perfield et al. 
2007).  
Conversely, protein phosphatase 1 dephosphorylates PLIN-1 (Egan, Greenberg 
et al. 1990).   
 
 3.1.  mTORC1 regulation of lipolysis 
ATGL regulation occurs not just post-translationally, but also, through its 
expression.  Upon starvation or physical exercise, biosynthesis of ATGL is 
increased allowing TG lipolysis to occur and supply energy to peripheral tissues 
(Chakrabarti, English et al. 2010, Schoiswohl, Schweiger et al. 2010, Yao-
Borengasser, Varma et al. 2011). In the fed state, however, adipocytes restrict 
the expression of ATGL which promotes fat storage (Zechner, Kienesberger et 
al. 2008, Lord and Brown 2012, Kratky, Obrowsky et al. 2014, Nielsen, Jessen et 
al. 2014). 
mTORC1 activation suppresses ATGL expression via the primary early growth 
response transcription factor Egr1 that directly binds to the ATGL promoter and 
inhibits its activity (Chakrabarti, Kim et al. 2013).  Insulin dramatically increases 
expression of Egr1 via an mTORC1-mediated mechanism (Chakrabarti, Kim et 
al. 2013), which takes place at the level of translation (Singh, Shin et al. 2015).  
The Egr1 mRNA lacks 5’-TOP but contains a highly structured 5'-UTR region with 
an estimated folding energy of 103.56 kcal/mol  (Singh, Shin et al. 2015). 




motifs, a hallmark of helicase eIF-4A-dependent transcripts (Chakrabarti, Kim et 
al. 2013).  Thereby mTORC1 activates expression of Egr1 at the level of 
translation through phosphorylation of 4EBP1/2. 
 
4.  Leptin 
 4.1.  Energy homeostasis and satiety 
Discovery of leptin came during the time where the scientific community focused 
on an organism's ability to maintain homeostasis from varying external stimuli 
including food (Keesey and Powley 2008).   Gordon Kennedy coined the 
“lipostatic” theory to explain the mechanism of homeostasis which claims that the 
body fat of an individual is constantly measured and maintained at a constant 
level, serving as a negative feedback loop  (Anand and Brobeck 1951).  Ablating 
the ventromedial portion of the hypothalamus (VMH) produced the phenotype in 
rodents of hyperphagia and obesity (Anand and Brobeck 1951).   Furthering this 
groundwork, Romaine Hervey utilized parabiosis, or the surgical joining of two 
living organisms to share the contents of the combined circulatory system, on 
VMH lesioned rats partnered with wild-type rats (Hervey 1959).   VMH lesioned 
rats maintained the hyperphagia and obesity phenotype, whereas their partner, 
with intact hypothalami, became hypophagic, lost significant fat mass and 
eventually starved to death (Hervey 1959).  Loss of the VMH disrupted 
communication to the brain with a blood-borne agent responsible for appetite 
suppression; this blood-borne agent is overproduced as a response to feedback 




organism severely suppressing appetite resulting in excessive weight loss (Harris 
2013, Hervey 2013).   
In parallel with this discovery, a murine model from the Jackson laboratory 
showed a similar phenotype to Kennedy’s surgeries; non-inbred V strain mice 
were born plumper compared to their counterparts, were hyperphagic and 
developed obesity and diabetes early into adulthood (Ingalls, Dickie et al. 1950).  
This was later characterized to be due to a single autosomal recessive gene 
mutation located on proximal chromosome 6 later named ob, short for obese 
(Dickie and Lane 1957).  An additional murine model with similar phenotypes 
was later discovered in C57BL/ks mice and identified to have an autosomal 
recessive gene located on chromosome 4, designated diabetes (db) (Hummel, 
Dickie et al. 1966).  Parabiosis of ob/ob with db/db showed a strong reduction in 
food intake, fat mass, insulinemia in ob/ob mice leading to death by starvation 
due to hypoglycemia; whereas the db/db mouse continued to increase in body 
weight and adipose tissue mass (Ingalls, Dickie et al. 1950, Coleman 1978).  
Coleman concluded that a “blood-borne factor”, overproduced yet unresponsive 
in db/db mice, crosses over to the blood supply of the partnered ob/ob mice, 
lacking this factor due to mutation, resulting in suppression of food intake and 
loss of body weight (Coleman 1978).  Body mass is proportionate to the 
production of this factor, as larger individuals overproduce it when compared to 
their leaner counterparts.  Lastly, that this factor acts on the hypothalamus for its 




to db/db, under parabiosis with rats maintaining intact hypothalami (Hervey 
1959). 
 4.2.  Genetic mapping and cloning of the ob gene that encodes leptin   
The genetic and physical mapping of both the ob and db genes were done in 
mice and humans by the Friedman lab (Bahary, Leibel et al. 1990, Friedman, 
Leibel et al. 1991, Friedman, Leibel et al. 1991, Truett, Bahary et al. 1991, 
Bahary, McGraw et al. 1993, Leibel, Bahary et al. 1993, Zhang, Proenca et al. 
1994).  The murine ob gene was identified as a 167 amino acid secreted protein 
located on chromosome 6 that originates in white adipose tissue; the human 
homolog located on chromosome 7q32.1 is 84% identical to the murine peptide 
(Green, Maffei et al. 1995, Maffei, Fei et al. 1995).  The ob gene mutation was 
due to one C to T transition which converted codon 105 into a stop codon 
(Zhang, Proenca et al. 1994).  ob was later officially named leptin, sharing the 
Greek root Leptos meaning thin, by Halaas et al (Halaas, Gajiwala et al. 1995).   
Antibodies produced against recombinant leptin protein detected a 16 kDa band 
in plasma of wild type mice that was absent in C57Bl6/J ob/ob mice and over-
expressed in db/db mice; leptin secreting into the bloodstream challenged the 
concept of passive energy storage for adipose tissue and progressed its 
classification to an active endocrine organ (Maffei, Fei et al. 1995).  The db gene 
was identified to be the receptor to which the hormone leptin binds to, thereby 
placing db, the leptin receptor located in the hypothalamus, downstream of leptin 




Administration of leptin to ob/ob mice through daily intraperitoneal injections 
resulted in decreased weight of adipose tissue, reduced food intake and lowered 
blood glucose and insulin levels.  Thirty days of daily injections converted ob/ob 
mice to normal wild type-like phenotype (Pelleymounter, Cullen et al. 1995).  
 4.3.  Leptin receptor and signaling pathway 
Upon the discovery of leptin, cognate receptor (LEPR) was shortly confirmed to 
be mutated in strains of db/db mice (Lee, Proenca et al. 1996, Lee, Li et al. 1997, 
Li, Ioffe et al. 1998), in fa/fa Zucker and fak/fak rats (Phillips, Liu et al. 1996, 
Strobel, Issad et al. 1998).  A proximal promoter (P1) produces, through 
alternative splicing, two different products: leptin receptor (LEPR) and Leptin 
Overlapping Transcript (LEPROT), which encodes endospanin-1 (Bailleul, 
Akerblom et al. 1997).  Additionally, a third distinct transcript is expressed from 
the second internal promoter (P2) creating different short LEPR isoforms (B219) 
that are hematopoietic cell-exclusive. 
LEPR, a homolog of other class I cytokine receptors, is identified as containing 6 
isoforms (Ob-Ra, Ob-Rb, Ob-Rc, Ob-Rd, Ob-Re and Ob-Rf); however, only the 
first four (Ob-Ra – Ob-Rd) are present in humans (Fig. 4).  These isoforms are 
dispersed in multiple organs such as the kidney, heart, ovaries, testes, pancreas, 
brain, spleen, gastrointestinal tract, liver and brain.  The isoforms share the first 
862 amino acids but differ in both the transmembrane domain within exon 16 and 
the lengths of their intracellular carboxyl terminal domain generated by 




but lacks a transmembrane domain.  Humans do not transcribe the Ob-Re 
isoform, rather proteolytic cleavage of transmembrane domains produces soluble 
LEPR to appear in circulation (Maamra, Ross et al. 2001).  The long LEPR 
isoform, Ob-Rb, contains a second box motif (Margetic, Gazzola et al. 2002) 
capable of activating all the known leptin-induced signaling pathways. The 
functions of the shorter isoforms are poorly understood, though some may be 
involved in leptin transport through the blood brain barrier and leptin clearance 
(Li, Ceccarini et al. 2013). 
The N-terminal portion of LEPR is composed of two conserved cytokine receptor 
homologous domains, CRH1 and CRH2, separated by a conserved 
immunoglobulin (Ig) domain.  Adjacent to the CRH2 domain are two fibronectin 
type 3 (FNIII) domains proximally located to the transmembrane domain.  Leptin 
binds to the N-terminal CRH2 domain in a 2:2 configuration pattern (Fig. 3) 
   4.3.1.  JAK/STAT signaling in hypothalamus 
Lacking intrinsic kinase activity, activated LEPR recruits Janus family tyrosine 
kinase (JAK2) to bind to the box 1 motif of LEPR located on amino acids 31-36 
(Bahrenberg, Behrmann et al. 2002, Kloek, Haq et al. 2002) and phosphorylate 
residues Tyr985, Tyr1077 and Tyr1138 (Bjorbaek and Kahn 2004, Kurzer, 
Argetsinger et al. 2004, Jiang, Li et al. 2008) in the cytoplasmic domain to recruit 
signal transducer and activator of transcription 3 (STAT3) (Sweeney 2002, Sahu 
2003, Ahima and Osei 2004, Hegyi, Fulop et al. 2004).  JAK2 phosphorylates 






Figure 4. Leptin receptor isoforms. 
CR = cytokine receptor domain, F-III = fibronectin type III domain, Box 1, 2, 3 = 






binds to the promoters and increases expression of pro-opiomelanocortin 
(POMC) and suppressor of cytokine signaling 3 (SOCS3), while repressing 
agouti-related peptide (AgRP) (Bjørbæk, Elmquist et al. 1998, Varela and 
Horvath 2012).  Accumulating evidence shows that STAT3 is critical for the 
leptin-mediated food intake and satiety, as disruption of its signaling induces 
severe obesity, increased food intake and insulin resistance in animal models 
(Bates, Stearns et al. 2003). 
STAT3 activation in POMC-expressing neurons, such as the arcuate nucleus of 
the hypothalamus, results in appetite suppression and satiation in rodents, 
similar to the physiological effects of leptin (Schwartz, Woods et al. 2000, 
Balthasar, Coppari et al. 2004, Hill, Elias et al. 2010).  AgRP, an orexigenic 
peptide, is normally activated by the hormone ghrelin and Neuropeptide Y (NPY) 
to escalate hunger and increase food intake, however STAT3 activation in AgRP-
expressing neurons results in suppressed transcription thus reducing appetite 
(Baskin, Hahn et al. 1999, Wilson, Bagnol et al. 1999, Mercer, Moar et al. 2000, 
Backberg, Madjid et al. 2004).  SOCS3  binds to phosphorylated Tyr985 and 
Tyr1077 in the LEPR OB-Rb receptor to compete against SHP2, which is required 
for leptin-activated ERK cascade (Villanueva and Myers 2008).  SOCS3 is 
capable of deactivating JAK2, thereby blocking STAT3 signaling (Sasaki, 





Phosphorylation of Ob-Rb at Tyr1077 recruits STAT5 which is also phosphorylated 
by JAK2, enabling its translocation into the nucleus.  STAT5 shows minor effects 
on regulating body weight and energy balance, as its disruption in Ob-Rb 
expressing cells is not as severe as what is observed with STAT3 signaling 
disruption (Patterson, Villanueva et al. 2012).  STAT5 deletion within the CNS 
has led to an obese phenotype with hyperleptinemia, insulin resistance and 
hyperphagia  
Other suppressors of LEPR include protein tyrosine phosphatase 1B (PTP1B), 
which dephosphorylates the leptin receptor-associated kinase, JAK2 (Zabolotny, 
Bence-Hanulec et al. 2002),  and T cell protein tyrosine phosphatase (TCPTP), 
which dephosphorylates STAT3 upon entry into the nucleus (Loh, Fukushima et 
al. 2011) (Zabolotny, Bence-Hanulec et al. 2002). 
   4.3.2.  The ERK cascade 
The ERK pathway in the POMC neurons in the arcuate nucleus of the 
hypothalamus plays an important role in regulation of food intake and energy 
balance (Rahmouni, Sigmund et al. 2009).  Phosphorylation of Ob-Rb at Tyr985 
recruits tyrosine phosphatase SH2-containing phosphatase-2 (SHP-2).  SHP-2 
binds to Tyr985, undergoes phosphorylation by JAK2 and binds to growth factor 
receptor-bound protein 2 (GRB2) leading to activation of the RAS/RAF/ERK 
pathway via son of sevenless homolog 1 (Sos1) (Hekerman, Zeidler et al. 2005, 
Frühbeck 2006, Qu, Chen et al. 2014).  The ERK pathway can be activated by 




Tyr985 followed by tyrosince phosphorylation of SHP-2.  The other is independent 
of tyrosine phosphorylation of LEPR but requires the phosphatase activity of 
SHP-2.  (Bjorbaek, Buchholz et al. 2001, Rahmouni, Sigmund et al. 2009). The 
cascade leads to the phosphorylation of extracellular signal-regulated kinase-1/2 
(ERK1/2) making its way into the nucleus and increasing the expression of cell 
proliferation and differentiation genes such as c-fox and early growth response 
protein 1 (Egr1) (Bjorbaek, Buchholz et al. 2001).   
Leptin activates p90 ribosomal S6 kinase (RSK), also known as MAPK-activated 
protein kinase-1 (MAPKAP-K1) that phosphorylates ribosomal protein S6 (rpS6) 
which is associated with cell growth and proliferation (Magnuson, Ekim et al. 
2012).  Both ERK and RSK are involved in the inhibition of tuberous sclerosis 1/2 
(TSC1/2). 
Evidence suggests that the ERK signaling pathway is involved in adjusting food 
intake and metabolism through leptin-mediated effects in the brain, though it is 
still uncertain if the effects are due to SHP-2 competing for binding to Tyr985 
against SOCS3 (Bjorbak, Lavery et al. 2000) 
 
   4.3.3. The PI3K (phosphatidylinositol 3-kinase)/PDE3B 
(phosphodiesterase 3b)/cAMP pathway 
The PI3K/PDE3b/cAMP pathway represents a key intersection between insulin 
and leptin signaling pathways (Hegyi, Fulop et al. 2004)  Leptin has been shown 




PDE3B and cAMP reduction (Zhao, Bornfeldt et al. 1998, Zhao, Shinohara et al. 
2000, Zhao, Huan et al. 2002).  Evidence first came from IRS2-null mice that 
expressed hyperphagia, hyperleptinemia and increased adiposity, though not as 
severe as db/db mice (Myers 2004).  Pharmacological inhibition of PI3K 
prevented leptin-induced repression of AgRP, thus repealing the appetite 
restriction effect of leptin (Niswender, Morton et al. 2001).   
Akt phosphorylates FOXO1 repressing its activity.  Phosphorylated on Thr24, 
Ser256 and Ser319 FOXO1 is retained in the cytoplasm by 14-3-3 proteins where it 
interacts with ubiquitin E3 ligases that induce its degradation (Ropelle, Pauli et al. 
2009, Xing, Li et al. 2018).  Unphosphorylated FOXO1 resides in the nucleus, 
stimulating transcription of orexigenic Neuropeptide Y (NPY) and AgRP, while 
also suppressing POMC expression through direct interaction with STAT3.    
 
   4.3.4.  The AMPK (adenosine monophosphate-activated protein kinase) 
Pathway 
Administration of leptin to mice induces p70S6 kinase to phosphorylate α2AMPK 
on Ser491, through a PI3K-Akt dependent mechanism, thus inhibiting AMPK 
within the arcuate, ventromedial, dorsomedial and paraventricular nuclei of the 
hypothalamus and presenting the phenotype of reduced body size and food 
intake (Dagon, Hur et al. 2012). 
Outside the hypothalamus, leptin was shown to stimulate fatty acid oxidation and 




hepatic AMPK through the CNS α-adrenergic effects of sympathetic nerves, 
regulating glucose and lipid metabolism (Miyamoto, Ebihara et al. 2012).   
 4.4.  Obesity and leptin 
Clinical implications of the newly discovered hormone leptin included direct 
symptom management of obesity within the expanding human population.  To 
patients with the rare case of leptin deficiency, daily leptin treatments corrected 
the neuroendocrine imbalance by suppressing appetite to within normal 
parameters (Farooqi, Jebb et al. 1999, Frank, Heni et al. 2013).  To the majority 
of the overweight population; however, the amount of energy excess stored in fat 
was proportional to circulating leptin levels; leptin treatment was unable to reduce 
body weight and food intake (Schwartz, Peskind et al. 1996, Schwartz and 
Seeley 1997, Van Heek, Compton et al. 1997).  Leptin treatment also showed 
little to no effect in lean, leptin sensitive, humans showing little promise as a 
weight loss miracle drug (Heymsfield, Greenberg et al. 1999).   
Obesity provides limitations for proper leptin delivery by means of poorer transfer 
through the blood-brain-barrier (BBB); in order to bypass the BBB leptin binds to 
a not yet identified saturable transport system (Banks, Kastin et al. 1996).  
Through studies in obese rats, it was found that obesity decreases the 
effectiveness of BBB transport of leptin, thus describing peripheral leptin 
resistance as a link to eating behavior changes (Banks, King et al. 2001, 




injections were able to partially reduce body weight and satiation (El-Haschimi, 
Pierroz et al. 2000). 
5.  Goals 
 
Leptin, a 16 kDa product of the ob gene (Zhang, Proenca et al. 1994), is 
synthesized predominantly in adipocytes and targets the central nervous system. 
Originally, it was thought that leptin worked as a "lipostat", as food intake and 
accumulation of energy stores in fat cells result in an increase in leptin production 
thus leading to inhibition of appetite and elevation of energy expenditure. With 
time, however, this simple or better, over-simplified model has been developed 
and modified. It is now believed that in humans, leptin's main role may be weight 
regulation and maintaining energy homeostasis especially in energy-deficient 
states (Ahima and Flier 2000, Unger 2004, Rosenbaum, Goldsmith et al. 2005). 
In particular, leptin has been established as a major metabolic regulator that 
controls food intake, energy expenditure, neuroendocrine functions, carbohydrate 
and lipid metabolism, and several other important physiological functions of the 
mammalian organism (Ahima and Flier 2000, Friedman 2009, Dalamaga, Chou 
et al. 2013, Zeng, Pirzgalska et al. 2015). The discovery of leptin two decades 
ago has changed the landscape of the metabolic research and opened a new era 
in obesity studies. 
Regardless of how leptin exerts its biological activity, it is essential that its 
production in adipocytes is coupled to nutrient uptake and energy status of the 




shortly after food deprivation (Frederich, Lollmann et al. 1995, Levy, LeGall-
Salmon et al. 1997, Ahima and Flier 2000).  Although in humans, this effect may 
not be as fast and robust as in rodents, all mammals studied thus far 
demonstrate a direct link between food intake and circulating leptin (Ahima and 
Flier 2000).  Based on these results, the predominant hypothesis in the field has 
been that leptin expression is controlled by nutrients and/or insulin. Indeed, 
multiple studies have shown that insulin increases leptin production by adipose 
cells both in vivo and in vitro (Ahima and Flier 2000). Although this regulatory 
connection is central to all proposed mechanisms of leptin action, its mechanism 
remains unknown. Here, we are showing that insulin/mTORC1-induced 
transcription factor Egr1 binds to the leptin promoter and activates leptin 
expression in 3T3-L1 adipocytes. 1 
 
                                            
Abbreviations: Egr1, early growth response protein 1; mTORC1, mechanistic target of 
rapamycin complex 1; RYGB surgery, Roux-en Y gastric bypass surgery; siRNA, 





Figure 5.  Model of leptin binding to LEPR unveiled by single-particle 
electron microscopy.   
Leptin epitopes II and II engage the CHR2 and Ig domain of 2 LEPR subunits of 






MATERIALS AND METHODS 
Materials 
Polyclonal antibodies against actin and Egr1 (15F7) used for Western blotting 
were purchased from Cell Signaling (Beverly, MA).  Polyclonal antibody against 
Egr1 for the ChIP analysis was purchased from Novus Biologicals (NBP1-78775, 
Centennial, CO).  Horseradish peroxidase-labeled anti-rabbit and anti-mouse 
IgG, human recombinant insulin, NP-40, bovine serum albumin, protease and 
phosphatase HALT inhibitor were obtained from Sigma Aldrich (St. Louis, MO).  
Bovine serum (BS) and fetal bovine serum (FBS) were purchased from Atlanta 
Biologicals (Lawrenceville, GA).  Dulbecco’s Modified Eagle’s Media (DMEM), 
0.25% Trypsin-EDTA, OptiMEM, penicillin, Lipofectamine 2000, TRIzol™  
reagent, and sheep anti-mouse Dynabeads m-280 were purchased from Thermo 
Fisher Scientific (Waltham, MA).  RIPA buffer was purchased from Millipore 
(Burlington, MA).  
Sterile zirconium oxide beads measuring in 1.0 mm diameter and bullet 
homogenizer (Standard BBX24) were purchased from Next Advance (Troy, NY). 
 
Animals 
 C57BL/6N synchronization 
12-16 weeks old male C57BL/6N mice were obtained from Charles River Labs 
(Wilmington, MA) and housed in complete darkness (free-running) for 72 hours 




6 hours (ZT6-ZT12) and injected with insulin (2 units/kg) intraperitoneally.  
Animals were euthanized by CO2 asphyxia followed by cervical dislocation at 
respective time points.  Cardiac puncture was performed on animals to collect 
blood into micro-centrifuge tubes.  Fat pads were removed rapidly, separated into 
aliquots for protein and RNA extraction, snap frozen, and stored at -80°C.  All 
experimental procedures were approved by Boston University Medical Center 
Animal Care and Use Committee. 
 4EBP1/2 double knockout mice 
4E-BP1/2  double knock out mice were kindly provided by the Sonenberg lab (Le 
Bacquer, Petroulakis et al. 2007).  Animals were euthanized by CO2 asphyxia 
followed by cervical dislocation.  Cardiac puncture was performed on animals to 
collect blood into micro-centrifuge tubes.  Epididymal fat pads were removed 
rapidly, separated into aliquots for protein and RNA extraction, snap frozen, and 
stored at -80°C.  All experimental procedures were approved by Boston University 
Medical Center Animal Care and Use Committee. 
 Adipocyte-specific doxycycline inducible constitutively active Rheb 
mice 
The mouse model is designed to specifically and transiently activate mTORC1 in 
mature adipocytes by induction of S16H (constitutively active or ca) Rheb in a 
doxycycline-sensitive fashion (Fig. 6). caRheb was sub-cloned into the pBI-G 




copies of tetO (Fig. 6).  This vector not only contains caRheb but also β-
galactosidase to allow for screening (Wang, Deng et al. 2010).  We successfully 
generated 2 lines of caRheb transgenic mice and crossed them with another line 
containing rtTA under the adiponectin promoter courtesy of the Scherer lab (Wang, 
Deng et al. 2010).  This approach allows for a Dox-activated Rheb expression 
specifically in adipocytes.   
Mice (n = 3) were given normal chow (Research Diets #D12450J) or high fat diet 
(HFD) (Research Diets #D12492) supplemented with or without Dox in chow over 










Experiments ex vivo 
Fat pads are then minced, washed and filtered before being plated in tissue 
culture dishes in low glucose (1.5 g/L) DMEM with 25 nM dexamethasone, 10 nM 
insulin, penicillin/streptomycin mixture with or without Dox and incubated for 48 h 
at 37°C in 5% CO2 
 
Glucose tolerance test 
Mice were housed singly in separate cages and were fasted overnight (16 h) with 
free access to water.  After fasting, tail vein blood is collected and read through a 
glucometer (OneTouch Ultra 2 and #23 glucometer strips) for baseline glucose 
concentration.  Mice were injected with 2 mg/body weight (g) glucose and blood 
was collected 15, 30, 60, 90 and 120 minutes for glucose measurement.  
Following GTT, mice were returned to their cages and given free access to food 
and water. 
 
Insulin tolerance test 
Mice were housed singly in separate cages and were fasted overnight (16 h) with 
free access to water.  After fasting, tail vein blood is collected and read through a 
glucometer (OneTouch Ultra 2 and #23 glucometer strips) for baseline glucose 
concentration.  Mice were injected with 1U/kg body weight insulin and blood was 
collected 15, 30, 45 and 60 minutes for glucose measurement.  Following ITT, 





Cell culture and differentiation 
3T3-L1 fibroblasts were cultured in DMEM supplemented with 10% BS, 100 
units/ml penicillin, 100 µg/ml streptomycin, and 2 mM L-glutamine. Two days 
post-confluency, cells were incubated in differentiation medium (DMEM with 10% 
FBS, 1.67 µM insulin, 1 µM dexamethasone, and 0.5 mM 3-isobutyl-1-
methylxanthine). After 3 days, differentiation medium was replaced with DMEM 
containing 10% FBS, 100 unites/ml penicillin, 100 µg/ml streptomycin, and 2 mM 
L-glutamine. 4E-BP1/2 double knock-out (DKO) mouse embryonic fibroblasts 
(MEFs) were a kind gift of Dr. Sonenberg (Le Bacquer, Petroulakis et al. 2007) 
 
X-gal staining 
X-gal staining is a histochemical technique used to detect reporter gene 
expression (Burn 2012). The bacterial LacZ gene is cloned in and under the 
control of TRE similar to caRheb, thus both requiring doxycycline to be 
expressed (Fig. 6).  Harvested epidydamal fat pads were dissected into small 
chunks no bigger than 5 mm in size and placed into plates containing PBS with 
2mM MgCl2.  Tissues were then fixed in 4% paraformaldehyde and kept on ice 
for 30 minutes.  40x X-gal stock (40 mg/ml) is diluted into X-gal reaction buffer 
containing 35 mM potassium ferrocyanide, 2 mM MgCl2, 0.02% Nonidet P-40 and 
0.01% Na deoxycholate in PBS.  Tissues are incubated in X-gal reaction buffer 




solution appears clear.  Tissues are imaged under bright field optics for 
detection.  Visualization of dark blue stains confirm LacZ expression and, in 
parallel, caRheb activation. 
 
Protein extraction from adipocytes 
Culture media was removed from 3T3-L1 adipocytes, cells were washed twice 
with cold PBS, and 200 µL cold RIPA buffer (Millipore, Burlington, MA) was 
added for 10 minutes on ice.  Cells were then harvested using a cell scraper, and 
lysates were transferred to microcentrifuge tubes.  Samples were spun at 14,000 
x g for 15 minutes, and supernatant was collected.  Protein concentration was 
determined using the Pierce BCA Protein Assay kit (Thermo Fisher Scientific, 
Waltham, MA) and a Biotek Synergy™ HT microplate reader (Biotek, Winooski, 
Vermont) 
Alternatively, fragments of freshly excised adipose tissue (ca. 100 mg) were 
placed into microcentrifuge tubes containing 1 scoop (measuring apparatus 
provided by Next Advance) of sterile 1.0 mm diameter RNase-free zirconium 
oxide beads and 200 µL of extraction buffer (40 mM HEPES, 120 mM NaCl and 
1 mM EDTA).  Tubes were inserted into the bullet blender homogenizer and 
homogenized twice for 5 minutes each at the maximum intensity.  Samples were 
then centrifuged at 1,000 x g for 5 minutes at 4°C to allow triglycerides to solidify 
at the top.  Samples were placed on ice and liquid phase was transferred to new 




Samples were placed on a shaker for 10 minutes at 4ºC and centrifuged at 
10,000 x g for 10 minutes at 4ºC.  Samples were then transferred to new tubes, 
and protein concentration was determined as described above. 
 
RNA extraction from adipocytes and real-time quantitative polymerase 
chain reaction (PCR) 
Total RNA was extracted from cultured cells using TRIzol™ reagent followed by 
extraction through RNeasy columns from EPOCH (Sugar Land, TX).  Total RNA 
(1 µg) underwent reverse transcription using random decamers through 
RETROscript kit from Ambion (Austin, TX). RNA expression was determined by 
real-time quantitative polymerase chain reaction (PCR). Reactions were 
performed in a total volume of 20 µL containing 1 µL of cDNA, SYBR green 
master mix (Brilliant II SYBR Green qPCR Master Mix), and gene-specific 
primers (CACCAAAACCCTCATCAAGAC and AGCTCTTAGAGAAGGCCAGCA 
for leptin) (CCACAACAACAGGGAGACCT and ACTGAGTGGCGAAGGCTTTA 
for Egr1).  Gene expression was normalized by 36B4 ribosomal subunit with the 
following primers:  TCACTGTGCCAGCTCAGAAC and  
AATTTCAATGGTGCCTCTGG. Expression was measured using ∆∆Ct method 
including fold expression of treatments compared to control. 
Alternatively, fragments of freshly excised adipose tissue (ca. 100 mg) were 
placed into microcentrifuge tubes containing 1 scoop (measuring apparatus 




oxide beads and 200 µL of TRIzol reagent.  Tubes were inserted into the bullet 
blender homogenizer and homogenized twice for 5 minutes each at the 
maximum intensity.  800 µL of TRIzol reagent is added to the homogenized 
sample to fully resuspend the tissue in 1 mL of reagent.  0.2 mL chloroform per 
ml TRIzol is added to each tube, shaken vigorously for 20 seconds and allowed 
to sit at room temperature for 2 minutes.  Samples are then centrifuged at 10,000 
x g for 18 minutes at 4°C.  The aqueous phase is transferred to new 
microcentrifuge tubes and slowly mixed with an equal volume of 100% RNA-free 
EtOH.  Sample is loaded into RNeasy columns from EPOCH (Sugar Land, TX) 
and spun to wash and later elute RNA.  All downstream applications are 
previously explained in the in-vitro protocol listed above. 
For human samples, fragments of subcutaneous human adipose tissue were 
added to tubes containing RNAlater solution (Sigma Aldrich St. Louis, MO) and 
stored at -80°C.  Samples are homogenized and total RNA is isolated using the 
QIAzol reagent and RNeasy Mini kits (Qiagen, Germantown, MD). RNA (0.5-1.5 
μg) was retro-transcribed with High Capacity cDNA Synthesis Kits (Life 
Technologies).  
 
Adenoviral infection of 3T3-L1 adipocytes 
Adenoviral vector containing Human Egr1 cDNA (AdEgr1) was kindly provided by 
E. Hofer (Medical University of Vienna, Vienna, Austria).  GFP containing 




Boston, MA). Differentiated 3T3-L1 adipocytes in 24-well plates were serum 
starved in Optimem media for 2 hours.  AdEGR1 or AdGFP were then added to 
cells at a multiplicity of infection of 4,000.  After 24 hours, the medium was 
replaced with DMEM supplemented with 10% FBS, 100 units/ml penicillin, 100 
µg/ml streptomycin, and 2 mM L-glutamine.  After 48 hours, cells were harvested 
for protein and RNA analysis.  
 
Knock out of Egr1 using siRNA 
Suspension transfections were performed according to Kilroy et al (Kilroy, Burk et 
al. 2009).  Briefly, 3T3-L1 cells were grown in 60 mm cell culture plates and 
differentiated till the day 4.  Cells were washed gently with PBS, treated with 1 
mL of 0.25% Trypsin-EDTA for 3-5 minutes and 10% FBS DMEM medium (5 mL) 
was added to suspended cells that were immediately placed into 24-well plates 
containing either Egr1 siRNA or scrambled siRNA.  To prepare siRNA, Egr1 
siRNA pool and scrambled siRNA (Dharmacon, Lafayette, CO) were mixed with 
Optimem media at a final concentration of 100 nM and allowed to sit for 5 
minutes at room temperature.  DharmaFECT Duo (Dharmacon, Lafayette, CO) 
was added to the previous mixture (1.4 µL/cm2 surface area of transfection).  The 
mixture was allowed to sit for 20 minutes at room temperature, and then 200 µL 
was added to each well of a 24 well plate.  Cells were incubated for 24 hours, 
and the media was replaced with 10% FBS DMEM. Cells were incubated for 





Chromatin immunoprecipitation (ChIP) 
ChIP was performed with the EZ-ChIP kit from Millipore (Burlington, MA).  Briefly, 
3T3-L1 adipocytes were pretreated with 1.67 µM insulin for 4 hours.  18.5% 
formaldehyde is then added to produce cross-links between protein and DNA for 
10 minutes at room temperature.  2mL of 10x Glycine (Millipore, Burlington, MA) 
is added to each dish and incubated at room temperature for 10 minutes to 
quench formaldehyde   Cells were washed with cold PBS, scraped and placed 
into conical tubes and spun at 700 x g at 4°C.  Pellets are then lysed in sodium 
dodecyl sulfate lysis buffer (Millipore, Burlington, MA).  To produce chromatin 
fragments, samples were sonicated in the Bioruptor Sonicator using 1.5 mL 
Bioruptor® Plus TPX microtubes both obtained through Diagenode (Denville, NJ) 
on ice 15 times (30 second with 30 second intervals) at 100% intensity.  
Sonicated samples were diluted 1:10 with Dilution Buffer (Millipore, Burlington, 
MA) and incubated with 60 µL Protein G Agarose at 4°C for 1 hour. Samples 
were briefly spun (3000-5000 x g for 1 minute) and chromatin-containing 
supernatant was transferred to new microcentrifuge tubes. Total lysates (1%) 
were saved before proceeding to immunoprecipitation.  Novus Egr1 antibody or 
non-specific mouse IgG (10 µg) is added to chromatin samples and incubated 
overnight at 4°C with rotation. Protein G Agarose (60 µL) was added to samples 
and incubated for 1 hour at 4°C with rotation.  Samples were centrifuged at 3000 




Agarose-antibody/chromatin complex is resuspended and washed with Low Salt 
Immune Complex Wash Buffer, followed by High Salt Immune Complex Wash 
Buffer, LiCl Immune Complex Wash Buffer and two washes of TE Buffer 
(Millipore, Burlington, MA).  Protein-DNA complexes were eluted, treated with 
RNase A and proteinase K and transferred to DNA purification spin columns to 
be eluted and stored in -20°C. 
Analysis of the eluates by qPCR was performed according to Cardamone et al 
(Cardamone, Orofino et al. 2018) using the following primers: 
TCCCGCCCCACCGCTAGCGAGCTC and 
GAGCTCGCTAGCGGTGGGGCGGGA for the leptin promoter. 
TCACTGTGCCAGCTCAGAAC and AATTTCAATGGTGCCTCTGG for loading 
control 36B4. 
Dilutions of total lysates (1/10, 1/100, and 1/1000) were amplified by PCR to form 
a standard reference curve.  Numbers from eluates relative to the total lysate 
were used to calculate the slope and intercept for the standard reference curve.  
CT values of samples were inputted in the following formula:  Relative input = 
10(CT-Intercept) *10/(Slope). 
 
Genetic engineering of the PGL4.1 luciferase vector with the leptin 
promoter  
C57BL/6 mouse genomic DNA was used to amplify the leptin promoter.  The -





TGCTTAAAGCTTACCTTGCAGCTGCTGGAGCAGGGATCC for leptin 
promoter).   
The -95/ +27 region of the leptin promoter was amplified with the following 
primers (TAAGCAGCTAGCAGTTGGCGCTCGCAGG and 
TGCTTAAAGCTTACCTTGCAGCTGCTGGAGCAGGGATCC). 
The -49/ +27 region was amplified with the following primers 
(TAAGCAGCTAGCGGCACTGGGGCAGTTATAAGA and 
TGCTTAAAGCTTACCTTGCAGCTGCTGGAGCAGGGATCC). 
The underlined sequences contain the restriction enzyme sites NheI for the 
forward primer and HindIII for reverse.  Upstream of the restriction enzyme sites 
are additional base pairs to reduce GC content.  PGL4.1 Luciferase vector was 
purchased from Promega (Madison WI).  The vector and insert were digested 
with NheI and HindIII (New England Biolabs, Ipswich, MA).  Samples were 
purified using the PCR purification kit (Qiagen, Hilden, Germany).  Digest and 
insert were ligated using the Quick Ligation kit (New England Biolabs, Ipswich, 
MA) following their protocol for overnight ligation.  Ligated plasmid was then 
transformed into DH5α supercompetent cells purchased from New England 
Biolabs (Ipswich, MA).  Successfully transformed colonies were extracted for 
plasmid DNA that was verified by sequencing. 





























Human embryonic kidney cells (HEK 293T) were cultured in DMEM 
supplemented with 10% FBS, 100 units/ml penicillin, 100 µg/ml streptomycin, 
and 2 mM L-glutamine in 24-well plates (Corning, Tewksbury MA) to 70% 
confluency and subsequently transfected with Lipofectamine 2000.  Briefly, two 
inoculations were prepared: one containing Lipofectamine 2000 plus Optimem 
media and the second containing vectors for transfection suspended in Optimem 
media.  Samples were transfected with 100 ng of PGL 4.1 luciferase vector with 
the leptin promoter (-350/+27) inserted upstream of the transcription start site. 
Samples were co-transfected with increasing amounts of pcDNA-hEgr1 vector as 




were co-transfected with 500 ng of both pcDNA-hEgr1 and FSP27 cDNA.  To 
normalize transfection efficiency samples were co-transfected with 100 ng of 
pRL-CMV-Renilla obtained from Promega (Madison, WI).  Samples were 
transfected for 4 h and then switched to DMEM containing 10% FBS and 
antibiotic cocktail.  48 hours after transfection, cells were harvested with the 
Dual-Luciferase® Reporter Assay System kit provided by Promega (Madison, 
WI).  Cells were washed twice with PBS and lysed with passive lysis buffer as 
supplied in the kit.  Luciferase and Renilla luciferase activity were read in a 
Biotek Synergy™ HT microplate reader (Biotek, Winooski, Vermont).  The 
relative luciferase activity was normalized by Renilla luminescence.   
Leptin ELISA 
Mouse blood samples (200 μL) were incubated at room temperature for 25 
minutes before being centrifuged at 2,000 x g for 10 minutes at -4°C.  Serum was 
then collected and circulating leptin was measured with the mouse leptin ELISA 
kit purchased from Thermo Fisher Scientific (Waltham, MA).  Samples were read 
at 450 nm absorbance by a microplate reader and were fitted by a standard 
curve to determine leptin concentration. Samples were read in a Biotek 
Synergy™ HT microplate reader (Biotek, Winooski, Vermont). 
Ablation of the 5’UTR of the Egr1 mRNA using CRISPR/Cas9 
The DNA region encoding the 5’UTR of the Egr1 message was deleted using 
CRISPR/Cas9 system in 3T3-L1 preadipocytes as previously described 




(GGGCCTTCCCCGCAGTCCCGAGG and GCCCTCAGTAGCTTCGGCCCCGG 
for sgRNAs) targeting either the upstream or downstream region of the 5’UTR 
encoding DNA were designed using online software (http://crispr.mit.edu).  
The lentiCRISPR v2 plasmid (52961; Addgene, Watertown, MA) was used to 
express sgRNAs and the Cas9 protein along with the lentiviral envelope plasmid 
pCMV-VSV-G and the packaging plasmid psPAX2. 3T3-L1 cells transduced with 
lentiviruses were treated with Puromycin (Invivogen, San Diego, CA) (5 μg/ml) for 
the selection of transfectants for four days. The genomic region surrounding the 
sgRNA target site was amplified by PCR using the primers: 
TGTTAACCTTGACGTCCCCG and GGGTGTCCCTAGACATCCCT for Egr1 
Δ5’UTR. 
 
Gel electrophoresis and western blotting 
Proteins were separated in either 8% or 12% SDS-polyacrylamide gels and run 
in Tris-Glycine-SDS running buffer (Boston Bioproducts, Boston, MA) at 85V for 
15 minutes followed by 110V for 60 minutes.  Gels were transferred to 0.45 µm 
Nitrocellulose membranes in 25 mM Tris and 192 mM glycine for 2 hours at 300 
mA at 4⁰C.  The membrane was blocked with 5% BSA in PBST for 1 hour at 
room temperature.  The blots are then probed overnight with the primary 
antibodies in PBST at 4ºC.  The following day the blot was incubated at room 
temperature with horseradish peroxidase-conjugated secondary antibodies (CST, 




Protein bands were imaged with immobilon Western Chemiluminescent HRP 
substrate purchased through Millipore (Burlington, MA) using a BioRad image 
station (Universal Hood II 170-8170, Biorad, Hercules, CA). 
 
Statistics 
A Student unpaired two-tailed t test was used to evaluate the statistical 
significance of directly comparable results.  ANOVA was performed on group 






1.  Egr1 drives leptin expression in response to insulin stimulation 
 
 1.1  Expression of Egr1 and leptin following insulin treatment 
In the following experiments, 3T3-L1 cells were incubated in differentiation 
medium to produce mature adipocytes. On day 7, cells were serum starved for 2 
hours prior to insulin treatment.  Treatment of differentiated 3T3-L1 adipocytes 
with insulin (1.67 µM) causes a strong but transient induction of Egr1, which our 
lab has proven before (Chakrabarti, Kim et al. 2013), however, leptin 
transcription follows in phase as well (Fig. 7A). 
A similar effect is seen in vivo with synchronized C57BL6/J male mice.  
Unpublished preliminary data has shown that leptin is regulated by circadian 
rhythm in both cells and mice.  Therefore we housed mice in complete darkness 
for 72 hours to establish a synchronized circadian baseline.  After being 
subjected to complete darkness for 72 hours, mice were then fasted for 6 hours 
before receiving 2 units/kg insulin via intraperitoneal injection.  Epididymal fat 
pads collected at various time points show a similar pattern with Egr1 induction 
followed by leptin mRNA expression (Fig. 7B).   
Tail vein blood was collected a various time points and spun down to collect 
serum.  Leptin ELISA performed on collected serum showed an increase in 








Figure 7. Induction of Egr1 precedes leptin expression both in vitro and in 
vivo.  
Panel A top: 3T3-L1 adipocytes were treated with insulin (100 nM) and 
harvested at the indicated time points.  Leptin mRNA levels were 
measured by qPCR (n=3).  Bottom: Egr1 protein levels were measured in 
whole cell lysates by Western blotting (50 µg per lane).  Actin was used as 
a loading control.  Panel B top: male mice received an intraperitoneal 
injection of insulin (2 units/kg).  Mice were sacrificed at the indicated time 
points, and total RNA was extracted from epidydimal fat pads (n=3).  
Leptin mRNA levels were measured by qPCR.  Bottom: Egr1 was 
detected in protein lysates of epidydimal fat pads (50 µg per lane).  Panel 
C: Following insulin injection (2 units/kg), mice were euthanized, serum 
was collected by cardiac puncture, and circulating leptin was measured by 
ELISA (Thermo Fisher Scientific, Waltham MA) (n=3).  Data are presented 







 1.2  Egr1 activates leptin transcription by directly binding to the 
leptin promoter 
Luciferase assay performed in HEK 293T cells, which produce negligible Egr1 
when insulin stimulated, demonstrate that induction of Egr1 not only precedes 
leptin expression in adipocytes, but Egr1 can activate the leptin promoter (Fig. 
8A).  Truncated leptin promoter (-95/ +27) contained higher basal leptin 
expression and maintained Egr-1-induced leptin activation (Fig. 8B), however, (-
49/ +27) truncated leptin promoter failed to be stimulated by Egr-1.  Furthermore, 
the chromatin immunoprecipitation assay carried out in differentiated 3T3-L1 
adipocytes shows that Egr1 directly binds to the leptin promoter in an insulin-
sensitive fashion (Fig. 8C).   
 1.3.  FSP27 inhibits Egr1-mediated activation of leptin transcription 
Previously, we have found that the lipid droplet protein FSP27 (a.k.a. CIDEC) co-
immunoprecipitates with Egr1 to increase its association with and inhibition of the 
ATGL promoter (Singh, Kaur et al. 2014).  In addition, FSP27 is found to have a 
significant fraction found in the nucleus of human adipocytes.  Placing FSP27 
within the nucleus suggests it plays additional roles in transcription regulation as 
was previously shown in Singh et al (Singh, Kaur et al. 2014). In agreement with 
these results, we show that FSP27 blocks the effect of Egr1 on the activity of the 
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Figure 8.  Egr1 directly activates the leptin promoter. 
  Panel A: HEK 293T cells were transiently transfected with the pGL4.1 vector 
containing leptin promoter linked to luciferase and increasing amounts of pcDNA-
hEgr1 vector.  For normalization of transfection efficiency, cells were co-
transfected with the pRL-CMV-Renilla vector.  After 48 hours, cells were 
harvested, and samples were analyzed in a microplate reader.  Panel B:  HEK 
293T cells were transiently transfected with PGL4.1 vector containing truncations 
of leptin promoter following the same methods. Panel C: 3T3-L1 adipocytes were 
treated with or without insulin for 4 hours, and ChIP was performed using an EZ-
ChIP kit (Millipore, Burlington, MA).  Samples were immunoprecipitated with the 
polyclonal Egr1 antibody (Novus Biologicals, Centennial CO) or non-specific 
mouse IgG antibody.  The graph represents a linear regression model of serial 
dilutions of the immunoprecipitate and the input.  Panel D:  HEK 293T cells were 
transiently transfected with pGL4.1 vector containing leptin promoter linked to 
luciferase and either 500 ng of pcDNA-hEgr1 vector or a combination of 500 ng 
pcDNA-hEgr1 and 500 ng of HA-FSP27 cDNA.  For normalization of transfection 
efficiency, cells were co-transfected with the pRL-CMV-Renilla vector.  After 48 
hours, cells were harvested, and samples were analyzed in a microplate reader.  
Data are presented as mean values ± S.E.M.  All panels show representative 





 1.4.  Knockdown of Egr1 reduces leptin expression 
To determine whether Egr1 is necessary for the effect of insulin on leptin 
transcription, we have knocked down Egr1 in 3T3-L1 adipocytes with the help of 
siRNA.  To enhance uptake of siRNAs, adipocytes were suspension transfected 
on day 4 of differentiation with lipofectamine 2000 and either Egr1 or scramble 
siRNAs.  As is shown in Fig. 9, knock down of Egr1 not only decreases expression 
of leptin in basal cells, but also, completely blocks up-regulation of leptin mRNA by 
insulin.  
 1.5.  Overexpression of Egr1 significantly increases leptin 
expression in adipocytes 
Overexpression of Egr1 was performed by adenoviral infection on adipocytes to 
determine the effects on leptin expression.  Interestingly, overexpression of Egr1 
in these cells with the help of adenoviral infection strongly increased levels of the 










Figure 9.  Knock down of Egr1 in 3T3-L1 adipocytes suppresses the effect 
of insulin on leptin expression.  
Top panel:  3T3-L1 adipocytes in suspension were transfected with SMARTpool 
Egr1 siRNA (Dharmacon, Lafayette CO) or scrambled siRNA at a final 
concentration of 100 nM for 72 hours.  Cells were then treated or not treated with 
insulin and leptin mRNA was measured by qPCR.  Bottom panel:  Egr1 was 
analyzed in whole cell lysates by Western blotting (50 µg per lane).  Actin was 
used as a loading control.  Data are expressed as the mean value normalized by 
36B4 ± S.E.M.  All panels show representative results of three independent 










Figure 10.  Over-expression of Egr1 in 3T3-L1 adipocytes increases leptin 
mRNA expression. 
Top panel: 3T3-L1 adipocytes were infected with adenovirus containing Egr1 
(AdEgr1) and GFP (AdGFP) and cultured for 72 hours. RNA was extracted and 
leptin mRNA levels were analyzed by qPCR.  Data are expressed as the mean 
value normalized by 36B4 ± S.E.M.  Bottom panel:  Egr1 protein levels were 
measured in whole cell lysates by Western blotting (50 µg per lane).  Actin was 
used as a loading control. All panels show representative results of three 





2.  Ablation of Eg1-regulating factors results in increased leptin 
transcription 
 
 2.1.  Deletion of Egr1 5’-UTR increases basal expression of Egr1 and 
leptin transcription. 
Previously, we have determined that the Egr1 mRNA has a highly structured 5’-
UTR, and that insulin increases translation of this message via the mTORC1-4E-
BP1/2 regulatory axis (Singh, Shin et al. 2015).  In order to mimic the effect of 
insulin on Egr1 expression, Dr. Ozdemir in our laboratory has deleted its 5’-UTR 
using the CRISPR/Cas9 technique (note the loss of the 2.5 kb band in the Δ5'UTR 
lane in Fig. 11A).  This procedure does not significantly change the levels of the 
Egr1 mRNA (Fig. 11B) but dramatically elevates expression of the Egr1 protein 
(Fig. 11C).  Administration of insulin to the “engineered” cells has only a minute 
stimulatory effect on the Egr1 protein levels suggesting that deletion of the 5’-UTR 
raises its biosynthesis to the maximum.  As expected, the luciferase assay has 
demonstrated that the activity of the leptin promoter in these cells is strongly 










Figure 11.  Deletion of the 5’UTR of Egr1 mRNA increases basal expression 
of the Egr1 protein and leptin transcription in 3T3-L1 adipocytes. 
 Panel A: genomic DNA was extracted from wild type 3T3-L1 cells and 3T3-L1 cells 
with deleted 5’UTR of the Egr1 mRNA (Δ5’UTR), and amplified by PCR using 
5’UTR Egr1 primers. The dotted line indicates that irrelevant lanes have been 
spliced out. Panel B:  wild type 3T3-L1 adipocytes and Δ5’UTR 3T3-L1 adipocytes 
were treated with insulin (100nM) and Egr1 was measured in whole cell lysates at 
multiple time points (minutes) by Western blotting (50 µg per lane).  Actin was used 
as a loading control.  Panel C:  Egr1 mRNA levels were analyzed in wild type 3T3-
L1 adipocytes and Δ5’UTR 3T3-L1 adipocytes by qPCR. Data are expressed as 
the mean value normalized by 36B4 ± S.E.M.  Panel D: wild type 3T3-L1 cells and 
Δ5’UTR 3T3-L1 cells were transfected with the pGL4.1 vector containing leptin 
promoter linked to luciferase together with the pRL-CMV-Renilla vector on day 4 
of differentiation, incubated for 72 hours and analyzed in a microplate reader. All 
panels show representative results of three independent experiments.  Data are 





 2.2. Knockout of 4EBP 1 and 2 increases Egr1 expression and 
leptin transcription 
To determine the long-term effects of Egr1 overexpression on leptin expression 
we obtained 4EBP1 and 2 double knockout (DKO) mouse embryonic fibroblasts 
(MEFs) as a gift from the Sonnenberg lab (Le Bacquer, Petroulakis et al. 2007).   
The 5’UTR of Egr1 mRNA contains a highly wound complex secondary structure 
requiring the use eukaryotic translation initiation factor  (eIFs).  4EBP1/2 normally 
binds to eukaryotic translation initiation factor 4F (eIF4F) preventing full assembly 
of the complex.  Knockout of 4EBP1/2 should free eIF4F to complex the complex 
and allow translation of Egr1 mRNA.  DKO MEFs express more Egr1 and at least 






Figure 12.  4EBP1/2 double knockout (DKO) mouse embryonic fibroblasts 
express more Egr1 protein and leptin mRNA. 
  Top panel: WT and DKO MEFs were grown to confluency, extracted for RNA 
and leptin mRNA levels were analyzed by qPCR.  Data are expressed as the 
mean value normalized by 36B4 ± S.E.M.  Bottom panel:  Egr1 protein levels 
were measured in whole cell lysates by Western blotting (50 µg per lane).  Actin 
was used as a loading control. All panels show representative results of three 




3.  Experiments in vivo 
 3.1. 4EBP1/2 double knockout mice express more leptin than WT 
animals 
Mice lacking both 4EBP1 and 2 (DKO) were obtained from the Sonnenberg lab (Le 
Bacquer, Petroulakis et al. 2007).  Fig. 13A displays the lack of phosphorylated 
4EBP found in male DKO mice compared to C57BL/6 WT males.  Leptin mRNA in 
epididymal fat pads of DKO mice is increased 20-fold in comparison to WT mice 
(Fig. 13B).   
In the next experiment, DKO and WT mice were fasted overnight for 16 hours 
before food was provided ad libitum.  Serum was collected at several intervals after 
the fast and analyzed for leptin concentration by ELISA.  DKO mice had increased 
circulating leptin following the fast compared to WT mice (Fig. 13C).  However, 
differences in food consumption between the cohorts were non-significant ruling 
out overconsumption of nutrients as an explanation for the increased expression 













Figure 13.  4EBP1/2 DKO mice display high leptin expression without 
changes in food consumption. 
  Panel A:  Protein was extracted from epididymal fat pads of 4EBP1/2 DKO and 
C57BL/6 (WT) mice.  Phosphorylated 4EBP protein levels were measured by 
Western blotting (50 µg per lane).  Actin was used as a loading control.  Panel B:  
RNA was extracted from epididymal fat pads of 4EBP1/2 DKO and C57BL/6 
(WT) mice, and leptin mRNA was analyzed by qPCR.  Data are expressed as the 
mean value normalized by 36B4 ± S.E.M.  Panel C: Serum leptin was 
determined by ELISA in starved and re-fed DKO and WT mice.  Panel D:  Food 





 3.2. Treated CaRheb mice display higher leptin production and 
resist loss of leptin after overnight fasting. 
It is well known that mTORC1 is involved in adipogenesis (Yeh, Bierer et al. 1995, 
Kim and Chen 2004, Polak, Cybulski et al. 2008, Zhang, Huang et al. 2009, 
Carnevalli, Masuda et al. 2010, Goorden, Hoogeveen-Westerveld et al. 2011).  
Therefore, the existing mouse models with constitutive activation or inhibition of 
mTORC1 may not be appropriate for understanding the metabolic role of mTORC1 
in differentiated fat. We have designed our mouse model to express caRheb in 
adipocytes in a doxycycline-inducible fashion, thereby leading to activation of 
mTORC1. In this set up, potential changes in the phenotype of transgenic animals 
cannot be attributed to developmental differences.  Two independent lines have 
been created to test this phenotype. 
We began to characterize the two independent transgenic mice lines to determine 
regulation of leptin.  X-Gal staining was performed to show activation of the 
transgene in doxycycline treated mice (Fig 14A).  In cohorts fed either normal chow 
or doxycycline fortified chow, the dox-treated cohort possessed higher circulating 
leptin than controls (Fig. 14B).  In a separate cohort, harvested epididymal fat pads 
were incubated in cell plates and treated with or without doxycycline.  Ex vivo 
doxycycline treatment resulted in a higher concentration of leptin in fat pad lysates 











Figure 14.  Doxycycline treated caRheb mice have increased leptin 
concentration both in vivo and ex vivo. 
  Panel A:  X-Gal staining of inguinal and epididymal fat pads shows activation of 
β-Gal in doxycycline-treated cohorts.  Panel B:  Blood serum was collected from 
two independent dox-inducible caRheb mice fed either normal chow or 
doxycycline-containing chow (n=3).  Leptin ELISA was performed to determine 
circulating leptin concentration.  Panel C, D.  Epididymal fat pads from both mouse 
lines were isolated and treated ex vivo with or without doxycycline and incubated 
for 48 hours (n=3).  Leptin concentration was determined in lysates (C ) and cell 
media (D) by ELISA. .  Data are expressed as the mean value ± S.E.M.  All panels 





Leptin levels drop in response to fasting to stimulate a hunger response in the 
organism.  We hypothesized that activation of Egr1, through doxycycline 
stimulation of caRheb, during fasting would rescue this phenotype.  Indeed, 
administration of doxycycline to fasted caRheb mice promoted higher levels of 
circulating leptin (Fig. 15A). 
 3.3. caRheb mice have improved glucose clearing when treated 
with insulin 
Glucose tolerance tests (GTT) performed on doxycycline-treated caRheb mice 
show a poor clearance of glucose (Fig. 16A). The very same cohorts were then 
placed on an 8-week HFD with or without doxycycline.  GTT showed no differences 
between dox-treated and not treated animals (Fig. 16B).  In addition, insulin 
tolerance tests (ITT) were performed a week following GTT in both cohorts.  Dox-
treated mice had stronger clearance of glucose, following insulin injection, under 
both normal chow and HFD conditions (Fig. 16C, D).  Doxycycline-treated caRheb 








Figure 15.  Doxycycline-treated caRheb mice have more circulating leptin 
upon fasting. 
  Panel A: 2 cohorts (n = 3) were injected with doxycycline or PBS over the 
course of 6 days before a 16 hour fast.  Serum was collected before and after 
fast and Leptin ELISA performed to quantify circulating leptin.  Data are 
presented as mean values ± S.E.M.; *, p < 0.05.  Panel B:  X-Gal staining of 








Figure 16.  Dox-treated caRheb mice fed normal chow demonstrate poorer 
glucose tolerance yet maintain higher insulin tolerance under both normal 
and HFD conditions. 
 Panel A,B:  Adipocyte-specific doxycycline inducible constitutively active Rheb (caRheb) 
mice were split into two groups receiving either normal chow with or without doxycycline 
(A) or HFD with or without doxycycline (B) for 8 weeks (n=3).  Glucose tolerance test 
(GTT) was performed.  Panel C,D:  Insulin tolerance tests (ITT) were performed in both 









We provide evidence that insulin/mTORC1-inducible transcription factor Egr1 
mediates the physiologically significant stimulatory effect of insulin on leptin 
transcription.  In analyzing these data, it is essential to keep in mind that leptin 
production by adipose cells is regulated at several different levels: transcription, 
translation, secretion, and degradation (Lee and Fried 2009, Kandror 2015).  
Importantly, both transcription (this report) and translation of leptin are positively 
regulated by insulin via the mTORC1-mediated pathway (Roh, Han et al. 2003, 
Lee, Yang et al. 2007, Chakrabarti, Anno et al. 2008) and therefore, should work 
in concert to deliver higher leptin amounts in response to nutrients and insulin.  
As activity of mTORC1 depends not only on insulin levels but also, on nutrient 
and energy availability (Sengupta, Peterson et al. 2010, Dibble and Manning 
2013), this model provides an additional physiological dimension to the regulation 
of leptin production. 
1.  Regulation of Leptin 
 1.1 Regulation of leptin production at the level of translation and 
transcription 
Isolated rat adipocytes treated with actinomycin D, a powerful inhibitor of 
transcription, were still capable of producing leptin when administered insulin, 
suggesting that a pathway independent of transcription regulates leptin 





Leptin expression may be regulated through a downstream protein activated by 
mTORC1 signaling, due to mTORC1 receiving input from both insulin and 
multiple nutrient and energy signals (Sengupta, Peterson et al. 2010, Dibble and 
Manning 2013).  Evidence supporting this model include leptin expression 
correlating with intracellular ATP levels (Levy, Gyarmati et al. 2000) and up-
regulated by leucine treatment in adipose tissue (Roh, Han et al. 2003).  
Administration of rapamycin, the inhibitor of mTORC1, blocks leptin expression 
with leucine and insulin present (Bradley and Cheatham 1999, Roh, Han et al. 
2003, Lee, Wang et al. 2007).  Leucine was found to phosphorylate 4EBP1/2 
greatly within the endoplasmic reticulum, placing leptin expression downstream 
of 4EBP1/2 (Roh, Han et al. 2002).  Leucine stimulation, however, did not 
contribute to an increase of leptin transcription. 
Additional activators of mTORC1, such as constitutively active Rheb and 
dominant negative AMPK, both contributed to elevated leptin expression on the 
level of translation, though no effects on transcription were observed 
(Chakrabarti, Anno et al. 2008).  Absence of leptin transcription could be 
explained by constitutively expressed stable cell lines masking the endogenous 
insulin response that operates in a pulsatile fashion.  Insulin operates in a 
pulsatile fashion by being released from the pancreas every 5 - 10 minutes; 
however the basal expression is quite low with feeding permitting a significant 
increase in amplitude of insulin secretion. In noninsulin-dependent diabetes 




Increased fasting insulin and glucose, 2) decreased relative amplitudes of insulin 
pulses, 3) reduced frequency of glucose oscillations, 4) decreased association 
between peaks of insulin pulses and glucose oscillations, (Gumbiner, Van Cauter 
et al. 1996, Hunter, Atkinson et al. 1996, Satin, Butler et al. 2015).  For those 
suffering from T2D there may be a malfunction in the ability of adipocytes to re-
sensitize in preparation for the next feeding event; rather, relative 
hyperinsulinemia could be maladaptive by enhancing weight gain, contributing to 
beta cell exhaustion or by exacerbating insulin receptor desensitization.  Loss of 
pulsatile insulin release may contribute towards hyperleptinemia.  
Adipocytes transfected with luciferase vector containing leptin 5’UTR showed an 
increase in basal leptin expression, however addition of insulin did not contribute 
to a rise in luciferase expression (Lee, Yang et al. 2007).  This suggests that 
4EBP1/2 does not directly inhibit translation of leptin mRNA; instead a 
downstream regulated target of 4EBP1/2 may be involved in increasing leptin 
transcription.  The discovery of the insulin-mediated mTORC1-Egr1-ATGL axis in 
addition to the inhibition of Egr1 translation by 4EBP1/2, placed the Egr1 as an 
optimal candidate.  Due to its role as a transcription factor suppressing lipolysis, 
primarily done post-prandial and subject to impairment following insulin 
resistance, it could also play a role in satiety through activation of leptin 
transcription (Chakrabarti, Kim et al. 2013, Singh, Shin et al. 2015).  
Transcription factor-binding prediction analysis of the human leptin promoter 




the hypothesis put forward: transcriptional expression of leptin is regulated 
through the mTORC1 pathway via direct binding of Egr1 to the leptin promoter. 
 
 1.2  Regulation of leptin production at the level of secretion 
Studies both in vivo and in vitro have shown adipocytes utilizing two methods of 
leptin secretion: constitutive and regulated.  Insulin produces the acute effect of 
leptin secretion that does not diminish following cycloheximide treatment (Roh, 
Thoidis et al. 2000, Lee and Fried 2006, Zeigerer, Rodeheffer et al. 2008), 
suggesting that independent mechanisms are involved with the biosynthesis, 
storage and release of leptin secretory vesicles.  Within adipocytes, the major 
pool of intracellular leptin is localized in small membrane vesicles that are 
released shortly after insulin stimulation (Barr, Malide et al. 1997, Roh, Thoidis et 
al. 2000, Roh, Roduit et al. 2001).  Leptin is also the only adipokine that contains 
a separate storage compartment; it also differs from other secretory vesicles in 
buoyant density, sedimentation behavior and kinetics of secretion (Roh, Thoidis 
et al. 2000).  The storage capacity of leptin secretory vesicles within adipose 
tissue is limited to an hour of constant secretion (Lee and Fried 2006), which 
doesn’t address how leptin expression is modulated for the long term in obese 
organisms.  In addition to the short-term connection with food intake, circulating 
leptin levels are known to be steadily elevated in obesity (Ahima and Flier 2000, 





 1.3  Regulation of Leptin Production at the Level of Degradation 
Half of newly synthesized leptin proteins are degraded in lysosomes instead of 
being secreted (Lee and Fried 2006). This is not uncommon in adipocytes as a 
large fraction of de novo synthesized secreted proteins undergo immediate 
lysosomal degradation (Olivecrona, Chernick et al. 1987, Appel and Fried 1992, 
Karki, Chakrabarti et al. 2011).  Constant cycles of biosynthesis and degradation 
could possibly provide a faster response to rapid changes in metabolic 
conditions.  Modulation towards transcription expression and 
induction/suppression of proteins would take a longer time than to shift vesicles 
labeled for degradation to be recycled for secretion and vice versa. This 
regulation of secretory proteins, such as leptin, provide a promising mechanism 
to adjust circulating leptin and improve metabolic symptoms in obese and insulin 
resistant patients. 
 
 1.4  Long term modulation of leptin expression 
At the cellular level, larger adipocytes contain and secrete more leptin than 
smaller cells (Hamilton, Paglia et al. 1995, Russell, Ricci et al. 2001).  Since the 
adipocyte size is defined primarily by the volume of the central lipid droplet, this 
phenomenon may show a cell-autonomous connection between the amount of 
stored energy (i.e. obesity at the molecular level) and leptin expression.  The 
correlation between the size of the adipocyte and the level of leptin production 




young rats starved for 14 hours it was noted that plasma leptin content 
decreased by over 75% with leptin mRNA levels reduced by 22% (Lee, Yang et 
al. 2007).  Injection of insulin following starvation increases the association of 
leptin mRNA within the polysomes, resulting 2-3 fold more leptin biosynthesis by 
2 - 3 fold, however leptin mRNA levels remained uncorrected (Lee, Yang et al. 
2007).  These findings show that a single act of food intake is unlikely to change 
the size of the adipocyte in a significant fashion, rather there lies a mechanism 
that should adjust the expression of leptin based on prior feeding events.  
Obesity caused by chronic over-nutrition leads to continuous activation of 
mTORC1 (Khamzina, Veilleux et al. 2005, Wang, Kim et al. 2009, Chakrabarti, 
Kim et al. 2013) leading towards increased triglyceride storage and stimulation of 
leptin production.  The size of the adipocyte may serve as an indicator of the 
cumulative mTORC1 activity that may explain the correlation between adipocyte 
size and levels of leptin production. Normally, this situation should create a 
feedback regulatory loop that terminates eating and limits the expansion of fat 
stores. Organisms, however, adapted and evolved to survive in calorically 
deprived situations, thus advancements in food production at the turn of the 20th 
produced strain on a metabolic system not designed to handle chronic 
overstimulation of mTORC1.  Elevated basal circulating leptin results from this 
feeding behavior and may lead to the leptin resistance found commonly in human 




Here we provide a possible feedback mechanism of hyperphagia triggering 
overexpression of leptin via the mTORC1 pathway.  In response to food 
consumption, adipose tissue releases leptin secretory vesicles and stimulates 
leptin transcription via Egr1 in preparation for the next feeding event.  Variables 
of food consumption, such as diet composition and timing of feeding, have been 
shown to alter leptin expression as well as body weight (Hatori, Vollmers et al. 
2012, Chaix, Zarrinpar et al. 2014).  The frequency and composition of an 
organism’s diet will then stimulate leptin transcription to prepare for future feeding 
events.  Therefore, increases in caloric consumption and/or eating frequency 
increases leptin transcription providing an explanation towards hyperleptinemia in 
obese subjects. 
 HFD has been shown to increase gliosis within the mediobasal 
hypothalamus in both rodents and obese humans.  Mice and rodents fed a HFD 
show hypothalamic gliosis and evidence of neuronal injury within 1 to 3 days 
(Thaler, Yi et al. 2012).  This independent inflammatory mechanism may play 
huge repercussions towards the ability of leptin to bind to its receptor at the VMH, 
thus reducing the satiating effect and inducing further leptin resistance. 
 
2.  Effects of circadian rhythm and food intake on leptin production  
In mammals, the hypothalamic suprachiasmatic nucleus (SCN) receives light 
signals, through the eye, and coordinates the expression of peripheral clock 




rhythm within peripheral tissue is handled through feedback loops of circadian 
genes, namely the heterodimer CLOCK/BMAL1, which induce the expression of 
metabolic pathways via E-box sequences in gene promoters (Gekakis, Staknis et 
al. 1998).  In addition, CLOCK/BMAL1 heterodimer also encodes its own 
repressors Cryptochromes (CRY1 and CRY2), Rev-erbα, Rev-erbβ and Period 
(PER1, PER2 and PER3) to regulate CLOCK/BMAL1 transcription and complex 
stability.  This dynamic relationship creates a sinusoidal wave that, in mice, has 
peak CLOCK/BMAL1 activity at daytime, which wanes in the evening as PER 
and CRY proteins accumulate and translocate into the nucleus to inhibit 
transcription of the heterodimer (Lee, Etchegaray et al. 2001, Lowrey and 
Takahashi 2011). 
Recent studies show that the circadian clock plays a critical role in long-term 
homeostasis of the leptin neuroendocrine feedback loop (Kettner, Mayo et al. 
2015). In adipocytes, the CLOCK/BMAL1 directly controls leptin expression by 
regulating the activity of CCAAT-enhancer-binding protein alpha (C/EBPα) 
(Hwang, Mandrup et al. 1996, Hollenberg, Susulic et al. 1997).  The promoters of 
Egr1, leptin and ATGL all contain E-box sequences, suggesting that circadian 
rhythm plays a large role in the management of metabolism both in food 
consumption and energy expenditure.  
In human adipocyte ex-vivo cultures, leptin expression follows in oscillatory 
pattern consistent with circadian rhythm (Gomez Abellan, Gomez Santos et al. 




mice.  Novel approaches towards managing obesity have revolved around 
studying the frequency and timing of eating in lieu of caloric consumption.  Dr. 
Panda’s group at the Salk institute have shown that time-restricted feeding (TRF) 
protects mice against excessive body weight while consuming HFD and equal 
calories as mice fed ad libitum (Chaix, Zarrinpar et al. 2014)  Livers in the TRF 
cohort contained increased levels of Rev-erbα which reduce expression of fatty 
acid synthase and also contribute to repressing CLOCK/BMAL1 activity (Cho, 
Zhao et al. 2012).  Interestingly, hyperleptinemia is associated in the HFD ad-
libitum cohort but absent in the TRF cohort (Hatori, Vollmers et al. 2012).  To 
further study this phenomena, a translational study in humans was performed to 
understand intermittent fasting and its possible health benefits in obese patients.  
In a 12-week trial obese subjects (BMI between 30 and 45 kg/m2) were tasked 
with recording all food consumed during the period.  There were no dietary 
restrictions, however, the time-restricted cohort was instructed to eat ad libitum 
during 10:00 to 18:00 and fast outside the window (Gabel, Hoddy et al. 2018).  
Body weight, energy intake, systolic blood pressure improved relative to the 
control group over the course.  Though the results are based on compliant 
patient data, this shines new light on the link between diet and weight loss. 
Both circadian rhythm and feeding frequency have been shown to influence the 
circulating concentration of leptin within the organism.  Mice time restricted to 
feeding during the 12-hour light period, outside their normal nocturnal feeding 




2004).  Though feeding plays a role in controlling the circadian rhythm of leptin 
signaling, recent studies have shown that circadian disruption can abolish diurnal 
oscillation of plasma leptin in both humans and animal models without changes 
in external food cues (Kalsbeek, Fliers et al. 2001, Scheer, Hilton et al. 2009).  
Lastly, fasting attenuates leptin diurnal rhythm and lowers plasma leptin below 
the basal level (Ahima, Prabakaran et al. 1996).   
 
3.  FSP27 may control TG levels by regulating expression of leptin and 
ATGL 
Recently, we have found that lipid droplets (LDs) can directly “talk” to the cell 
nucleus, and the central role in this process belongs to the LD protein FSP27 
(a.k.a. CIDEC) (Puri, Konda et al. 2007).  According to our findings (Singh, Kaur 
et al. 2014), FSP27 is localized not only on the surface of LDs, but is also 
present in the cell nucleus where it binds to and regulates transcriptional activity 
of Egr1.  In agreement with these results, we are now showing that FSP27 blocks 
the effect of Egr1 on the activity of the leptin promoter (Fig. 8C).   
In addition, it has been established that fat storage in adipocytes is also 
controlled by mTORC1.  In particular, inhibition of mTORC1 signaling suppresses 
early adipogenesis (Yeh, Bierer et al. 1995, Kim and Chen 2004, Polak, Cybulski 
et al. 2008, Zhang, Huang et al. 2009, Carnevalli, Masuda et al. 2010) and/or 
lipogenesis (Porstmann, Santos et al. 2008, Laplante and Sabatini 2009, 




2013, Ricoult and Manning 2013).  In parallel, mTORC1 inhibits lipolysis in 
adipocytes via the Egr1-mediated transcriptional suppression of the rate-limiting 
lipolytic enzyme, ATGL (Chakrabarti, English et al. 2010, Chakrabarti, Kim et al. 
2013).  The latter effect of mTORC1 may be especially significant since 
mTORC1-mediated inhibition of lipolysis contributes to overall TG accumulation 
in adipocytes at least 10 times more than stimulation of de novo lipogenesis 
(Chakrabarti, English et al. 2010). 
 
Thus, we hypothesize that FSP27 may link the size of LDs (that account for most 
of the adipocyte volume) to leptin expression by inhibiting Egr1.  We propose a 
model to explain the role of FSP27 during feeding and fasting.  In a fed state, 
growing adipocytes would “pull” FSP27 out of the nucleus to promote LD fusion 
and stabilize the expanding LD.  Egr1, in response to mTORC1 activation, 
represses ATGL expression, to inhibit lipolysis, and promotes leptin expression, 
to promote satiety, within the adipocyte.  When the organism goes through a 
period of fasting, activity of lipolytic enzymes release FAs to export energy, thus 
shrinking the LD volume; a fraction of FSP27 will not be LD-bound, thus 
translocating into the nucleus and interacting with Egr1 to alter its transcriptional 
activity.  When the organism is fed following a prolonged fast, FSP27, due to low 
LD volume, would bind to Egr1 leading to suppression of leptin and ATGL 




would cease lipolysis in addition to suppressing satiety to encourage the 
organism to continue feeding and replenish its depleted energy stores. 
 
 3.1.  Leptin resistance and obesity 
It has been recently shown that, following a 48 hour fast in rats, hypoleptinemia 
alters many hormonal functions through the hypothalamic-pituitary-adrenal (HPA) 
axis, increases WAT lipolysis and hepatic acetyl-CoA content to maintain 
euglycemia since neurons feed exclusively on glucose (Perry, Wang et al. 2018).  
When rats were given a physiological replacement dose of leptin after prolonged 
fasting, there was a rapid reduction in HPA axis activity (noted by reduced 
plasma corticotropin releasing hormone (CRH), adrenocorticotropic hormone 
(ACTH) and corticosterone concentrations) followed by suppression of WAT 
lipolysis and gluconeogenesis (Perry and Shulman 2018).  Conversely, high 
doses of leptin increased WAT lipolysis, hepatic acetyl CoA and 
gluconeogenesis.  This dose dependent paradox could be partially explained due 
to the switching between the fed and fasted state.  In the fasted state strong 
inhibition of mTORC1 due to a lack of nutrients and insulinand increased 
inhibitory phosphorylation of raptor by AMPK, would result in increased lipolysis 
(Gwinn, Shackelford et al. 2008).  Acute leptin treatment has varying effects on 
different organs, however AMPK activation and ACC repression in muscles result 
in increased fatty acid metabolism (Minokoshi, Kim et al. 2002).  Within 




insulin, including glucose transport stimulation, glycogen synthase, lipogenesis, 
inhibition of lipolysis and PKA activation (Muller, Ertl et al. 1997).   
 
Clinically, obese and/or diabetic patients would present chronic hyperleptinemia, 
thus further impairing insulin function.  Functional magnetic resonance imaging 
studies done in weight loss patients repleted with leptin injections showed 
increased functional activity (blood flow) with the mid-insula and the central and 
parietal operculae, suggesting a down-regulated sensitivity to visual food stimuli 
compared to placebo injections (Hinkle, Cordell et al. 2013).  Previous studies by 
Rosenbaum lab also show a reduction in bioactive thyroid hormone when leptin 
repletion is involved in weight loss patients (Rosenbaum, Goldsmith et al. 2005).  
Limitations of the study are due to leptin repletion being set at a specific time 
when circulating leptin is suspected to be at a low circulating level (8 am).  With 
new studies showing the sinusoidal rhythm of leptin and other crucial hormones a 
more focused study could reveal deeper mechanisms between the post-prandial 
effects of adipose tissue with the neural connection reshaping occurring 
chronically within both the obese and weight loss population.  
 
In recent years efforts to combat the populations’ growing waist size led to the 
increase in gastric bypass surgeries performed (English, DeMaria et al. 2018).  
Roux-en-Y gastric bypass (RYGB) creates a small gastric pouch in the upper 




stomach and upper small intestines.  This procedure reduces the size of the 
stomach volume while sparing the fundus of the stomach to produce HCl to 
digest food.  Patients undergoing RYGB note earlier satiety, significant 
weightloss and reduction in numerous metabolic markers within the first few 
months post operatively.  Additional effects on absorption have been noted in 
patients receiving RYGB, notably reduced gastric volume, increased gastric pH, 
delayed gastric emptying, and decreased surface area for absorption of nutrients 
and drugs (Nocca, Krawczykowski et al. 2008, Padwal, Brocks et al. 2010). 
Several recent studies (Billeter, Vittas et al. 2017, Liu, Mu et al. 2017) describe a 
decrease in circulating leptin after Roux-en-Y gastric bypass (RYGB) surgery.  
We suggest that reduced meal-portion size, due to RYGB, may sensitize 
adipocytes to insulin or other secretagogues, reducing release of leptin and 
alleviating leptin resistance. 
Diabetic patients, following RYGB surgery, have significant reductions in glucose, 
HbA1c and HOMA score 6 months following surgery, however insulin 
concentrations did not decrease significantly (Sierzantowicz, Lewko et al. 2017).  
Hyperinsulinemia detected in a fasted blood tests suggests unresolved metabolic 
dysfunction, which if not corrected will provoke the re-emergence of 
comorbidities in these cohorts.  The sinusoidal rhythm of plasma leptin following 
a meal allows for the appropriate satiation of the organism, re-sensitization and 
preparation of adipocytes prior to the next feeding event.  Though 




by Panda lab have shown decreases in plasma leptin outside the feeding window 
regardless of diet (Hatori, Vollmers et al. 2012, Chaix, Zarrinpar et al. 2014, 
Gabel, Hoddy et al. 2018).  Clinical case studies have demonstrated in insulin-
dependent T2D patients that therapeutic fasting reversed insulin resistance, 
decreased waist circumference and were able to manage blood glucose levels 
with less reliance on external insulin (Furmli, Elmasry et al. 2018).  The side 
effects of time-restricted feeding are miniscule compared to the complications 
that arise during and after RYGB, however, more research is required to better 








. Leptin Regulation and Clinical Applications. M. Sam Dagogo-Jack, Springer, Cham: 18. 
Abraham, D., K. Podar, M. Pacher, M. Kubicek, N. Welzel, B. A. Hemmings, S. M. 
Dilworth, H. Mischak, W. Kolch and M. Baccarini (2000). "Raf-1-associated protein 
phosphatase 2A as a positive regulator of kinase activation." Journal of Biological 
Chemistry 275(29): 22300-22304. 
Adeyo, O., P. J. Horn, S. Lee, D. D. Binns, A. Chandrahas, K. D. Chapman and J. M. 
Goodman (2011). "The yeast lipin orthologue Pah1p is important for biogenesis of lipid 
droplets." The Journal of cell biology 192(6): 1043-1055. 
Ahima, R. S. and J. S. Flier (2000). "Leptin." Annual Review of Physiology 62: 413-437. 
Ahima, R. S. and S. Y. Osei (2004). "Leptin signaling." Physiology & Behavior 81(2): 
223-241. 
Ahima, R. S., D. Prabakaran, C. Mantzoros, D. Qu, B. Lowell, E. Maratos-Flier and J. S. 
Flier (1996). "Role of leptin in the neuroendocrine response to fasting." Nature 382(6588): 
250-252. 
Akter, M. H., T. Yamaguchi, F. Hirose and T. Osumi (2008). "Perilipin, a critical regulator 
of fat storage and breakdown, is a target gene of estrogen receptor-related receptor alpha." 
Biochemical and Biophysical Research Communications 368(3): 563-568. 
Anand, B. K. and J. R. Brobeck (1951). "Localization of a "feeding center" in the 
hypothalamus of the rat." Proceedings of the Society for Experimental Biology and 
Medicine 77(2): 323-324. 
Appel, B. and S. K. Fried (1992). "Effects of insulin and dexamethasone on lipoprotein 
lipase in human adipose tissue." American Journal of Physiology 262(5 Pt 1): E695-699. 
Arner, P. and D. Langin (2014). "Lipolysis in lipid turnover, cancer cachexia, and obesity-




Avruch, J., A. Khokhlatchev, J. M. Kyriakis, Z. Luo, G. Tzivion, D. Vavvas and X. F. 
Zhang (2001). "Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP 
kinase cascade." Recent Progress in Hormone Research 56: 127-155. 
Aylett, C. H., E. Sauer, S. Imseng, D. Boehringer, M. N. Hall, N. Ban and T. Maier (2016). 
"Architecture of human mTOR complex 1." Science 351(6268): 48-52. 
Backberg, M., N. Madjid, S. O. Ogren and B. Meister (2004). "Down-regulated expression 
of agouti-related protein (AGRP) mRNA in the hypothalamic arcuate nucleus of 
hyperphagic and obese tub/tub mice." Brain Research: Molecular Brain Research 125(1-
2): 129-139. 
Bahary, N., R. L. Leibel, L. Joseph and J. M. Friedman (1990). "Molecular mapping of the 
mouse db mutation." Proceedings of the National Academy of Sciences of the United States 
of America 87(21): 8642-8646. 
Bahary, N., D. E. McGraw, R. Shilling and J. M. Friedman (1993). "Microdissection and 
microcloning of mid-chromosome 4: genetic mapping of 41 microdissection clones." 
Genomics 16(1): 113-122. 
Bahrenberg, G., I. Behrmann, A. Barthel, P. Hekerman, P. C. Heinrich, H. G. Joost and W. 
Becker (2002). "Identification of the critical sequence elements in the cytoplasmic domain 
of leptin receptor isoforms required for Janus kinase/signal transducer and activator of 
transcription activation by receptor heterodimers." Molecular Endocrinology 16(4): 859-
872. 
Bailleul, B., I. Akerblom and A. D. Strosberg (1997). "The leptin receptor promoter 
controls expression of a second distinct protein." Nucleic Acids Research 25(14): 2752-
2758. 
Bakan, I. and M. Laplante (2012). "Connecting mTORC1 signaling to SREBP-1 
activation." Current Opinion in Lipidology 23(3): 226-234. 
Balthasar, N., R. Coppari, J. McMinn, S. M. Liu, C. E. Lee, V. Tang, C. D. Kenny, R. A. 
McGovern, S. C. Chua, Jr., J. K. Elmquist and B. B. Lowell (2004). "Leptin receptor 





Banks, W. A., A. J. Kastin, W. Huang, J. B. Jaspan and L. M. Maness (1996). "Leptin 
enters the brain by a saturable system independent of insulin." Peptides 17(2): 305-311. 
Banks, W. A., B. M. King, K. N. Rossiter, R. D. Olson, G. A. Olson and A. J. Kastin 
(2001). "Obesity-inducing lesions of the central nervous system alter leptin uptake by the 
blood-brain barrier." Life Sciences 69(23): 2765-2773. 
Bar-Peled, L., L. Chantranupong, A. D. Cherniack, W. W. Chen, K. A. Ottina, B. C. 
Grabiner, E. D. Spear, S. L. Carter, M. Meyerson and D. M. Sabatini (2013). "A Tumor 
Suppressor Complex with GAP Activity for the Rag GTPases That Signal Amino Acid 
Sufficiency to mTORC1." Science 340(6136): 1100-1106. 
Bar-Peled, L., L. D. Schweitzer, R. Zoncu and D. M. Sabatini (2012). "Ragulator is a GEF 
for the rag GTPases that signal amino acid levels to mTORC1." Cell 150(6): 1196-1208. 
Barr, V. A., D. Malide, M. J. Zarnowski, S. I. Taylor and S. W. Cushman (1997). "Insulin 
stimulates both leptin secretion and production by rat white adipose tissue." Endocrinology 
138(10): 4463-4472. 
Barr, V. A., D. Malide, M. J. Zarnowski, S. I. Taylor and S. W. Cushman (1997). "Insulin 
stimulates both leptin secretion and production by rat white adipose tissue." Endocrinology 
138(10): 4463-4472. 
Baskin, D. G., T. M. Hahn and M. W. Schwartz (1999). "Leptin sensitive neurons in the 
hypothalamus." Hormone and Metabolic Research 31(5): 345-350. 
Bates, S. H., W. H. Stearns, T. A. Dundon, M. Schubert, A. W. Tso, Y. Wang, A. S. Banks, 
H. J. Lavery, A. K. Haq, E. Maratos-Flier, B. G. Neel, M. W. Schwartz and M. G. Myers, 
Jr. (2003). "STAT3 signalling is required for leptin regulation of energy balance but not 
reproduction." Nature 421(6925): 856-859. 
Bernardi, R., I. Guernah, D. Jin, S. Grisendi, A. Alimonti, J. Teruya-Feldstein, C. Cordon-
Cardo, M. Celeste Simon, S. Rafii and P. P. Pandolfi (2006). "PML inhibits HIF-1α 
translation and neoangiogenesis through repression of mTOR." Nature 442: 779. 
Bernotiene, E., G. Palmer and C. Gabay (2006). "The role of leptin in innate and adaptive 




Bezaire, V., A. Mairal, C. Ribet, C. Lefort, A. Girousse, J. Jocken, J. Laurencikiene, R. 
Anesia, A. M. Rodriguez, M. Ryden, B. M. Stenson, C. Dani, G. Ailhaud, P. Arner and D. 
Langin (2009). "Contribution of Adipose Triglyceride Lipase and Hormone-sensitive 
Lipase to Lipolysis in hMADS Adipocytes." Journal of Biological Chemistry 284(27): 
18282-18291. 
Bickel, P. E., J. T. Tansey and M. A. Welte (2009). "PAT proteins, an ancient family of 
lipid droplet proteins that regulate cellular lipid stores." Biochimica et Biophysica Acta 
(BBA) - Bioenergetics 1791(6): 419-440. 
Billeter, A. T., S. Vittas, B. Israel, K. M. Scheurlen, A. Hidmark, T. H. Fleming, S. Kopf, 
M. W. Buchler and B. P. Muller-Stich (2017). "Gastric bypass simultaneously improves 
adipose tissue function and insulin-dependent type 2 diabetes mellitus." Langenbecks Arch 
Surg 402(6): 901-910. 
Bjorbaek, C., R. M. Buchholz, S. M. Davis, S. H. Bates, D. D. Pierroz, H. Gu, B. G. Neel, 
M. G. Myers, Jr. and J. S. Flier (2001). "Divergent roles of SHP-2 in ERK activation by 
leptin receptors." Journal of Biological Chemistry 276(7): 4747-4755. 
Bjørbæk, C., J. K. Elmquist, J. D. Frantz, S. E. Shoelson and J. S. Flier (1998). 
"Identification of SOCS-3 as a Potential Mediator of Central Leptin Resistance." Molecular 
Cell 1(4): 619-625. 
Bjorbaek, C. and B. B. Kahn (2004). "Leptin signaling in the central nervous system and 
the periphery." Recent Progress in Hormone Research 59: 305-331. 
Bjorbak, C., H. J. Lavery, S. H. Bates, R. K. Olson, S. M. Davis, J. S. Flier and M. G. 
Myers, Jr. (2000). "SOCS3 mediates feedback inhibition of the leptin receptor via Tyr985." 
Journal of Biological Chemistry 275(51): 40649-40657. 
Bodosi, B., J. Gardi, I. Hajdu, E. Szentirmai, F. Obal, Jr. and J. M. Krueger (2004). 
"Rhythms of ghrelin, leptin, and sleep in rats: effects of the normal diurnal cycle, restricted 
feeding, and sleep deprivation." American Journal of Physiology: Regulatory, Integrative 
and Comparative Physiology 287(5): R1071-1079. 
Bostrom, P., L. Andersson, M. Rutberg, J. Perman, U. Lidberg, B. R. Johansson, J. 




proteins mediate fusion between cytosolic lipid droplets and are implicated in insulin 
sensitivity." Nature Cell Biology 9(11): 1286-1293. 
Boucher, J., A. Kleinridders and C. R. Kahn "Insulin receptor signaling in normal and 
insulin-resistant states." Cold Spring Harbor Perspectives in Biology 6(1): a009191. 
Bouzakri, K., A. Zachrisson, L. Al-Khalili, B. B. Zhang, H. A. Koistinen, A. Krook and J. 
R. Zierath (2006). "siRNA-based gene silencing reveals specialized roles of IRS-1/Akt2 
and IRS-2/Akt1 in glucose and lipid metabolism in human skeletal muscle." Cell 
Metabolism 4(1): 89-96. 
Bradley, R. L. and B. Cheatham (1999). "Regulation of ob gene expression and leptin 
secretion by insulin and dexametasone in rat adipocytes." Diabetes 48: 272-278. 
Brasaemle, D. L., G. Dolios, L. Shapiro and R. Wang (2004). "Proteomic Analysis of 
Proteins Associated with Lipid Droplets of Basal and Lipolytically Stimulated 3T3-L1 
Adipocytes." Journal of Biological Chemistry 279(45): 46835-46842. 
Brasaemle, D. L., G. Dolios, L. Shapiro and R. Wang (2004). "Proteomic analysis of 
proteins associated with lipid droplets of basal and lipolytically stimulated 3T3-L1 
adipocytes." J Biol Chem 279(45): 46835-46842. 
Brown, E. J., M. W. Albers, T. B. Shin, K. Ichikawa, C. T. Keith, W. S. Lane and S. L. 
Schreiber (1994). "A mammalian protein targeted by G1-arresting rapamycin-receptor 
complex." Nature 369(6483): 756-758. 
Brown, N. F., M. Stefanovic-Racic, I. J. Sipula and G. Perdomo (2007). "The mammalian 
target of rapamycin regulates lipid metabolism in primary cultures of rat hepatocytes." 
Metabolism 56(11): 1500-1507. 
Brugarolas, J., K. Lei, R. L. Hurley, B. D. Manning, J. H. Reiling, E. Hafen, L. A. Witters, 
L. W. Ellisen and W. G. Kaelin, Jr. (2004). "Regulation of mTOR function in response to 
hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex." Genes & 
Development 18(23): 2893-2904. 
Burn, S. F. (2012). Detection of β-Galactosidase Activity: X-gal Staining. Kidney 




Burnett, P. E., R. K. Barrow, N. A. Cohen, S. H. Snyder and D. M. Sabatini (1998). 
"RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1." 
Proceedings of the National Academy of Sciences of the United States of America 95(4): 
1432-1437. 
Cafferkey, R., P. R. Young, M. M. McLaughlin, D. J. Bergsma, Y. Koltin, G. M. Sathe, L. 
Faucette, W. K. Eng, R. K. Johnson and G. P. Livi (1993). "Dominant missense mutations 
in a novel yeast protein related to mammalian phosphatidylinositol 3-kinase and VPS34 
abrogate rapamycin cytotoxicity." Molecular and Cellular Biology 13(10): 6012-6023. 
Cancello, R., C. Henegar, N. Viguerie, S. Taleb, C. Poitou, C. Rouault, M. Coupaye, V. 
Pelloux, D. Hugol, J. L. Bouillot, A. Bouloumie, G. Barbatelli, S. Cinti, P. A. Svensson, 
G. S. Barsh, J. D. Zucker, A. Basdevant, D. Langin and K. Clement (2005). "Reduction of 
macrophage infiltration and chemoattractant gene expression changes in white adipose 
tissue of morbidly obese subjects after surgery-induced weight loss." Diabetes 54(8): 2277-
2286. 
Cardamone, M. D., J. Orofino, A. Labadorf and V. Perissi (2018). "Chromatin 
Immunoprecipitation of Murine Brown Adipose Tissue." JoVE(141): e58682. 
Carnevalli, L. S., K. Masuda, F. Frigerio, O. Le Bacquer, S. H. Um, V. Gandin, I. 
Topisirovic, N. Sonenberg, G. Thomas and S. C. Kozma (2010). "S6K1 Plays a Critical 
Role in Early Adipocyte Differentiation." Developmental Cell 18(5): 763-774. 
Carnevalli, L. S., K. Masuda, F. Frigerio, O. Le Bacquer, S. H. Um, V. Gandin, I. 
Topisirovic, N. Sonenberg, G. Thomas and S. C. Kozma (2010). "S6K1 plays a critical role 
in early adipocyte differentiation." Dev Cell 18(5): 763-774. 
Chaix, A., A. Zarrinpar, P. Miu and S. Panda (2014). "Time-restricted feeding is a 
preventative and therapeutic intervention against diverse nutritional challenges." Cell 
metabolism 20(6): 991-1005. 
Chakrabarti, P., T. Anno, B. D. Manning, Z. Luo and K. V. Kandror (2008). "The 
mammalian target of rapamycin complex 1 regulates leptin biosynthesis in adipocytes at 
the level of translation: the role of the 5'-untranslated region in the expression of leptin 




Chakrabarti, P., T. Anno, B. D. Manning, Z. Luo and K. V. Kandror (2008). "The 
Mammalian Target of Rapamycin Complex 1 Regulates Leptin Biosynthesis in Adipocytes 
at the Level of Translation: The Role of the 5′-Untranslated Region in the Expression of 
Leptin Messenger Ribonucleic Acid." Molecular Endocrinology 22(10): 2260-2267. 
Chakrabarti, P., T. English, J. Shi, C. M. Smas and K. V. Kandror (2010). "The mTOR 
complex 1 suppresses lipolysis, stimulates lipogenesis and promotes fat storage." Diabetes 
59: 775-781. 
Chakrabarti, P. and K. V. Kandror (2009). "FoxO1 controls insulin-dependent ATGL 
expression and lipolysis in adipocytes." Journal of Biological Chemistry 284(20): 13296-
13300. 
Chakrabarti, P., J. Y. Kim, M. Singh, Y. K. Shin, J. Kim, J. Kumbrink, Y. Wu, M. J. Lee, 
K. H. Kirsch, S. K. Fried and K. V. Kandror (2013). "Insulin Inhibits Lipolysis in 
Adipocytes via the Evolutionarily Conserved mTORC1-Egr1-ATGL-Mediated Pathway." 
Molecular and Cellular Biology 33(18): 3659-3666. 
Chakrabarti, P., J. Y. Kim, M. Singh, Y. K. Shin, J. Kim, J. Kumbrink, Y. Wu, M. J. Lee, 
K. H. Kirsch, S. K. Fried and K. V. Kandror (2013). "Insulin inhibits lipolysis in adipocytes 
via the evolutionary conserved mTORC1-Egr1-ATGL-mediated pathway." Molecular and 
Cellular Biology 33: 3659-3666. 
Chen, Z., J. Y. Norris and B. N. Finck (2010). "Peroxisome proliferator-activated receptor-
gamma coactivator-1alpha (PGC-1alpha) stimulates VLDL assembly through activation of 
cell death-inducing DFFA-like effector B (CideB)." Journal of Biological Chemistry 
285(34): 25996-26004. 
Cheng, Z., Y. Tseng and M. F. White (2010). "Insulin signaling meets mitochondria in 
metabolism." Trends in Endocrinology and Metabolism 21(10): 589-598. 
Chitraju, C., M. Trotzmuller, J. Hartler, H. Wolinski, G. G. Thallinger, A. Lass, R. Zechner, 
R. Zimmermann, H. C. Kofeler and F. Spener (2012). "Lipidomic analysis of lipid droplets 
from murine hepatocytes reveals distinct signatures for nutritional stress." Journal of Lipid 
Research 53(10): 2141-2152. 
Cho, H., X. Zhao, M. Hatori, R. T. Yu, G. D. Barish, M. T. Lam, L. W. Chong, L. 




M. Evans (2012). "Regulation of circadian behaviour and metabolism by REV-ERB-alpha 
and REV-ERB-beta." Nature 485(7396): 123-127. 
Choe, S. S., J. Y. Huh, I. J. Hwang, J. I. Kim and J. B. Kim (2016). "Adipose Tissue 
Remodeling: Its Role in Energy Metabolism and Metabolic Disorders." Frontiers in 
Endocrinology 7: 30-30. 
Choi, S. M., D. F. Tucker, D. N. Gross, R. M. Easton, L. M. DiPilato, A. S. Dean, B. R. 
Monks and M. J. Birnbaum (2010). "Insulin regulates adipocyte lipolysis via an Akt-
independent signaling pathway." Molecular and Cellular Biology 30(21): 5009-5020. 
Coleman, D. L. (1978). "Obese and diabetes: two mutant genes causing diabetes-obesity 
syndromes in mice." Diabetologia 14(3): 141-148. 
Copps, K. D., N. J. Hançer, W. Qiu and M. F. White (2016). "Serine 302 Phosphorylation 
of Mouse Insulin Receptor Substrate 1 (IRS1) Is Dispensable for Normal Insulin Signaling 
and Feedback Regulation by Hepatic S6 Kinase." The Journal of biological chemistry 
291(16): 8602-8617. 
Czech, M. P. (2017). "Insulin action and resistance in obesity and type 2 diabetes." Nature 
Medicine 23(7): 804-814. 
Dagogo-Jack, M. D. S. and SpringerLink (Online service). (2015). Leptin Regulation and 
Clinical Applications. Cham, Springer International Publishing : Imprint: Springer. 
Dagon, Y., E. Hur, B. Zheng, K. Wellenstein, L. C. Cantley and B. B. Kahn (2012). "p70S6 
kinase phosphorylates AMPK on serine 491 to mediate leptin's effect on food intake." Cell 
Metab 16(1): 104-112. 
Dalamaga, M., S. H. Chou, K. Shields, P. Papageorgiou, S. A. Polyzos and C. S. Mantzoros 
(2013). "Leptin at the intersection of neuroendocrinology and metabolism: current 
evidence and therapeutic perspectives." Cell Metab 18(1): 29-42. 
Dalen, K. T., T. Dahl, E. Holter, B. Arntsen, C. Londos, C. Sztalryd and H. I. Nebb (2007). 
"LSDP5 is a PAT protein specifically expressed in fatty acid oxidizing tissues." Biochimica 




Delibegovic, M., D. Zimmer, C. Kauffman, K. Rak, E.-G. Hong, Y.-R. Cho, J. K. Kim, B. 
B. Kahn, B. G. Neel and K. K. Bence (2009). "Liver-specific deletion of protein-tyrosine 
phosphatase 1B (PTP1B) improves metabolic syndrome and attenuates diet-induced 
endoplasmic reticulum stress." Diabetes 58(3): 590-599. 
Dennis, M. D., L. S. Jefferson and S. R. Kimball (2012). "Role of p70S6K1-mediated 
phosphorylation of eIF4B and PDCD4 proteins in the regulation of protein synthesis." 
Journal of Biological Chemistry 287(51): 42890-42899. 
Dennis, P. B., A. Jaeschke, M. Saitoh, B. Fowler, S. C. Kozma and G. Thomas (2001). 
"Mammalian TOR: a homeostatic ATP sensor." Science 294(5544): 1102-1105. 
Dhillon, A. S., S. Hagan, O. Rath and W. Kolch (2007). "MAP kinase signalling pathways 
in cancer." Oncogene 26: 3279. 
Dibble, C. C., W. Elis, S. Menon, W. Qin, J. Klekota, J. M. Asara, P. M. Finan, D. J. 
Kwiatkowski, L. O. Murphy and B. D. Manning (2012). "TBC1D7 Is a Third Subunit of 
the TSC1-TSC2 Complex Upstream of mTORC1." Molecular Cell. 
Dibble, C. C. and B. D. Manning (2013). "Signal integration by mTORC1 coordinates 
nutrient input with biosynthetic output." Nature Cell Biology 15(6): 555-564. 
Dibble, C. C. and B. D. Manning (2013). "Signal integration by mTORC1 coordinates 
nutrient input with biosynthetic output." Nat Cell Biol 15(6): 555-564. 
Dickie, M. and P. Lane (1957). "Plus letter to Roy robinson 7/7/70." Mouse News Lett 17: 
52. 
Donnelly, K. L., C. I. Smith, S. J. Schwarzenberg, J. Jessurun, M. D. Boldt and E. J. Parks 
(2005). "Sources of fatty acids stored in liver and secreted via lipoproteins in patients with 
nonalcoholic fatty liver disease." Journal of Clinical Investigation 115(5): 1343-1351. 
Dorrello, N. V., A. Peschiaroli, D. Guardavaccaro, N. H. Colburn, N. E. Sherman and M. 
Pagano (2006). "S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein 




Duncan, R. E., M. Ahmadian, K. Jaworski, E. Sarkadi-Nagy and H. S. Sul (2007). 
"Regulation of Lipolysis in Adipocytes." Annual Review of Nutrition 27(1): 79-101. 
Egan, J. J., A. S. Greenberg, M. K. Chang and C. Londos (1990). "Control of endogenous 
phosphorylation of the major cAMP-dependent protein kinase substrate in adipocytes by 
insulin and beta-adrenergic stimulation." Journal of Biological Chemistry 265(31): 18769-
18775. 
El-Haschimi, K., D. D. Pierroz, S. M. Hileman, C. Bjørbaek and J. S. Flier (2000). "Two 
defects contribute to hypothalamic leptin resistance in mice with diet-induced obesity." 
The Journal of clinical investigation 105(12): 1827-1832. 
English, W. J., E. J. DeMaria, S. A. Brethauer, S. G. Mattar, R. J. Rosenthal and J. M. 
Morton (2018). "American Society for Metabolic and Bariatric Surgery estimation of 
metabolic and bariatric procedures performed in the United States in 2016." Surgery for 
Obesity and Related Diseases 14(3): 259-263. 
Farmer, S. R. (2003). "The Forkhead Transcription Factor Foxo1: A Possible Link between 
Obesity and Insulin Resistance." Molecular Cell 11(1): 6-8. 
Farooqi, I. S., S. A. Jebb, G. Langmack, E. Lawrence, C. H. Cheetham, A. M. Prentice, I. 
A. Hughes, M. A. McCamish and S. O'Rahilly (1999). "Effects of Recombinant Leptin 
Therapy in a Child with Congenital Leptin Deficiency." New England Journal of Medicine 
341(12): 879-884. 
Frank, S., M. Heni, A. Moss, J. von Schnurbein, S. Farooqi, H.-U. Häring, A. Fritsche, H. 
Preissl and M. Wabitsch (2013). "Long-term stabilization effects of leptin on brain 
functions in a leptin-deficient patient." PloS One 8(6): e65893-e65893. 
Frederich, R. C., B. Lollmann, A. Hamann, A. Napolitano-Rosen, B. B. Kahn, B. B. Lowell 
and J. S. Flier (1995). "Expression of ob mRNA and its encoded protein in rodents. Impact 
of nutrition and obesity." Journal of Clinical Investigation 96(3): 1658-1663. 
Frias, M. A., C. C. Thoreen, J. D. Jaffe, W. Schroder, T. Sculley, S. A. Carr and D. M. 
Sabatini (2006). "mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define 




Friedman, J. M. (2009). "Leptin at 14 y of age: an ongoing story." American Journal of 
Clinical Nutrition 89(3): 973S-979S. 
Friedman, J. M., R. L. Leibel and N. Bahary (1991). "Molecular mapping of obesity genes." 
Mammalian Genome 1(3): 130-144. 
Friedman, J. M., R. L. Leibel, N. Bahary, D. A. Siegel and G. Truett (1991). "Genetic 
analysis of complex disorders. Molecular mapping of obesity genes in mice and humans." 
Annals of the New York Academy of Sciences 630: 100-115. 
Frühbeck, G. (2006). "Intracellular signalling pathways activated by leptin." The 
Biochemical journal 393(Pt 1): 7-20. 
Furmli, S., R. Elmasry, M. Ramos and J. Fung (2018). "Therapeutic use of intermittent 
fasting for people with type 2 diabetes as an alternative to insulin." BMJ Case Reports 
2018. 
Gabel, K., K. K. Hoddy, N. Haggerty, J. Song, C. M. Kroeger, J. F. Trepanowski, S. Panda 
and K. A. Varady (2018). "Effects of 8-hour time restricted feeding on body weight and 
metabolic disease risk factors in obese adults: A pilot study." Nutrition and healthy aging 
4(4): 345-353. 
Gagnon, A., S. Lau and A. Sorisky (2001). "Rapamycin-sensitive phase of 3T3-L1 
preadipocyte differentiation after clonal expansion." Journal of Cellular Physiology 
189(1): 14-22. 
Gekakis, N., D. Staknis, H. B. Nguyen, F. C. Davis, L. D. Wilsbacher, D. P. King, J. S. 
Takahashi and C. J. Weitz (1998). "Role of the CLOCK protein in the mammalian circadian 
mechanism." Science 280(5369): 1564-1569. 
Gesta, S., Y. H. Tseng and C. R. Kahn (2007). "Developmental origin of fat: tracking 
obesity to its source." Cell 131(2): 242-256. 
Gingras, A.-C., B. Raught and N. Sonenberg (1999). "eIF4 INITIATION FACTORS: 
Effectors of mRNA Recruitment to Ribosomes and Regulators of Translation." Annual 




Gingras, A. C., S. P. Gygi, B. Raught, R. D. Polakiewicz, R. T. Abraham, M. F. Hoekstra, 
R. Aebersold and N. Sonenberg (1999). "Regulation of 4E-BP1 phosphorylation: a novel 
two-step mechanism." Genes & Development 13(11): 1422-1437. 
Goh, V. J. and D. L. Silver (2013). "The lipid droplet as a potential therapeutic target in 
NAFLD." Seminars in Liver Disease 33(4): 312-320. 
Gomez Abellan, P., C. Gomez Santos, J. A. Madrid, F. I. Milagro, J. Campion, J. A. 
Martinez, J. A. Lujan, J. M. Ordovas and M. Garaulet (2011). "Site-specific circadian 
expression of leptin and its receptor in human adipose tissue." Nutricion Hospitalaria 26(6): 
1394-1401. 
Gong, J., Z. Sun, L. Wu, W. Xu, N. Schieber, D. Xu, G. Shui, H. Yang, R. G. Parton and 
P. Li (2011). "Fsp27 promotes lipid droplet growth by lipid exchange and transfer at lipid 
droplet contact sites." Journal of Cell Biology 195(6): 953-963. 
Goorden, S. M., M. Hoogeveen-Westerveld, C. Cheng, G. M. van Woerden, M. Mozaffari, 
L. Post, H. J. Duckers, M. Nellist and Y. Elgersma (2011). "Rheb is essential for murine 
development." Molecular and Cellular Biology 31(8): 1672-1678. 
Grahn, T. H., R. Kaur, J. Yin, M. Schweiger, V. M. Sharma, M. J. Lee, Y. Ido, C. M. Smas, 
R. Zechner, A. Lass and V. Puri (2014). "FSP27 interacts with ATGL to regulate lipolysis 
and insulin sensitivity in human adipocytes." Journal of Biological Chemistry. 
Green, E. D., M. Maffei, V. V. Braden, R. Proenca, U. DeSilva, Y. Zhang, S. C. Chua, Jr., 
R. L. Leibel, J. Weissenbach and J. M. Friedman (1995). "The human obese (OB) gene: 
RNA expression pattern and mapping on the physical, cytogenetic, and genetic maps of 
chromosome 7." Genome Research 5(1): 5-12. 
Gregor, M. F. and G. S. Hotamisligil (2007). "Thematic review series: Adipocyte Biology. 
Adipocyte stress: the endoplasmic reticulum and metabolic disease." Journal of Lipid 
Research 48(9): 1905-1914. 
Grönke, S., A. Mildner, S. Fellert, N. Tennagels, S. Petry, G. Müller, H. Jäckle and R. P. 
Kühnlein (2005). "Brummer lipase is an evolutionary conserved fat storage regulator in 




Gross, D. A., C. Zhan and D. L. Silver (2011). "Direct binding of triglyceride to fat storage-
inducing transmembrane proteins 1 and 2 is important for lipid droplet formation." 
Proceedings of the National Academy of Sciences of the United States of America 108(49): 
19581-19586. 
Guertin, D. A., D. M. Stevens, C. C. Thoreen, A. A. Burds, N. Y. Kalaany, J. Moffat, M. 
Brown, K. J. Fitzgerald and D. M. Sabatini (2006). "Ablation in mice of the mTORC 
components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to 
Akt-FOXO and PKCalpha, but not S6K1." Developmental Cell 11(6): 859-871. 
Gumbiner, B., E. Van Cauter, W. F. Beltz, T. M. Ditzler, K. Griver, K. S. Polonsky and R. 
R. Henry (1996). "Abnormalities of insulin pulsatility and glucose oscillations during 
meals in obese noninsulin-dependent diabetic patients: effects of weight reduction." J Clin 
Endocrinol Metab 81(6): 2061-2068. 
Guo, Q., S. Jin, H. Hu, Y. Zhou, Y. Yan, H. Zong, Y. Wang, H. He, Y. Oh, C. Liu and N. 
Gu (2017). "Hypoxia in 3T3-L1 adipocytes suppresses adiponectin expression via the 
PERK and IRE1 unfolded protein response." Biochemical and Biophysical Research 
Communications 493(1): 346-351. 
Gwinn, D. M., D. B. Shackelford, D. F. Egan, M. M. Mihaylova, A. Mery, D. S. Vasquez, 
B. E. Turk and R. J. Shaw (2008). "AMPK Phosphorylation of Raptor Mediates a 
Metabolic Checkpoint." Molecular Cell 30(2): 214-226. 
Haemmerle, G. (2006). "Defective Lipolysis and Altered Energy Metabolism in Mice 
Lacking Adipose Triglyceride Lipase." Science 312(5774): 734-737. 
Halaas, J. L., K. S. Gajiwala, M. Maffei, S. L. Cohen, B. T. Chait, D. Rabinowitz, R. L. 
Lallone, S. K. Burley and J. M. Friedman (1995). "Weight-reducing effects of the plasma 
protein encoded by the obese gene." Science 269(5223): 543-546. 
Hamilton, B. S., D. Paglia, A. Y. Kwan and M. Deitel (1995). "Increased obese mRNA 
expression in omental fat cells from massively obese humans." Nature Medicine 1(9): 953-
956. 
Hara, K., Y. Maruki, X. Long, K. Yoshino, N. Oshiro, S. Hidayat, C. Tokunaga, J. Avruch 
and K. Yonezawa (2002). "Raptor, a binding partner of target of rapamycin (TOR), 




Harrington, L. S., G. M. Findlay, A. Gray, T. Tolkacheva, S. Wigfield, H. Rebholz, J. 
Barnett, N. R. Leslie, S. Cheng, P. R. Shepherd, I. Gout, C. P. Downes and R. F. Lamb 
(2004). "The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of 
IRS proteins." Journal of Cell Biology 166(2): 213-223. 
Harris, R. B. S. (2013). "Is leptin the parabiotic "satiety" factor? Past and present 
interpretations." Appetite 61(1): 111-118. 
Hatori, M., C. Vollmers, A. Zarrinpar, L. DiTacchio, E. A. Bushong, S. Gill, M. Leblanc, 
A. Chaix, M. Joens, J. A. J. Fitzpatrick, M. H. Ellisman and S. Panda (2012). "Time-
restricted feeding without reducing caloric intake prevents metabolic diseases in mice fed 
a high-fat diet." Cell metabolism 15(6): 848-860. 
Hegyi, K., K. Fulop, K. Kovacs, S. Toth and A. Falus (2004). "Leptin-induced signal 
transduction pathways." Cell Biology International 28(3): 159-169. 
Hekerman, P., J. Zeidler, S. Bamberg-Lemper, H. Knobelspies, D. Lavens, J. Tavernier, 
H. G. Joost and W. Becker (2005). "Pleiotropy of leptin receptor signalling is defined by 
distinct roles of the intracellular tyrosines." FEBS Journal 272(1): 109-119. 
Hervey, G. R. (1959). "The effects of lesions in the hypothalamus in parabiotic rats." The 
Journal of physiology 145(2): 336-352. 
Hervey, G. R. (2013). "Control of appetite. Personal and departmental recollections." 
Appetite 61: 100-110. 
Heymsfield, S. B., A. S. Greenberg, K. Fujioka, R. M. Dixon, R. Kushner, T. Hunt, J. A. 
Lubina, J. Patane, B. Self, P. Hunt and M. McCamish (1999). "Recombinant Leptin for 
Weight Loss in Obese and Lean AdultsA Randomized, Controlled, Dose-Escalation Trial." 
JAMA 282(16): 1568-1575. 
Hill, J. W., C. F. Elias, M. Fukuda, K. W. Williams, E. D. Berglund, W. L. Holland, Y.-R. 
Cho, J.-C. Chuang, Y. Xu, M. Choi, D. Lauzon, C. E. Lee, R. Coppari, J. A. Richardson, 
J. M. Zigman, S. Chua, P. E. Scherer, B. B. Lowell, J. C. Brüning and J. K. Elmquist 
(2010). "Direct insulin and leptin action on pro-opiomelanocortin neurons is required for 




Hinkle, W., M. Cordell, R. Leibel, M. Rosenbaum and J. Hirsch (2013). "Effects of reduced 
weight maintenance and leptin repletion on functional connectivity of the hypothalamus in 
obese humans." PloS One 8(3): e59114-e59114. 
Hoeffer, C. A. and E. Klann (2010). "mTOR signaling: at the crossroads of plasticity, 
memory and disease." Trends in Neurosciences 33(2): 67-75. 
Hollenberg, A. N., V. S. Susulic, J. P. Madura, B. Zhang, D. E. Moller, P. Tontonoz, P. 
Sarraf, B. M. Spiegelman and B. B. Lowell (1997). "Functional antagonism between 
CCAAT/Enhancer binding protein-alpha and peroxisome proliferator-activated receptor-
gamma on the leptin promoter." Journal of Biological Chemistry 272(8): 5283-5290. 
Holm, C. (2003). "Molecular mechanisms regulating hormone-sensitive lipase and 
lipolysis." Biochemical Society Transactions 31(Pt 6): 1120-1124. 
Hsu, P. P., S. A. Kang, J. Rameseder, Y. Zhang, K. A. Ottina, D. Lim, T. R. Peterson, Y. 
Choi, N. S. Gray, M. B. Yaffe, J. A. Marto and D. M. Sabatini (2011). "The mTOR-
regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of 
growth factor signaling." Science 332(6035): 1317-1322. 
Huang, C., A. C. Thirone, X. Huang and A. Klip (2005). "Differential contribution of 
insulin receptor substrates 1 versus 2 to insulin signaling and glucose uptake in l6 
myotubes." Journal of Biological Chemistry 280(19): 19426-19435. 
Hummel, K. P., M. M. Dickie and D. L. Coleman (1966). "Diabetes, a new mutation in the 
mouse." Science 153(3740): 1127-1128. 
Hunter, S. J., A. B. Atkinson, C. N. Ennis, B. Sheridan and P. M. Bell (1996). "Association 
between insulin secretory pulse frequency and peripheral insulin action in NIDDM and 
normal subjects." Diabetes 45(5): 683-686. 
Hwang, C. S., S. Mandrup, O. A. MacDougald, D. E. Geiman and M. D. Lane (1996). 
"Transcriptional activation of the mouse obese (ob) gene by CCAAT/enhancer binding 
protein alpha." Proceedings of the National Academy of Sciences of the United States of 




Ingalls, A. M., M. M. Dickie and G. D. Snell (1950). "Obese, a new mutation in the house 
mouse." Journal of Heredity 41(12): 317-318. 
Inohara, N., T. Koseki, S. Chen, X. Wu and G. Núñez (1998). "CIDE, a novel family of 
cell death activators with homology to the 45 kDa subunit of the DNA fragmentation 
factor." The EMBO journal 17(9): 2526-2533. 
Inoki, K., Y. Li, T. Xu and K. L. Guan (2003). "Rheb GTPase is a direct target of TSC2 
GAP activity and regulates mTOR signaling." Genes & Development 17(15): 1829-1834. 
Inoki, K., T. Zhu and K. L. Guan (2003). "TSC2 mediates cellular energy response to 
control cell growth and survival." Cell 115(5): 577-590. 
Jacinto, E., V. Facchinetti, D. Liu, N. Soto, S. Wei, S. Y. Jung, Q. Huang, J. Qin and B. Su 
(2006). "SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt 
phosphorylation and substrate specificity." Cell 127(1): 125-137. 
Jacinto, E., R. Loewith, A. Schmidt, S. Lin, M. A. Ruegg, A. Hall and M. N. Hall (2004). 
"Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive." 
Nature Cell Biology 6(11): 1122-1128. 
Jambunathan, S., J. Yin, W. Khan, Y. Tamori and V. Puri (2011). "FSP27 promotes lipid 
droplet clustering and then fusion to regulate triglyceride accumulation." PloS One 6(12): 
e28614. 
Jaumot, M. and J. F. Hancock (2001). "Protein phosphatases 1 and 2A promote Raf-1 
activation by regulating 14-3-3 interactions." Oncogene 20(30): 3949-3958. 
Jefferies, H. B., C. Reinhard, S. C. Kozma and G. Thomas (1994). "Rapamycin selectively 
represses translation of the "polypyrimidine tract" mRNA family." Proceedings of the 
National Academy of Sciences of the United States of America 91(10): 4441-4445. 
Jenkins, C. M., D. J. Mancuso, W. Yan, H. F. Sims, B. Gibson and R. W. Gross (2004). 
"Identification, Cloning, Expression, and Purification of Three Novel Human Calcium-
independent Phospholipase A2 Family Members Possessing Triacylglycerol Lipase and 





Jiang, L., Z. Li and L. Rui (2008). "Leptin stimulates both JAK2-dependent and JAK2-
independent signaling pathways." Journal of Biological Chemistry 283(42): 28066-28073. 
Kaizuka, T., T. Hara, N. Oshiro, U. Kikkawa, K. Yonezawa, K. Takehana, S. Iemura, T. 
Natsume and N. Mizushima (2010). "Tti1 and Tel2 are critical factors in mammalian target 
of rapamycin complex assembly." Journal of Biological Chemistry 285(26): 20109-20116. 
Kalsbeek, A., E. Fliers, J. A. Romijn, S. E. La Fleur, J. Wortel, O. Bakker, E. Endert and 
R. M. Buijs (2001). "The suprachiasmatic nucleus generates the diurnal changes in plasma 
leptin levels." Endocrinology 142(6): 2677-2685. 
Kandror, K. V. (2015). "Translational and post-translational control of leptin production 
by fat cells.  ." Post-transcriptional Mechanisms in Endocrine Regulation, Menon, K.M.J., 
Goldstrohm, Aaron C. (Eds.), Springer: 221-233. 
Kantidakis, T., B. A. Ramsbottom, J. L. Birch, S. N. Dowding and R. J. White (2010). 
"mTOR associates with TFIIIC, is found at tRNA and 5S rRNA genes, and targets their 
repressor Maf1." Proceedings of the National Academy of Sciences of the United States of 
America 107(26): 11823-11828. 
Karanasios, E., A. D. Barbosa, H. Sembongi, M. Mari, G. S. Han, F. Reggiori, G. M. 
Carman and S. Siniossoglou (2013). "Regulation of lipid droplet and membrane biogenesis 
by the acidic tail of the phosphatidate phosphatase Pah1p." Molecular Biology of the Cell 
24(13): 2124-2133. 
Karki, S., P. Chakrabarti, G. Huang, H. Wang, S. R. Farmer and K. V. Kandror (2011). 
"The multi-level action of Fatty acids on adiponectin production by fat cells." PloS One 
6(11): e28146. 
Keesey, R. E. and T. L. Powley (2008). "Body energy homeostasis." Appetite 51(3): 442-
445. 
Keller, P., J. T. Petrie, P. De Rose, I. Gerin, W. S. Wright, S. H. Chiang, A. R. Nielsen, C. 
P. Fischer, B. K. Pedersen and O. A. MacDougald (2008). "Fat-specific Protein 27 





Kershaw, E. E. (2006). "Adipose Triglyceride Lipase: Function, Regulation by Insulin, and 
Comparison With Adiponutrin." Diabetes 55(1): 148-157. 
Kettner, N. M., S. A. Mayo, J. Hua, C. Lee, D. D. Moore and L. Fu (2015). "Circadian 
Dysfunction Induces Leptin Resistance in Mice." Cell metabolism 22(3): 448-459. 
Khamzina, L., A. Veilleux, S. Bergeron and A. Marette (2005). "Increased Activation of 
the Mammalian Target of Rapamycin Pathway in Liver and Skeletal Muscle of Obese Rats: 
Possible Involvement in Obesity-Linked Insulin Resistance." Endocrinology 146(3): 1473-
1481. 
Kilroy, G., D. H. Burk and Z. E. Floyd (2009). "High Efficiency Lipid-Based siRNA 
Transfection of Adipocytes in Suspension." PLoS One 4(9): e6940. 
Kim, D. H., D. D. Sarbassov, S. M. Ali, J. E. King, R. R. Latek, H. Erdjument-Bromage, 
P. Tempst and D. M. Sabatini (2002). "mTOR interacts with raptor to form a nutrient-
sensitive complex that signals to the cell growth machinery." Cell 110(2): 163-175. 
Kim, D. H., D. D. Sarbassov, S. M. Ali, R. R. Latek, K. V. Guntur, H. Erdjument-Bromage, 
P. Tempst and D. M. Sabatini (2003). "GbetaL, a positive regulator of the rapamycin-
sensitive pathway required for the nutrient-sensitive interaction between raptor and 
mTOR." Molecular Cell 11(4): 895-904. 
Kim, E., P. Goraksha-Hicks, L. Li, T. P. Neufeld and K. L. Guan (2008). "Regulation of 
TORC1 by Rag GTPases in nutrient response." Nature Cell Biology 10(8): 935-945. 
Kim, J. E. and J. Chen (2004). "regulation of peroxisome proliferator-activated receptor-
gamma activity by mammalian target of rapamycin and amino acids in adipogenesis." 
Diabetes 53(11): 2748-2756. 
Kloek, C., A. K. Haq, S. L. Dunn, H. J. Lavery, A. S. Banks and M. G. Myers, Jr. (2002). 
"Regulation of Jak kinases by intracellular leptin receptor sequences." Journal of 
Biological Chemistry 277(44): 41547-41555. 
Kratky, D., S. Obrowsky, D. Kolb and B. Radovic (2014). "Pleiotropic regulation of 





Kunz, J., R. Henriquez, U. Schneider, M. Deuter-Reinhard, N. R. Movva and M. N. Hall 
(1993). "Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase 
homolog required for G1 progression." Cell 73(3): 585-596. 
Kurat, C. F., K. Natter, J. Petschnigg, H. Wolinski, K. Scheuringer, H. Scholz, R. 
Zimmermann, R. Leber, R. Zechner and S. D. Kohlwein (2005). "Obese Yeast: 
Triglyceride Lipolysis Is Functionally Conserved from Mammals to Yeast." Journal of 
Biological Chemistry 281(1): 491-500. 
Kurzer, J. H., L. S. Argetsinger, Y.-J. Zhou, J.-L. K. Kouadio, J. J. O'Shea and C. Carter-
Su (2004). "Tyrosine 813 Is a Site of JAK2 Autophosphorylation Critical for Activation of 
JAK2 by SH2-Bβ." Molecular and Cellular Biology 24(10): 4557-4570. 
Lafontan, M. and D. Langin (2009). "Lipolysis and lipid mobilization in human adipose 
tissue." Progress in Lipid Research 48(5): 275-297. 
Lamming, D. W. and D. M. Sabatini (2013). "A Central role for mTOR in lipid 
homeostasis." Cell Metab 18(4): 465-469. 
Laplante, M. and D. M. Sabatini (2009). "An emerging role of mTOR in lipid 
biosynthesis." Curr Biol 19(22): R1046-1052. 
Laplante, M. and D. M. Sabatini (2009). "An Emerging Role of mTOR in Lipid 
Biosynthesis." Current Biology 19(22): R1046-R1052. 
Large, V., S. Reynisdottir, D. Langin, K. Fredby, M. Klannemark, C. Holm and P. Arner 
(1999). "Decreased expression and function of adipocyte hormone-sensitive lipase in 
subcutaneous fat cells of obese subjects." Journal of Lipid Research 40(11): 2059-2066. 
Le Bacquer, O., E. Petroulakis, S. Paglialunga, F. Poulin, D. Richard, K. Cianflone and N. 
Sonenberg (2007). "Elevated sensitivity to diet-induced obesity and insulin resistance in 
mice lacking 4E-BP1 and 4E-BP2." Journal of Clinical Investigation 117(2): 387-396. 
Lee, C., J. P. Etchegaray, F. R. Cagampang, A. S. Loudon and S. M. Reppert (2001). 





Lee, G., C. Li, J. Montez, J. Halaas, J. Darvishzadeh and J. M. Friedman (1997). "Leptin 
receptor mutations in 129 db3J/db3J mice and NIH facp/facp rats." Mammalian Genome 
8(6): 445-447. 
Lee, G. H., R. Proenca, J. M. Montez, K. M. Carroll, J. G. Darvishzadeh, J. I. Lee and J. 
M. Friedman (1996). "Abnormal splicing of the leptin receptor in diabetic mice." Nature 
379(6566): 632-635. 
Lee, M. J. and S. K. Fried (2006). "Multilevel regulation of leptin storage, turnover, and 
secretion by feeding and insulin in rat adipose tissue." Journal of Lipid Research 47(9): 
1984-1993. 
Lee, M. J. and S. K. Fried (2009). "Integration of hormonal and nutrient signals that 
regulate leptin synthesis and secretion." American Journal of Physiology: Endocrinology 
and Metabolism 296(6): E1230-1238. 
Lee, M. J., Y. Wang, M. R. Ricci, S. Sullivan, C. D. Russell and S. K. Fried (2007). "Acute 
and chronic regulation of leptin synthesis, storage, and secretion by insulin and 
dexamethasone in human adipose tissue." American Journal of Physiology: Endocrinology 
and Metabolism 292(3): E858-864. 
Lee, M. J., R. Z. Yang, D. W. Gong and S. K. Fried (2007). "Feeding and insulin increase 
leptin translation. Importance of the leptin mRNA untranslated regions." Journal of 
Biological Chemistry 282(1): 72-80. 
Leibel, R. L., N. Bahary and J. M. Friedman (1993). "Strategies for the molecular genetic 
analysis of obesity in humans." Critical Reviews in Food Science and Nutrition 33(4-5): 
351-358. 
Levy, J. R., J. Gyarmati, J. M. Lesko, R. A. Adler and W. Stevens (2000). "Dual regulation 
of leptin secretion: intracellular energy and calcium dependence of regulated pathway." 
American Journal of Physiology: Endocrinology and Metabolism 278(5): E892-901. 
Levy, J. R., E. LeGall-Salmon, M. Santos, W. M. Pandak and W. Stevens (1997). "Effect 
of enteral versus parenteral nutrition on leptin gene expression and release into the 




Li, C., E. Ioffe, N. Fidahusein, E. Connolly and J. M. Friedman (1998). "Absence of soluble 
leptin receptor in plasma from dbPas/dbPas and other db/db mice." Journal of Biological 
Chemistry 273(16): 10078-10082. 
Li, J. Z., J. Ye, B. Xue, J. Qi, J. Zhang, Z. Zhou, Q. Li, Z. Wen and P. Li (2007). "Cideb 
regulates diet-induced obesity, liver steatosis, and insulin sensitivity by controlling 
lipogenesis and fatty acid oxidation." Diabetes 56(10): 2523-2532. 
Li, S., M. S. Brown and J. L. Goldstein (2010). "Bifurcation of insulin signaling pathway 
in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of 
gluconeogenesis." Proc Natl Acad Sci U S A 107(8): 3441-3446. 
Li, Y., S. Xu, M. M. Mihaylova, B. Zheng, X. Hou, B. Jiang, O. Park, Z. Luo, E. Lefai, J. 
Y. Shyy, B. Gao, M. Wierzbicki, T. J. Verbeuren, R. J. Shaw, R. A. Cohen and M. Zang 
(2011). "AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis 
and atherosclerosis in diet-induced insulin-resistant mice." Cell Metab 13(4): 376-388. 
Li, Z., G. Ceccarini, M. Eisenstein, K. Tan and J. M. Friedman (2013). "Phenotypic effects 
of an induced mutation of the ObRa isoform of the leptin receptor." Molecular metabolism 
2(4): 364-375. 
Lim, M. A., H. Riedel and F. Liu (2004). "Grb10: more than a simple adaptor protein." 
Frontiers in Bioscience 9: 387-403. 
Liu, J. Y., S. Mu, S. P. Zhang, W. Guo, Q. F. Li, X. Q. Xiao, J. Zhang and Z. H. Wang 
(2017). "Roux-en-Y gastric bypass surgery suppresses hypothalamic PTP1B protein level 
and alleviates leptin resistance in obese rats." Exp Ther Med 14(3): 2536-2542. 
Liu, L., T. P. Cash, R. G. Jones, B. Keith, C. B. Thompson and M. C. Simon (2006). 
"Hypoxia-Induced Energy Stress Regulates mRNA Translation and Cell Growth." 
Molecular Cell 21(4): 521-531. 
Loh, K., A. Fukushima, X. Zhang, S. Galic, D. Briggs, P. J. Enriori, S. Simonds, F. Wiede, 
A. Reichenbach, C. Hauser, N. A. Sims, K. K. Bence, S. Zhang, Z.-Y. Zhang, B. B. Kahn, 
B. G. Neel, Z. B. Andrews, M. A. Cowley and T. Tiganis (2011). "Elevated hypothalamic 





Long, X., Y. Lin, S. Ortiz-Vega, K. Yonezawa and J. Avruch (2005). "Rheb Binds and 
Regulates the mTOR Kinase." Current Biology 15(8): 702-713. 
Lord, C. C. and J. M. Brown (2012). "Distinct roles for alpha-beta hydrolase domain 5 
(ABHD5/CGI-58) and adipose triglyceride lipase (ATGL/PNPLA2) in lipid metabolism 
and signaling." Adipocyte 1(3): 123-131. 
Lowrey, P. L. and J. S. Takahashi (2011). "Genetics of circadian rhythms in Mammalian 
model organisms." Advances in Genetics 74: 175-230. 
Lu, H. and H. Huang (2011). "FOXO1: a potential target for human diseases." Current 
Drug Targets 12(9): 1235-1244. 
Lu, X., J. Gruia-Gray, N. G. Copeland, D. J. Gilbert, N. A. Jenkins, C. Londos and A. R. 
Kimmel (2001). "The murine perilipin gene: the lipid droplet-associated perilipins derive 
from tissue-specific, mRNA splice variants and define a gene family of ancient origin." 
Mammalian Genome 12(9): 741-749. 
Maamra, M., R. J. M. Ross, C. J. Strasburger, M. Bidlingmaier, Z. Wu and M.-C. Postel-
Vinay (2001). "Generation of Human Soluble Leptin Receptor by Proteolytic Cleavage of 
Membrane-Anchored Receptors." Endocrinology 142(10): 4389-4393. 
Maffei, M., H. Fei, G. H. Lee, C. Dani, P. Leroy, Y. Zhang, R. Proenca, R. Negrel, G. 
Ailhaud and J. M. Friedman (1995). "Increased expression in adipocytes of ob RNA in 
mice with lesions of the hypothalamus and with mutations at the db locus." Proceedings of 
the National Academy of Sciences of the United States of America 92(15): 6957-6960. 
Magnuson, B., B. Ekim and D. C. Fingar (2012). "Regulation and function of ribosomal 
protein S6 kinase (S6K) within mTOR signalling networks." Biochemical Journal 441(1): 
1-21. 
Margetic, S., C. Gazzola, G. G. Pegg and R. A. Hill (2002). "Leptin: a review of its 
peripheral actions and interactions." International Journal of Obesity and Related 




Mauvoisin, D., G. Rocque, O. Arfa, A. Radenne, P. Boissier and C. Mounier (2007). "Role 
of the PI3-kinase/mTor pathway in the regulation of the stearoyl CoA desaturase (SCD1) 
gene expression by insulin in liver." J Cell Commun Signal 1(2): 113-125. 
Mayer, C., J. Zhao, X. Yuan and I. Grummt (2004). "mTOR-dependent activation of the 
transcription factor TIF-IA links rRNA synthesis to nutrient availability." Genes & 
Development 18(4): 423-434. 
McIntosh, A. L., S. M. Storey and B. P. Atshaves (2010). "Intracellular lipid droplets 
contain dynamic pools of sphingomyelin: ADRP binds phospholipids with high affinity." 
Lipids 45(6): 465-477. 
McKay, M. M. and D. K. Morrison (2007). "Integrating signals from RTKs to 
ERK/MAPK." Oncogene 26: 3113. 
Menon, S., C. C. Dibble, G. Talbott, G. Hoxhaj, A. J. Valvezan, H. Takahashi, L. C. 
Cantley and B. D. Manning (2014). "Spatial control of the TSC complex integrates insulin 
and nutrient regulation of mTORC1 at the lysosome." Cell 156(4): 771-785. 
Mercer, J. G., K. M. Moar, A. W. Ross, N. Hoggard and P. J. Morgan (2000). "Photoperiod 
regulates arcuate nucleus POMC, AGRP, and leptin receptor mRNA in Siberian hamster 
hypothalamus." American Journal of Physiology: Regulatory, Integrative and Comparative 
Physiology 278(1): R271-281. 
Minokoshi, Y., Y.-B. Kim, O. D. Peroni, L. G. D. Fryer, C. Müller, D. Carling and B. B. 
Kahn (2002). "Leptin stimulates fatty-acid oxidation by activating AMP-activated protein 
kinase." Nature 415: 339. 
Miyamoto, L., K. Ebihara, T. Kusakabe, D. Aotani, S. Yamamoto-Kataoka, T. Sakai, M. 
Aizawa-Abe, Y. Yamamoto, J. Fujikura, T. Hayashi, K. Hosoda and K. Nakao (2012). 
"Leptin activates hepatic 5'-AMP-activated protein kinase through sympathetic nervous 
system and alpha1-adrenergic receptor: a potential mechanism for improvement of fatty 
liver in lipodystrophy by leptin." Journal of Biological Chemistry 287(48): 40441-40447. 
Miyoshi, H., J. W. Perfield, 2nd, S. C. Souza, W. J. Shen, H. H. Zhang, Z. S. Stancheva, 
F. B. Kraemer, M. S. Obin and A. S. Greenberg (2007). "Control of adipose triglyceride 
lipase action by serine 517 of perilipin A globally regulates protein kinase A-stimulated 




Miyoshi, H., J. W. Perfield, M. S. Obin and A. S. Greenberg (2008). "Adipose triglyceride 
lipase regulates basal lipolysis and lipid droplet size in adipocytes." Journal of Cellular 
Biochemistry 105(6): 1430-1436. 
Montminy, M., S. H. Koo and X. Zhang (2004). "The CREB family: key regulators of 
hepatic metabolism." Annales d'Endocrinologie 65(1): 73-75. 
Muller, G., J. Ertl, M. Gerl and G. Preibisch (1997). "Leptin impairs metabolic actions of 
insulin in isolated rat adipocytes." Journal of Biological Chemistry 272(16): 10585-10593. 
Murphy, D. J. (2012). "The dynamic roles of intracellular lipid droplets: from archaea to 
mammals." Protoplasma 249(3): 541-585. 
Myers, M. G., Jr. (2004). "Leptin receptor signaling and the regulation of mammalian 
physiology." Recent Progress in Hormone Research 59: 287-304. 
Nagai, S., C. Shimizu, M. Umetsu, S. Taniguchi, M. Endo, H. Miyoshi, N. Yoshioka, M. 
Kubo and T. Koike (2004). "Identification of a functional peroxisome proliferator-
activated receptor responsive element within the murine perilipin gene." Endocrinology 
145(5): 2346-2356. 
Nakae, J., V. Barr and D. Accili (2000). "Differential regulation of gene expression by 
insulin and IGF-1 receptors correlates with phosphorylation of a single amino acid residue 
in the forkhead transcription factor FKHR." EMBO Journal 19(5): 989-996. 
Nakae, J., T. Kitamura, D. L. Silver and D. Accili (2001). "The forkhead transcription 
factor Foxo1 (Fkhr) confers insulin sensitivity onto glucose-6-phosphatase expression." 
Journal of Clinical Investigation 108(9): 1359-1367. 
Nicklin, P., P. Bergman, B. Zhang, E. Triantafellow, H. Wang, B. Nyfeler, H. Yang, M. 
Hild, C. Kung, C. Wilson, V. E. Myer, J. P. MacKeigan, J. A. Porter, Y. K. Wang, L. C. 
Cantley, P. M. Finan and L. O. Murphy (2009). "Bidirectional transport of amino acids 
regulates mTOR and autophagy." Cell 136(3): 521-534. 
Nielsen, T. S., N. Jessen, J. O. Jorgensen, N. Moller and S. Lund (2014). "Dissecting 
adipose tissue lipolysis: molecular regulation and implications for metabolic disease." 




Nishimoto, Y. and Y. Tamori (2017). "CIDE Family-Mediated Unique Lipid Droplet 
Morphology in White Adipose Tissue and Brown Adipose Tissue Determines the 
Adipocyte Energy Metabolism." Journal of Atherosclerosis and Thrombosis 24(10): 989-
998. 
Nishino, N., Y. Tamori, S. Tateya, T. Kawaguchi, T. Shibakusa, W. Mizunoya, K. Inoue, 
R. Kitazawa, S. Kitazawa, Y. Matsuki, R. Hiramatsu, S. Masubuchi, A. Omachi, K. 
Kimura, M. Saito, T. Amo, S. Ohta, T. Yamaguchi, T. Osumi, J. Cheng, T. Fujimoto, H. 
Nakao, K. Nakao, A. Aiba, H. Okamura, T. Fushiki and M. Kasuga (2008). "FSP27 
contributes to efficient energy storage in murine white adipocytes by promoting the 
formation of unilocular lipid droplets." Journal of Clinical Investigation 118(8): 2808-
2821. 
Niswender, K. D., G. J. Morton, W. H. Stearns, C. J. Rhodes, M. G. Myers, Jr. and M. W. 
Schwartz (2001). "Intracellular signalling. Key enzyme in leptin-induced anorexia." Nature 
413(6858): 794-795. 
Nocca, D., D. Krawczykowski, B. Bomans, P. Noel, M.-C. Picot, P. M Blanc, C. de Seguin 
de Hons, B. Millat, M. Gagner, L. Monnier and J. M Fabre (2008). A Prospective 
Multicenter Study of 163 Sleeve Gastrectomies: Results at 1 and 2 Years. 
O'Mahony, F., K. Wroblewski, S. M. O'Byrne, H. Jiang, K. Clerkin, J. Benhammou, W. S. 
Blaner and S. W. Beaven (2015). "Liver X receptors balance lipid stores in hepatic stellate 
cells through Rab18, a retinoid responsive lipid droplet protein." Hepatology 62(2): 615-
626. 
Olivecrona, T., S. S. Chernick, G. Bengtsson-Olivecrona, M. Garrison and R. O. Scow 
(1987). "Synthesis and secretion of lipoprotein lipase in 3T3-L1 adipocytes. Demonstration 
of inactive forms of lipase in cells." Journal of Biological Chemistry 262(22): 10748-
10759. 
Ozcan, U., Q. Cao, E. Yilmaz, A. H. Lee, N. N. Iwakoshi, E. Ozdelen, G. Tuncman, C. 
Gorgun, L. H. Glimcher and G. S. Hotamisligil (2004). "Endoplasmic reticulum stress links 
obesity, insulin action, and type 2 diabetes." Science 306(5695): 457-461. 
Padwal, R., D. Brocks and A. M. Sharma (2010). "A systematic review of drug absorption 





Patterson, C. M., E. C. Villanueva, M. Greenwald-Yarnell, M. Rajala, I. E. Gonzalez, N. 
Saini, J. Jones and M. G. Myers, Jr. (2012). "Leptin action via LepR-b Tyr1077 contributes 
to the control of energy balance and female reproduction." Mol Metab 1(1-2): 61-69. 
Pearce, L. R., X. Huang, J. Boudeau, R. Pawlowski, S. Wullschleger, M. Deak, A. F. 
Ibrahim, R. Gourlay, M. A. Magnuson and D. R. Alessi (2007). "Identification of Protor 
as a novel Rictor-binding component of mTOR complex-2." Biochemical Journal 405(3): 
513-522. 
Pearce, L. R., E. M. Sommer, K. Sakamoto, S. Wullschleger and D. R. Alessi (2011). 
"Protor-1 is required for efficient mTORC2-mediated activation of SGK1 in the kidney." 
Biochemical Journal 436(1): 169-179. 
Pelleymounter, M., M. Cullen, M. Baker, R. Hecht, D. Winters, T. Boone and F. Collins 
(1995). "Effects of the obese gene product on body weight regulation in ob/ob mice." 
Science 269(5223): 540-543. 
Peng, M., N. Yin and M. O. Li (2017). "SZT2 dictates GATOR control of mTORC1 
signalling." Nature 543: 433. 
Peng, T., T. R. Golub and D. M. Sabatini (2002). "The immunosuppressant rapamycin 
mimics a starvation-like signal distinct from amino acid and glucose deprivation." 
Molecular and Cellular Biology 22(15): 5575-5584. 
Perry, R. J. and G. I. Shulman (2018). "The Role of Leptin in Maintaining Plasma Glucose 
During Starvation." Postdoc journal : a journal of postdoctoral research and postdoctoral 
affairs 6(3): 3-19. 
Perry, R. J., Y. Wang, G. W. Cline, A. Rabin-Court, J. D. Song, S. Dufour, X. M. Zhang, 
K. F. Petersen and G. I. Shulman (2018). "Leptin Mediates a Glucose-Fatty Acid Cycle to 
Maintain Glucose Homeostasis in Starvation." Cell 172(1-2): 234-248.e217. 
Peterson, T. R., M. Laplante, C. C. Thoreen, Y. Sancak, S. A. Kang, W. M. Kuehl, N. S. 
Gray and D. M. Sabatini (2009). "DEPTOR is an mTOR inhibitor frequently overexpressed 




Phillips, M. S., Q. Liu, H. A. Hammond, V. Dugan, P. J. Hey, C. J. Caskey and J. F. Hess 
(1996). "Leptin receptor missense mutation in the fatty Zucker rat." Nature Genetics 13(1): 
18-19. 
Polak, P., N. Cybulski, J. N. Feige, J. Auwerx, M. A. Ruegg and M. N. Hall (2008). 
"Adipose-specific knockout of raptor results in lean mice with enhanced mitochondrial 
respiration." Cell Metab 8(5): 399-410. 
Porstmann, T., C. R. Santos, B. Griffiths, M. Cully, M. Wu, S. Leevers, J. R. Griffiths, Y. 
L. Chung and A. Schulze (2008). "SREBP activity is regulated by mTORC1 and 
contributes to Akt-dependent cell growth." Cell Metab 8(3): 224-236. 
Puri, V., S. Konda, S. Ranjit, M. Aouadi, A. Chawla, M. Chouinard, A. Chakladar and M. 
P. Czech (2007). "Fat-specific protein 27, a novel lipid droplet protein that enhances 
triglyceride storage." J Biol Chem 282(47): 34213-34218. 
Puri, V., S. Konda, S. Ranjit, M. Aouadi, A. Chawla, M. Chouinard, A. Chakladar and M. 
P. Czech (2007). "Fat-specific Protein 27, a Novel Lipid Droplet Protein That Enhances 
Triglyceride Storage." Journal of Biological Chemistry 282(47): 34213-34218. 
Qi, L., M. Saberi, E. Zmuda, Y. Wang, J. Altarejos, X. Zhang, R. Dentin, S. Hedrick, G. 
Bandyopadhyay, T. Hai, J. Olefsky and M. Montminy (2009). "Adipocyte CREB promotes 
insulin resistance in obesity." Cell metabolism 9(3): 277-286. 
Qu, Y., Q. Chen, X. Lai, C. Zhu, C. Chen, X. Zhao, R. Deng, M. Xu, H. Yuan, Y. Wang, 
J. Yu and J. Huang (2014). "SUMOylation of Grb2 enhances the ERK activity by 
increasing its binding with Sos1." Molecular Cancer 13: 95. 
Quilliam, L. A., R. Khosravi-Far, S. Y. Huff and C. J. Der (1995). "Guanine nucleotide 
exchange factors: activators of the Ras superfamily of proteins." Bioessays 17(5): 395-404. 
Rachdi, L., N. Balcazar, F. Osorio-Duque, L. Elghazi, A. Weiss, A. Gould, K. J. Chang-
Chen, M. J. Gambello and E. Bernal-Mizrachi (2008). "Disruption of Tsc2 in pancreatic 
beta cells induces beta cell mass expansion and improved glucose tolerance in a TORC1-
dependent manner." Proceedings of the National Academy of Sciences of the United States 




Rahmouni, K., C. D. Sigmund, W. G. Haynes and A. L. Mark (2009). "Hypothalamic ERK 
mediates the anorectic and thermogenic sympathetic effects of leptin." Diabetes 58(3): 536-
542. 
Ricoult, S. J. and B. D. Manning (2013). "The multifaceted role of mTORC1 in the control 
of lipid metabolism." EMBO Rep 14(3): 242-251. 
Rodriguez-Viciana, P., J. Oses-Prieto, A. Burlingame, M. Fried and F. McCormick (2006). 
"A phosphatase holoenzyme comprised of Shoc2/Sur8 and the catalytic subunit of PP1 
functions as an M-Ras effector to modulate Raf activity." Molecular Cell 22(2): 217-230. 
Roh, C., J. Han, A. Tzatsos and K. V. Kandror (2002). "Nutrient-sensing mTOR-mediated 
pathway regulates leptin production in isolated rat adipocytes." American Journal of 
Physiology - Endocrinology And Metabolism 284(2): E322-E330. 
Roh, C., J. Han, A. Tzatsos and K. V. Kandror (2003). "Nutrient-sensing mTOR-mediated 
pathway regulates leptin production in isolated rat adipocytes." American Journal of 
Physiology: Endocrinology and Metabolism 284(2): E322-330. 
Roh, C., R. Roduit, B. Thorens, S. Fried and K. V. Kandror (2001). "Lipoprotein lipase 
and leptin are accumulated in different secretory compartments in rat adipocytes." Journal 
of Biological Chemistry 276(38): 35990-35994. 
Roh, C., G. Thoidis, S. R. Farmer and K. V. Kandror (2000). "Identification and 
characterization of leptin-containing intracellular compartment in rat adipose cells." 
American Journal of Physiology-Endocrinology and Metabolism 279(4): E893-E899. 
Ropelle, E. R., J. R. Pauli, P. Prada, D. E. Cintra, G. Z. Rocha, J. C. Moraes, M. J. 
Frederico, G. da Luz, R. A. Pinho, J. B. Carvalheira, L. A. Velloso, M. A. Saad and C. T. 
De Souza (2009). "Inhibition of hypothalamic Foxo1 expression reduced food intake in 
diet-induced obesity rats." Journal of Physiology 587(Pt 10): 2341-2351. 
Rosenbaum, M., R. Goldsmith, D. Bloomfield, A. Magnano, L. Weimer, S. Heymsfield, 
D. Gallagher, L. Mayer, E. Murphy and R. L. Leibel (2005). "Low-dose leptin reverses 
skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced 




Rosenbaum, M., R. Goldsmith, D. Bloomfield, A. Magnano, L. Weimer, S. Heymsfield, 
D. Gallagher, L. Mayer, E. Murphy and R. L. Leibel (2005). "Low-dose leptin reverses 
skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced 
weight." The Journal of clinical investigation 115(12): 3579-3586. 
Roux, P. P., B. A. Ballif, R. Anjum, S. P. Gygi and J. Blenis (2004). "Tumor-promoting 
phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor 
complex via p90 ribosomal S6 kinase." Proceedings of the National Academy of Sciences 
of the United States of America 101(37): 13489-13494. 
Rozengurt, E. (2007). "Mitogenic signaling pathways induced by G protein-coupled 
receptors." Journal of Cellular Physiology 213(3): 589-602. 
Russell, C. D., M. R. Ricci, R. E. Brolin, E. Magill and S. K. Fried (2001). "Regulation of 
the leptin content of obese human adipose tissue." American Journal of Physiology: 
Endocrinology and Metabolism 280(3): E399-404. 
Sabatini, D. M., H. Erdjument-Bromage, M. Lui, P. Tempst and S. H. Snyder (1994). 
"RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion 
and is homologous to yeast TORs." Cell 78(1): 35-43. 
Sabers, C. J., M. M. Martin, G. J. Brunn, J. M. Williams, F. J. Dumont, G. Wiederrecht 
and R. T. Abraham (1995). "Isolation of a protein target of the FKBP12-rapamycin 
complex in mammalian cells." Journal of Biological Chemistry 270(2): 815-822. 
Sahu-Osen, A., G. Montero-Moran, M. Schittmayer, K. Fritz, A. Dinh, Y. F. Chang, D. 
McMahon, A. Boeszoermenyi, I. Cornaciu, D. Russell, M. Oberer, G. M. Carman, R. 
Birner-Gruenberger and D. L. Brasaemle (2015). "CGI-58/ABHD5 is phosphorylated on 
Ser239 by protein kinase A: control of subcellular localization." Journal of Lipid Research 
56(1): 109-121. 
Sahu, A. (2003). "Leptin signaling in the hypothalamus: emphasis on energy homeostasis 
and leptin resistance." Frontiers in Neuroendocrinology 24(4): 225-253. 
Sancak, Y., L. Bar-Peled, R. Zoncu, A. L. Markhard, S. Nada and D. M. Sabatini (2010). 
"Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its 




Sancak, Y., T. R. Peterson, Y. D. Shaul, R. A. Lindquist, C. C. Thoreen, L. Bar-Peled and 
D. M. Sabatini (2008). "The Rag GTPases bind raptor and mediate amino acid signaling to 
mTORC1." Science 320(5882): 1496-1501. 
Sancak, Y., C. C. Thoreen, T. R. Peterson, R. A. Lindquist, S. A. Kang, E. Spooner, S. A. 
Carr and D. M. Sabatini (2007). "PRAS40 is an insulin-regulated inhibitor of the mTORC1 
protein kinase." Molecular Cell 25(6): 903-915. 
Sanjana, N. E., O. Shalem and F. Zhang (2014). "Improved vectors and genome-wide 
libraries for CRISPR screening." Nature Methods 11: 783. 
Sarbassov, D., S. M. Ali, D. H. Kim, D. A. Guertin, R. R. Latek, H. Erdjument-Bromage, 
P. Tempst and D. M. Sabatini (2004). "Rictor, a novel binding partner of mTOR, defines a 
rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton." 
Current Biology 14(14): 1296-1302. 
Sarbassov, D. D., S. M. Ali, D. H. Kim, D. A. Guertin, R. R. Latek, H. Erdjument-Bromage, 
P. Tempst and D. M. Sabatini (2004). "Rictor, a novel binding partner of mTOR, defines a 
rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton." 
Current Biology 14(14): 1296-1302. 
Sarbassov, D. D., D. A. Guertin, S. M. Ali and D. M. Sabatini (2005). "Phosphorylation 
and regulation of Akt/PKB by the rictor-mTOR complex." Science 307(5712): 1098-1101. 
Sasaki, A., H. Yasukawa, A. Suzuki, S. Kamizono, T. Syoda, I. Kinjyo, M. Sasaki, J. A. 
Johnston and A. Yoshimura (1999). "Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) 
inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region 
as well as SH2 domain." Genes to Cells 4(6): 339-351. 
Satin, L. S., P. C. Butler, J. Ha and A. S. Sherman (2015). "Pulsatile insulin secretion, 
impaired glucose tolerance and type 2 diabetes." Molecular Aspects of Medicine 42: 61-
77. 
Saxton, R. A., K. E. Knockenhauer, T. U. Schwartz and D. M. Sabatini (2016). "The apo-





Scarpace, P. J. and N. Tümer (2001). "Peripheral and hypothalamic leptin resistance with 
age-related obesity." Physiology & Behavior 74(4): 721-727. 
Scheer, F. A., M. F. Hilton, C. S. Mantzoros and S. A. Shea (2009). "Adverse metabolic 
and cardiovascular consequences of circadian misalignment." Proceedings of the National 
Academy of Sciences of the United States of America 106(11): 4453-4458. 
Schoiswohl, G., M. Schweiger, R. Schreiber, G. Gorkiewicz, K. Preiss-Landl, U. Taschler, 
K. A. Zierler, F. P. Radner, T. O. Eichmann, P. C. Kienesberger, S. Eder, A. Lass, G. 
Haemmerle, T. J. Alsted, B. Kiens, G. Hoefler, R. Zechner and R. Zimmermann (2010). 
"Adipose triglyceride lipase plays a key role in the supply of the working muscle with fatty 
acids." Journal of Lipid Research 51(3): 490-499. 
Schwartz, M. W., E. Peskind, M. Raskind, E. J. Boyko and D. Porte (1996). "Cerebrospinal 
fluid leptin levels: Relationship to plasma levels and to adiposity in humans." Nature 
Medicine 2(5): 589-593. 
Schwartz, M. W. and R. J. Seeley (1997). "The new biology of body weight regulation." 
Journal of the American Dietetic Association 97(1): 54-58; quiz 59-60. 
Schwartz, M. W., S. C. Woods, D. Porte Jr, R. J. Seeley and D. G. Baskin (2000). "Central 
nervous system control of food intake." Nature 404: 661. 
Sears, B. and M. Perry (2015). "The role of fatty acids in insulin resistance." Lipids in 
Health and Disease 14: 121-121. 
Semenza, G. L. (2002). "Signal transduction to hypoxia-inducible factor 1." Biochemical 
Pharmacology 64(5): 993-998. 
Sengupta, S., T. R. Peterson and D. M. Sabatini (2010). "Regulation of the mTOR complex 
1 pathway by nutrients, growth factors, and stress." Mol Cell 40(2): 310-322. 
Sengupta, S., T. R. Peterson and D. M. Sabatini (2010). "Regulation of the mTOR Complex 




Shor, B., J. Wu, Q. Shakey, L. Toral-Barza, C. Shi, M. Follettie and K. Yu (2010). 
"Requirement of the mTOR kinase for the regulation of Maf1 phosphorylation and control 
of RNA polymerase III-dependent transcription in cancer cells." Journal of Biological 
Chemistry 285(20): 15380-15392. 
Shoshani, T., A. Faerman, I. Mett, E. Zelin, T. Tenne, S. Gorodin, Y. Moshel, S. Elbaz, A. 
Budanov, A. Chajut, H. Kalinski, I. Kamer, A. Rozen, O. Mor, E. Keshet, D. Leshkowitz, 
P. Einat, R. Skaliter and E. Feinstein (2002). "Identification of a Novel Hypoxia-Inducible 
Factor 1-Responsive Gene, <em>RTP801</em>, Involved in Apoptosis." Molecular and 
Cellular Biology 22(7): 2283-2293. 
Sierzantowicz, R., J. Lewko, L. Trochimowicz, B. Kirpsza, J. Dadan and H. R. Hady 
(2017). "The effect of bariatric procedures on selected laboratory parameters of patients 
from rural areas in Poland." Adv Clin Exp Med 26(4): 679-686. 
Singh, M., R. Kaur, M. J. Lee, R. T. Pickering, V. M. Sharma, V. Puri and K. V. Kandror 
(2014). "Fat-specific protein 27 inhibits lipolysis by facilitating the inhibitory effect of 
transcription factor Egr1 on transcription of adipose triglyceride lipase." Journal of 
Biological Chemistry 289(21): 14481-14487. 
Singh, M., R. Kaur, M. J. Lee, R. T. Pickering, V. M. Sharma, V. Puri and K. V. Kandror 
(2014). "Fat specific protein 27 inhibits lipolysis by facilitating the inhibitory effect of Egr1 
on transcription of adipose triglyceride lipase." Journal of Biological Chemistry 289(21): 
14481-14487. 
Singh, M., Y. K. Shin, X. Yang, B. Zehr, P. Chakrabarti and K. V. Kandror (2015). "4E-
BPs Control Fat Storage by Regulating the Expression of Egr1 and ATGL." Journal of 
Biological Chemistry 290(28): 17331-17338. 
Smirnova, E., E. B. Goldberg, K. S. Makarova, L. Lin, W. J. Brown and C. L. Jackson 
(2006). "ATGL has a key role in lipid droplet/adiposome degradation in mammalian cells." 
EMBO Rep 7(1): 106-113. 
Sofer, A., K. Lei, C. M. Johannessen and L. W. Ellisen (2005). "Regulation of mTOR and 





Sonenberg, N. and A. G. Hinnebusch (2009). "Regulation of translation initiation in 
eukaryotes: mechanisms and biological targets." Cell 136(4): 731-745. 
Sparks, L. M., H. Xie, R. A. Koza, R. Mynatt, M. W. Hulver, G. A. Bray and S. R. Smith 
(2005). "A high-fat diet coordinately downregulates genes required for mitochondrial 
oxidative phosphorylation in skeletal muscle." Diabetes 54(7): 1926-1933. 
Strobel, A., T. Issad, L. Camoin, M. Ozata and A. D. Strosberg (1998). "A leptin missense 
mutation associated with hypogonadism and morbid obesity." Nature Genetics 18(3): 213-
215. 
Su, C. L., C. Sztalryd, J. A. Contreras, C. Holm, A. R. Kimmel and C. Londos (2003). 
"Mutational analysis of the hormone-sensitive lipase translocation reaction in adipocytes." 
Journal of Biological Chemistry 278(44): 43615-43619. 
Subramanian, V., A. Garcia, A. Sekowski and D. L. Brasaemle (2004). "Hydrophobic 
sequences target and anchor perilipin A to lipid droplets." Journal of Lipid Research 
45(11): 1983-1991. 
Sun, Z., J. Gong, H. Wu, W. Xu, L. Wu, D. Xu, J. Gao, J. W. Wu, H. Yang, M. Yang and 
P. Li (2013). "Perilipin1 promotes unilocular lipid droplet formation through the activation 
of Fsp27 in adipocytes." Nat Commun 4: 1594. 
Sweeney, G. (2002). "Leptin signalling." Cellular Signalling 14(8): 655-663. 
Szymanski, K. M., D. Binns, R. Bartz, N. V. Grishin, W. P. Li, A. K. Agarwal, A. Garg, 
R. G. Anderson and J. M. Goodman (2007). "The lipodystrophy protein seipin is found at 
endoplasmic reticulum lipid droplet junctions and is important for droplet morphology." 
Proceedings of the National Academy of Sciences of the United States of America 104(52): 
20890-20895. 
Tee, A. R., B. D. Manning, P. P. Roux, L. C. Cantley and J. Blenis (2003). "Tuberous 
sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting 





Thaler, J. P., C.-X. Yi, E. A. Schur, S. J. Guyenet, B. H. Hwang, M. O. Dietrich, X. Zhao, 
D. A. Sarruf, V. Izgur, K. R. Maravilla, H. T. Nguyen, J. D. Fischer, M. E. Matsen, B. E. 
Wisse, G. J. Morton, T. L. Horvath, D. G. Baskin, M. H. Tschöp and M. W. Schwartz 
(2012). "Obesity is associated with hypothalamic injury in rodents and humans." The 
Journal of clinical investigation 122(1): 153-162. 
Thedieck, K., P. Polak, M. L. Kim, K. D. Molle, A. Cohen, P. Jeno, C. Arrieumerlou and 
M. N. Hall (2007). "PRAS40 and PRR5-like protein are new mTOR interactors that 
regulate apoptosis." PloS One 2(11): e1217. 
Thiele, C. and J. Spandl (2008). "Cell biology of lipid droplets." Current Opinion in Cell 
Biology 20(4): 378-385. 
Tolman, K. G., V. Fonseca, A. Dalpiaz and M. H. Tan (2007). "Spectrum of liver disease 
in type 2 diabetes and management of patients with diabetes and liver disease." Diabetes 
Care 30(3): 734-743. 
Truett, G. E., N. Bahary, J. M. Friedman and R. L. Leibel (1991). "Rat obesity gene fatty 
(fa) maps to chromosome 5: evidence for homology with the mouse gene diabetes (db)." 
Proceedings of the National Academy of Sciences of the United States of America 88(17): 
7806-7809. 
Tsun, Z.-Y., L. Bar-Peled, L. Chantranupong, R. Zoncu, T. Wang, C. Kim, E. Spooner and 
David M. Sabatini (2013). "The Folliculin Tumor Suppressor Is a GAP for the RagC/D 
GTPases That Signal Amino Acid Levels to mTORC1." Molecular Cell 52(4): 495-505. 
Tzatsos, A. and K. V. Kandror (2006). "Nutrients suppress phosphatidylinositol 3-
kinase/Akt signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 
phosphorylation." Molecular and Cellular Biology 26(1): 63-76. 
Um, S. H., F. Frigerio, M. Watanabe, F. Picard, M. Joaquin, M. Sticker, S. Fumagalli, P. 
R. Allegrini, S. C. Kozma, J. Auwerx and G. Thomas (2004). "Absence of S6K1 protects 
against age- and diet-induced obesity while enhancing insulin sensitivity." Nature 
431(7005): 200-205. 





Van Heek, M., D. S. Compton, C. F. France, R. P. Tedesco, A. B. Fawzi, M. P. Graziano, 
E. J. Sybertz, C. D. Strader and H. R. Davis, Jr. (1997). "Diet-induced obese mice develop 
peripheral, but not central, resistance to leptin." The Journal of clinical investigation 99(3): 
385-390. 
Vander Haar, E., S. I. Lee, S. Bandhakavi, T. J. Griffin and D. H. Kim (2007). "Insulin 
signalling to mTOR mediated by the Akt/PKB substrate PRAS40." Nature Cell Biology 
9(3): 316-323. 
Varela, L. and T. L. Horvath (2012). "Leptin and insulin pathways in POMC and AgRP 
neurons that modulate energy balance and glucose homeostasis." EMBO reports 13(12): 
1079-1086. 
Villanueva, E. C. and M. G. Myers, Jr. (2008). "Leptin receptor signaling and the regulation 
of mammalian physiology." International Journal of Obesity (2005) 32 Suppl 7(Suppl 7): 
S8-S12. 
Villena, J. A., S. Roy, E. Sarkadi-Nagy, K. H. Kim and H. S. Sul (2004). "Desnutrin, an 
Adipocyte Gene Encoding a Novel Patatin Domain-containing Protein, Is Induced by 
Fasting and Glucocorticoids: ECTOPIC EXPRESSION OF DESNUTRIN INCREASES 
TRIGLYCERIDE HYDROLYSIS." Journal of Biological Chemistry 279(45): 47066-
47075. 
Wang, C. Y., H. H. Kim, Y. Hiroi, N. Sawada, S. Salomone, L. E. Benjamin, K. Walsh, 
M. A. Moskowitz and J. K. Liao (2009). "Obesity increases vascular senescence and 
susceptibility to ischemic injury through chronic activation of Akt and mTOR." Sci Signal 
2(62): ra11. 
Wang, J. M., B. Lang, H. Y. Zhu, H. T. Du, Y. M. Tian and Y. H. Su (2014). "Cloning and 
transcriptional activity analysis of the porcine cofilin 2 gene promoter." Gene 547(2): 280-
287. 
Wang, L., T. E. Harris, R. A. Roth and J. C. Lawrence, Jr. (2007). "PRAS40 regulates 
mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding." Journal 




Wang, W., N. Lv, S. Zhang, G. Shui, H. Qian, J. Zhang, Y. Chen, J. Ye, Y. Xie, Y. Shen, 
M. R. Wenk and P. Li (2012). "Cidea is an essential transcriptional coactivator regulating 
mammary gland secretion of milk lipids." Nature Medicine 18(2): 235-243. 
Wang, X., Z. Hu, J. Hu, J. Du and W. E. Mitch (2006). "Insulin resistance accelerates 
muscle protein degradation: Activation of the ubiquitin-proteasome pathway by defects in 
muscle cell signaling." Endocrinology 147(9): 4160-4168. 
Wang, Z. V., Y. Deng, Q. A. Wang, K. Sun and P. E. Scherer (2010). "Identification and 
characterization of a promoter cassette conferring adipocyte-specific gene expression." 
Endocrinology 151(6): 2933-2939. 
Werner, E. D., J. Lee, L. Hansen, M. Yuan and S. E. Shoelson (2004). "Insulin resistance 
due to phosphorylation of insulin receptor substrate-1 at serine 302." Journal of Biological 
Chemistry 279(34): 35298-35305. 
Wilson, B. D., D. Bagnol, C. B. Kaelin, M. M. Ollmann, I. Gantz, S. J. Watson and G. S. 
Barsh (1999). "Physiological and anatomical circuitry between Agouti-related protein and 
leptin signaling." Endocrinology 140(5): 2387-2397. 
Winder, D. G., K. C. Martin, I. A. Muzzio, D. Rohrer, A. Chruscinski, B. Kobilka and E. 
R. Kandel (1999). "ERK plays a regulatory role in induction of LTP by theta frequency 
stimulation and its modulation by beta-adrenergic receptors." Neuron 24(3): 715-726. 
Wolfson, R. L., L. Chantranupong, R. A. Saxton, K. Shen, S. M. Scaria, J. R. Cantor and 
D. M. Sabatini (2016). "Sestrin2 is a leucine sensor for the mTORC1 pathway." Science 
351(6268): 43-48. 
Wolfson, R. L., L. Chantranupong, G. A. Wyant, X. Gu, J. M. Orozco, K. Shen, K. J. 
Condon, S. Petri, J. Kedir, S. M. Scaria, M. Abu-Remaileh, W. N. Frankel and D. M. 
Sabatini (2017). "KICSTOR recruits GATOR1 to the lysosome and is necessary for 
nutrients to regulate mTORC1." Nature 543: 438. 
Wolfson, R. L. and D. M. Sabatini (2017). "The Dawn of the Age of Amino Acid Sensors 




Woods, A., D. Vertommen, D. Neumann, R. Turk, J. Bayliss, U. Schlattner, T. Wallimann, 
D. Carling and M. H. Rider (2003). "Identification of phosphorylation sites in AMP-
activated protein kinase (AMPK) for upstream AMPK kinases and study of their roles by 
site-directed mutagenesis." Journal of Biological Chemistry 278(31): 28434-28442. 
Wu, L., D. Xu, L. Zhou, B. Xie, L. Yu, H. Yang, L. Huang, J. Ye, H. Deng, Y. A. Yuan, 
S. Chen and P. Li (2014). "Rab8a-AS160-MSS4 Regulatory Circuit Controls Lipid Droplet 
Fusion and Growth." Developmental Cell 30(4): 378-393. 
Xing, Y.-q., A. Li, Y. Yang, X.-x. Li, L.-n. Zhang and H.-c. Guo (2018). "The regulation 
of FOXO1 and its role in disease progression." Life Sciences 193: 124-131. 
Xu, L., L. Zhou and P. Li (2012). "CIDE Proteins and Lipid Metabolism." Arteriosclerosis, 
Thrombosis, and Vascular Biology 32(5): 1094-1098. 
Xu, W., L. Wu, M. Yu, F. J. Chen, M. Arshad, X. Xia, H. Ren, J. Yu, L. Xu, D. Xu, J. Z. 
Li, P. Li and L. Zhou (2016). "Differential Roles of Cell Death-inducing DNA 
Fragmentation Factor-alpha-like Effector (CIDE) Proteins in Promoting Lipid Droplet 
Fusion and Growth in Subpopulations of Hepatocytes." Journal of Biological Chemistry 
291(9): 4282-4293. 
Xue, X., J. H. Piao, A. Nakajima, S. Sakon-Komazawa, Y. Kojima, K. Mori, H. Yagita, K. 
Okumura, H. Harding and H. Nakano (2005). "Tumor necrosis factor alpha (TNFalpha) 
induces the unfolded protein response (UPR) in a reactive oxygen species (ROS)-
dependent fashion, and the UPR counteracts ROS accumulation by TNFalpha." Journal of 
Biological Chemistry 280(40): 33917-33925. 
Yamaguchi, T., S. Matsushita, K. Motojima, F. Hirose and T. Osumi (2006). "MLDP, a 
novel PAT family protein localized to lipid droplets and enriched in the heart, is regulated 
by peroxisome proliferator-activated receptor alpha." Journal of Biological Chemistry 
281(20): 14232-14240. 
Yang, H., D. G. Rudge, J. D. Koos, B. Vaidialingam, H. J. Yang and N. P. Pavletich (2013). 
"mTOR kinase structure, mechanism and regulation." Nature 497(7448): 217-223. 
Yao-Borengasser, A., V. Varma, R. H. Coker, G. Ranganathan, B. Phanavanh, N. Rasouli 




and muscle. Role in insulin resistance and response to training and pioglitazone." 
Metabolism 60(7): 1012-1020. 
Yasukawa, H., H. Misawa, H. Sakamoto, M. Masuhara, A. Sasaki, T. Wakioka, S. Ohtsuka, 
T. Imaizumi, T. Matsuda, J. N. Ihle and A. Yoshimura (1999). "The JAK-binding protein 
JAB inhibits Janus tyrosine kinase activity through binding in the activation loop." EMBO 
Journal 18(5): 1309-1320. 
Ye, J., J. Z. Li, Y. Liu, X. Li, T. Yang, X. Ma, Q. Li, Z. Yao and P. Li (2009). "Cideb, an 
ER- and Lipid Droplet-Associated Protein,&#xa0;Mediates VLDL Lipidation and 
Maturation by&#xa0;Interacting with Apolipoprotein B." Cell Metabolism 9(2): 177-190. 
Yeh, W. C., B. E. Bierer and S. L. McKnight (1995). "Rapamycin inhibits clonal expansion 
and adipogenic differentiation of 3T3-L1 cells." Proceedings of the National Academy of 
Sciences of the United States of America 92(24): 11086-11090. 
Yonezawa, T., R. Kurata, M. Kimura and H. Inoko (2011). "Which CIDE are you on? 
Apoptosis and energy metabolism." Mol Biosyst 7(1): 91-100. 
Yoo, Y. J., H. Kim, S. R. Park and Y. J. Yoon (2017). "An overview of rapamycin: from 
discovery to future perspectives." Journal of Industrial Microbiology & Biotechnology 
44(4-5): 537-553. 
Yu, S., K. Matsusue, P. Kashireddy, W. Q. Cao, V. Yeldandi, A. V. Yeldandi, M. S. Rao, 
F. J. Gonzalez and J. K. Reddy (2003). "Adipocyte-specific gene expression and 
adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor 
gamma1 (PPARgamma1) overexpression." Journal of Biological Chemistry 278(1): 498-
505. 
Yu, Y., S.-O. Yoon, G. Poulogiannis, Q. Yang, X. M. Ma, J. Villén, N. Kubica, G. R. 
Hoffman, L. C. Cantley, S. P. Gygi and J. Blenis (2011). "Phosphoproteomic analysis 
identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling." 
Science (New York, N.Y.) 332(6035): 1322-1326. 
Zabolotny, J. M., K. K. Bence-Hanulec, A. Stricker-Krongrad, F. Haj, Y. Wang, Y. 
Minokoshi, Y.-B. Kim, J. K. Elmquist, L. A. Tartaglia, B. B. Kahn and B. G. Neel (2002). 





Zechner, R., P. C. Kienesberger, G. Haemmerle, R. Zimmermann and A. Lass (2008). 
"Adipose triglyceride lipase and the lipolytic catabolism of cellular fat stores." The Journal 
of Lipid Research 50(1): 3-21. 
Zeigerer, A., M. S. Rodeheffer, T. E. McGraw and J. M. Friedman (2008). "Insulin 
regulates leptin secretion from 3T3–L1 adipocytes by a PI 3 kinase independent 
mechanism." Experimental Cell Research 314(11): 2249-2256. 
Zeng, W., R. M. Pirzgalska, M. M. Pereira, N. Kubasova, A. Barateiro, E. Seixas, Y. H. 
Lu, A. Kozlova, H. Voss, G. G. Martins, J. M. Friedman and A. I. Domingos (2015). 
"Sympathetic neuro-adipose connections mediate leptin-driven lipolysis." Cell 163(1): 84-
94. 
Zhang, C.-S., S. A. Hawley, Y. Zong, M. Li, Z. Wang, A. Gray, T. Ma, J. Cui, J.-W. Feng, 
M. Zhu, Y.-Q. Wu, T. Y. Li, Z. Ye, S.-Y. Lin, H. Yin, H.-L. Piao, D. G. Hardie and S.-C. 
Lin (2017). "Fructose-1,6-bisphosphate and aldolase mediate glucose sensing by AMPK." 
Nature 548: 112. 
Zhang, C.-S., B. Jiang, M. Li, M. Zhu, Y. Peng, Y.-L. Zhang, Y.-Q. Wu, Terytty Y. Li, Y. 
Liang, Z. Lu, G. Lian, Q. Liu, H. Guo, Z. Yin, Z. Ye, J. Han, J.-W. Wu, H. Yin, S.-Y. Lin 
and S.-C. Lin (2014). "The Lysosomal v-ATPase-Ragulator Complex Is a Common 
Activator for AMPK and mTORC1, Acting as a Switch between Catabolism and 
Anabolism." Cell Metab 20(3): 526-540. 
Zhang, C. and P. Liu (2017). "The lipid droplet: A conserved cellular organelle." Protein 
& cell 8(11): 796-800. 
Zhang, H. H., J. Huang, K. Duvel, B. Boback, S. Wu, R. M. Squillace, C. L. Wu and B. D. 
Manning (2009). "Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 
pathway." PloS One 4(7): e6189. 
Zhang, Y.-L., H. Guo, C.-S. Zhang, S.-Y. Lin, Z. Yin, Y. Peng, H. Luo, Y. Shi, G. Lian, 
C. Zhang, M. Li, Z. Ye, J. Ye, J. Han, P. Li, J.-W. Wu and S.-C. Lin (2013). "AMP as a 
Low-Energy Charge Signal Autonomously Initiates Assembly of AXIN-AMPK-LKB1 




Zhang, Y., R. Proenca, M. Maffei, M. Barone, L. Leopold and J. M. Friedman (1994). 
"Positional cloning of the mouse obese gene and its human homologue." Nature 372(6505): 
425-432. 
Zhao, A. Z., K. E. Bornfeldt and J. A. Beavo (1998). "Leptin inhibits insulin secretion by 
activation of phosphodiesterase 3B." Journal of Clinical Investigation 102(5): 869-873. 
Zhao, A. Z., J. N. Huan, S. Gupta, R. Pal and A. Sahu (2002). "A phosphatidylinositol 3-
kinase phosphodiesterase 3B-cyclic AMP pathway in hypothalamic action of leptin on 
feeding." Nature Neuroscience 5(8): 727-728. 
Zhao, A. Z., M. M. Shinohara, D. Huang, M. Shimizu, H. Eldar-Finkelman, E. G. Krebs, 
J. A. Beavo and K. E. Bornfeldt (2000). "Leptin induces insulin-like signaling that 
antagonizes cAMP elevation by glucagon in hepatocytes." Journal of Biological Chemistry 
275(15): 11348-11354. 
Zhou, Z., S. Yon Toh, Z. Chen, K. Guo, C. Peng Ng, S. Ponniah, S.-C. Lin, W. Hong and 
P. Li (2003). "Cidea-deficient mice have lean phenotype and are resistant to obesity." 
Nature Genetics 35: 49. 
Zimmermann, R. (2004). "Fat Mobilization in Adipose Tissue Is Promoted by Adipose 
Triglyceride Lipase." Science 306(5700): 1383-1386. 
Zoncu, R., L. Bar-Peled, A. Efeyan, S. Wang, Y. Sancak and D. M. Sabatini (2011). 
"mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires 





CURRICULUM VITAE  
146 
 
 
147 
 
 
